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1. MOLECULAR IMAGING 
Molecular imaging is a rapidly developing discipline envisaging early detection, characterisation and 
real-time monitoring of disease in complex biological processes of living organisms. Classical anatomy 
based imaging techniques, such as static x-ray imaging, magnetic resonance imaging (MRI), X-ray 
computed tomography (CT), and ultrasound scans are limited to detect macroscopic and anatomical 
abnormalities. Molecular imaging however, visualises functionality and molecular changes occurring 
prior to anatomic changes of tissue and organs thus providing a clear diagnostic advantage.1 In vivo 
visualisation of biological processes at the cellular and subcellular level, within living organisms, can 
aid in diagnosis, follow-up of disease and direct the proper course of treatment. Moreover, 
molecular imaging is an important tool in research and can speed up drastically the drug 
development process.2 Single photon emission computed tomography (SPECT) and positron emission 
tomography (PET) are the two major molecular imaging modalities within nuclear medicine.3 
2. RADIONUCLIDE IMAGING AND THERAPY 
Radionuclides are elements with an excess of nuclear energy, making them unstable. These 
radioisotopes either have a heavy nucleus (Z>83) or possess an imbalance in proton/neutron ratio, or 
are in a metastable energy state and will undergo radioactive decay. The excess of energy in the 
nucleus of the unstable element can result in emission of either particles (α, β+/-) and/or 
electromagnetic radiation (gamma ray photons (γ)) and as a secondary effect X-rays, conversion 
electrons and Auger electrons.4 Radionuclides occur naturally or are artificially made using nuclear 
reactors, cyclotrons, particle accelerators or are generated by decay of other radionuclides and 
obtained from radionuclide generators.5 A rapidly expanding number of radionuclides with a broad 
variety of half-lives, emission types and energies for application of radionuclide imaging studies are 
routinely produced. Table 1 lists the properties of radionuclides used most commonly in nuclear 
medicine. 
The availability of a wide range of radionuclides makes it possible to carefully pick the best matching 
radionuclide for a certain application.7 Depending on the decay properties of the radionuclide, it can 
be used for PET, SPECT and/or therapeutic applications.8 When choosing the most suitable 
radionuclide for a certain application, one should not only consider the decay properties and 
availability of the radionuclide, it is also of great importance that the physical half-life of the 
radionuclide matches the biological half-life of the vector molecule.9 This biological half-life can be in 
the range of minutes (small organic molecules), hours (peptides, antibody fragments) or even days 
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(monoclonal antibodies). Longer-lived radioisotopes should be selected when an extended time is 
required to achieve optimal target tissue to background ratios. 
Table 1: Selection of radionuclides frequently used in nuclear medicine for diagnosis or therapy, their 
properties and source. EC = electron capture, IT = isomeric transition, IC = internal conversion 4-7  
 Radionuclide Half-
life 
Decay 
mode 
(abundance 
in %) 
E (keV) Max.  ß+-
range in 
H2O (mm) 
Production method 
R
ad
io
m
et
al
s 
68Ga 68 min ß+ (90%) 
EC (10%) 
ß+Emax:1899 8.9 
68Ge/68Ga generator 
  
99mTc 6 h IT (89%) y:141  99Mo/99mTc generator 
64Cu 12.7 h ß+ (18%) 
EC (24%) 
ß- (37%) 
ß+Emax:653 2.4 Cyclotron, 
64Ni(p,n)64Cu 
90Y 2.7 d ß-  ß-Emax:2280  Nuclear reactor, 
90Zr(n,p)90Y 
111In 2.8 d EC  γ:172, 245  Cyclotron, 
111Cd(p,n)111In 
67Ga 3.3 d EC  y:93, 184, 300  Cyclotron, 
68Zn(p,2n)67Ga 
89Zr 3.3 d ß+ (23%) 
EC (77%) 
ß+Emax:897 
γ:909 
3.6 Cyclotron, 89Y(p,n)89Zr 
  
177Lu 6.6 d ß-  ß-Emax:497 
y:208 
  
 Nuclear reactor, 
176Lu(n,γ)177Lu 
223Ra 11.4 d α  Emax:5850 
 
 227Ac/223Ra generator 
R
ad
io
h
al
o
ge
n
s 
18F 109.8 
min 
 ß+ (97%) 
EC (3%) 
ß+Emax:634 2.3 Cyclotron, 
18O(p,n)18F 
124I 4.2 d ß+ (23%) 
EC (77%) 
ß+Emax:1535, 2138 
γ:602, 722, 1691 
6.9, 10.2 Cyclotron, 
124Te(p,n)124I 
  
131I 8.0 d ß- ß-Emax:606 
 y:80, 284, 364, 
637 
 Nuclear reactor,  
235U(n,f)131Te --> 131I  
125I 60.1 d EC γ:35 
Te-X (IC):27 
  Nuclear reactor,  
124Xe(n,γ)125Xe --> 125I  
O
th
er
s 
15O 2.0 
min 
ß+  ß+Emax:1732 8.0 Cyclotron, 
14N(d,n)15O 
13N 10.0 
min 
ß+  ß+Emax:1198 5.1 Cyclotron, 
16O(p,α)13N 
11C 20.3 
min 
ß+ ß+Emax:960 3.9 Cyclotron, 
14N(p,α)11C 
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Important to note is that several elements have multiple radioactive isotopes that are useful for 
diagnostic or therapeutic purposes. Isotopes of a given element have identical chemistry, thus, a 
single radiopharmaceutical agent can be radiolabelled with different radioisotopes of the same 
element (e.g. 86/90Y), while maintaining the same biological behaviour and distribution in vivo.7 This 
class of radiopharmaceuticals is called theranostic agents. 
Most radionuclides used in nuclear medicine belong to one of two subgroups (Table 1). Radiometals 
and radiohalogens are radioactive isotopes of metallic elements or halogens respectively, and both 
can be applied for biological applications as such. Radiometals are often used as a complex with a 
suitable chelator (ligand) that is used as such (e.g. most 99mTc-complexes) or covalently linked to a 
biologically active targeting molecule, making an active radiopharmaceutical agent. In contrast, 
radiohalogens are mostly incorporated in a targeting molecule by standard carbon-halogen bond 
formation.10 
3. CHELATION CHEMISTRY 
Each (radio)metal ion has different chemical properties, including coordination number, coordination 
geometry and ligand donor atom preferences (e.g. N,O,S, hard/soft). Therefore, it is important to find 
the optimal match between chelator and (radio)metal. The properties of an ideal chelator for 
preparation of a radiopharmaceutical are that it can efficiently bind the (radio)metal in high yields 
(quantitative reaction) and within a short reaction time in aqueous medium at low temperature 
(conditions compatible with heat-sensitive molecules). In general, macrocyclic chelators are known 
to form more kinetically inert complexes than acyclic chelators.7 However, crucial properties where 
most acyclic chelators excel and most macrocycles suffer are the coordination kinetics and 
radiolabelling efficiency. Fast kinetics of (radio)metal incorporation (association, kass) often also mean 
fast (radio)metal release (dissociation, kdis). The rate of dissociation in vivo is what directs the kinetic 
inertness of a radiometal complex, and these off-rates are highly influenced by the high dilution 
factor when a radiopharmaceutical (often only micrograms) is diluted into the blood pool (Figure 1). 
Therefore, the stability and kinetic inertness of the chelate should be experimentally determined in 
vitro as well as in vivo. The consequence of radiometal loss from a radiopharmaceutical in vivo 
depends on the properties and biological behavior of the specific radiometal ion in question. For 
example, 67/68Ga3+, {Al18F}2+ and 89Zr4+ are known to accumulate in bone, whereas 64Cu2+ is known to 
accumulate in the liver.7  
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Figure 1: Metal ion coordination kinetics and enhanced in vivo dissociation (kdis) kinetics due to 
extremely dilute conditions. Possible routes of radiometal ions in vivo (adapted from Eric W Price and 
Chris Orvig)7 
4. POSITRON EMISSION TOMOGRAPHY 
PET provides a non-invasive, sensitive and quantitative visualisation of biochemical and physiological 
phenomena in vivo, which can be used to study the function of cells, receptors, neurotransmitters, 
genes and drug pharmacokinetics.11 High quality three-dimensional images are quantified relative to 
the total injected activity of radiotracer, usually labelled with short-lived positron-emitting 
radionuclides.12 Positron emitters are unstable due to a proton excess in their nucleus. Here, a 
spontaneous process called β+-decay is triggered in which one of the protons in the nucleus is 
converted to a neutron, a positron (e+), and a neutrino (ν). The atomic number of the daughter 
nucleus is decreased with one unit compared to the parent nuclide. 
p+ → n + e+ + ν 
The emitted positron, also known as the anti-particle of an electron (e-), travels a short distance (0-10 
mm, depending on its kinetic energy and density of the tissue) during which it loses kinetic energy. 
When the positron is decelerated, it collides with a random nearby electron of the surrounding tissue 
to yield a positronium. This positronium almost immediately annihilates resulting into two anti-
parallel 511-keV photons. Detection of such events is achieved using circular arrays of bismuth 
germanium oxide or cerium-doped lutetium oxyorthosilicate scintillation detectors. When the 
opposing gamma rays simultaneously reach two scintillation detector crystals they cause a flash of 
light (scintillation), the energy of which is used to release electrons at a photocathode which are then 
multiplied by a photomultiplier tube (PMT). By combining the information of millions of annihilations 
using mathematical techniques, it is possible to visualise the distribution of the radionuclide in the 
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body (Figure 2).9 The maximal positron range (unique for each radionuclide) and the inherent 
characteristics of the crystals and PMTs determine the final resolution of the clinical PET image, 
which is typically 4-6 mm in each space direction. However, spatial resolution of newer clinical 
systems (dedicated for brain imaging) has been improved up to 2.5 mm and in small animal PET 
imaging systems a resolution of 0.8-1.5 mm can be achieved. 
 
Figure 2: Schematic illustration of the origin of PET-gamma rays and detection by a PET camera 
The use of PET in combination with anatomy based imaging techniques such as CT (PET/CT) and MRI 
(PET/MRI) offers the advantage of a simultaneous assessment of both anatomical and functional 
processes. These hybrid imaging techniques provide unique opportunities for an accurate localisation 
of pathological changes in certain diseases.12  
Nuclear medicine is rapidly becoming the first choice for detecting early signs of disease, small 
tumors and even infections.1 Compared to SPECT, PET imaging offers indisputably superior images 
that are characterised by (1) higher spatial resolution, (2) better imaging contrast, (3) less scatter, 
and (4) better attenuation correction.13 Furthermore, PET-radioisotopes such as carbon-11 and 
fluorine-18 can be incorporated with little to no change in biological behaviour from their non-
labelled counterparts.5,14 The drawbacks of PET are predominantly its high costs and the need to 
produce short half-life positron-emitters using a particle accelerator (cyclotron), except for 68Ga, 
which is obtained from a 68Ge/68Ga-generator.11 
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Figure 3: PET/MRI apparatus located at UZ Leuven  
5. FLUORINE-18: THE RADIONUCLIDE OF CHOICE FOR PET 
Among β+-emitting radioisotopes, the halogen fluorine-18 is the most commonly used due to its 
optimal chemical properties and almost ideal nuclear decay characteristics. The low maximum 
energy (0.635 MeV) of its positron emissions enables high resolution PET images as a result of the 
short range tissue penetration prior to annihilation.1,15 The half-life of 109.8 min is short enough to 
avoid prolonged irradiation of subjects, yet still long enough to allow multistep synthesis, extended in 
vivo investigations and commercial distribution to remote imaging centres without an on-site 
cyclotron.5,14 Additionally, 18F- is readily manufactured in high radioactive quantities from highly 
enriched 18O-water ([18O]H2O). However, 
18F-radiopharmaceuticals have a high production cost. One 
should not only consider the costs of radiochemists, cyclotron, lead shielded hot cells, remote 
handling and synthesis equipment and PET scanners, but also the cost of implementation and 
maintenance of a good manufacturing practice (GMP) quality system. The success and medical 
importance of one single 18F-labelled radiopharmaceutical, namely 2-[18F]fluoro-2-deoxy-D-glucose 
([18F]FDG), have led to the installation of many of these expensive infrastructures all over the world 
(Figure 4). Consequently, fluorine-18 is now readily available in more and more hospitals and 
research centres and the infrastructure is in place to expand its application far beyond [18F]FDG.7 
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Figure 4: Picture of lead shielded hot cells located at the GMP facility in UZ Leuven and chemical 
structure of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) 
The production of 18F-PET tracers can be summarised in three steps. The first step is the production 
of fluorine-18 with a cyclotron. The second step entails the incorporation of fluorine-18 in the vector 
molecule to obtain the radiopharmaceutical, followed by purification. Finally, the PET-tracer is 
submitted to a battery of quality-control (QC) tests before it is released to be administered to 
patients.  
6. PRODUCTION OF FLUORINE-18 
The first step in de production of 18F-PET tracers is the generation of fluorine-18. Radionuclides that 
decay by positron emission can be produced by addition of a proton to a stable nucleus. However, 
both proton and nucleus are positively charged and the resulting coulomb repulsion will require the 
proton to possess a high kinetic energy. The proton is charged and can thus be accelerated in a 
cyclotron in order to acquire this kinetic energy. In the ion source of the cyclotron, positioned at the 
centre of the vacuum chambre, H- and H+ ions are formed by flowing hydrogen gas through a plasma 
of electrons. The H- ions are extracted from the ion source and accelerated using an alternating high 
voltage applied on two electrodes (D’s).4 To avoid collisions of the accelerated H- particle with gas 
molecules, the acceleration chamber of the cyclotron is kept under high vacuum. Magnets (above 
and below the dees) generate a static magnetic field perpendicular to the electrode plane which 
forces the H- particles to follow a spiral path. Both the centripetal force and the magnetic (Lorentz) 
force determine the trajectory of the H- ions. During each acceleration cycle, the kinetic energy of the 
H- ions and as a consequence also the radius of the spiral path increases and eventually the 
accelerated ions will reach the maximal radius and thus maximal energy. The electrons are now 
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stripped from the H- ions by passage through a thin carbon foil (“stripper”). The resulting positively 
charged protons, subjected to a centrifugal magnetic Lorentz force are deflected out of the cyclotron 
to strike the target, filled with [18O]H2O where the 
18O(p,n)18F nuclear reaction takes place.15 Figure 5 
shows an internal view and schematic representation of a cyclotron. 
 
Figure 5: Internal view and schematic representation of a cyclotron (adapted from Verbruggen A. and 
Bormans G.)4 
7. RADIOFLUORINATION OF VECTOR MOLECULES 
7.1 Radiolabelling by carbon-fluorine bond formation 
7.1.2 Standard fluorine-18 labelling 
In order to achieve high radiochemical yields, high specific activity (SA) and considering the relative 
short physical half-life of fluorine-18, the radiolabelling process must be quick and involve as few 
reaction steps as possible. In addition, the incorporation of the radionuclide is ideally the last step in 
the process. Labelling organic molecules with 18F is performed by reactions in which 18F is either 
electrophilic or nucleophilic in nature.10 
The major shortcoming of electrophilic substitution with [18F]F2 gas is the low specific activity of the 
final compound. Moreover, [18F]F2 gas is a non-specific reactive agent that requires specialised 
equipment and often a mixture of unwanted by-products is obtained.  
In most cases, 18F is attached to a small organic molecule by binding to one of its carbon atoms via an 
aliphatic or aromatic nucleophilic substitution reaction.10 The nucleophilic method can potentially 
yield higher specific radioactivity than the electrophilic approach because it can be used with no-
carrier-added fluoride [18F]F-. 
As mentioned higher, fluorine-18 in the form of fluoride is obtained as an aqueous solution by proton 
irradiation of [18O]H2O. However, aqueous environment severely decreases the nucleophilicity of 
fluoride ions due to the formation of strong hydrogen bonds and a tightly bound hydration sphere. 
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To increase nucleophilicity, several time-consuming drying steps, anhydrous aprotic solvents and 
high temperatures need to be applied.16 Even after these drying procedures, the nucleophilicity of 
the fluoride ions is lower compared to that of other halides. Therefore, a highly reactive electrophilic 
substrate, containing an excellent leaving group, is often required to obtain satisfactory 
radiochemical yields. The most used leaving groups for aliphatic nucleophilic substitution are sulfonic 
acid esters such as mesylate, tosylate or triflate moieties. These electrophiles can react readily with a 
wide variety of functional groups that are more nucleophilic than fluoride. Therefore, protection of 
functional groups is often required, introducing the need for post-labelling deprotection and in that 
way increasing the number of reaction steps. In the case of biomolecules, incorporating potent 
leaving groups is problematic because of the overabundance of nucleophilic groups present in the 
amino acid side chains. Finally, after the successful incorporation of fluorine-18 in a vector molecule, 
a purification step is required. This can be done by using either preparative high performance liquid 
chromatography (HPLC) or solid phase extraction cartridges. Although preparative HPLC is more time 
consuming than solid phase extraction, it is more selective and efficient in separating the final 
compound from impurities such as fluoride-18, precursor molecules or other (radioactive) impurities. 
For radiolabelling of heat-sensitive peptides or biomolecules, labelling techniques using suitable 
radiometals such as 99mTc and 111In for SPECT or 68Ga and 64Cu for PET, have been developed.1,3 
Nevertheless, 18F with its growing availability and its nearly ideal physical properties, is also a very 
attractive radionuclide for radiolabelling biomolecules.15 However, only a limited number of methods 
are available for introducing fluorine-18 into complex and sensitive biomolecules in a rapid and 
efficient way. A solution to overcome the complications caused by the low nucleophilicity of 18F- in 
aqueous media is the use of fluorine-18 labelled prosthetic groups.  
7.1.2 Fluorine-18 labelled prosthetic groups 
Fluorine-18 labelled prosthetic groups (or secondary labelling agents) are small and simple fluorine-
18 containing molecules that facilitate the radiolabelling process of complex molecules. 18F-
prosthetic groups are generally coupled to proteins via conjugation with amines, carboxyl or thiol 
groups, followed by purification.17 This approach avoids exposing the biomolecule to harsh 
conditions but intrinsically requires time consuming synthesis procedures that often include several 
HPLC purification steps.18 Some well-known prosthetic groups are N-succinimidyl 4-
[18F]fluorobenzoate ([18F]SFB)19 and 6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([18F]F-
Py-TFP).20  
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Figure 6: Structural formulas of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB)19, 6-[18F]fluoronicotinic 
acid 2,3,5,6-tetrafluorophenyl ester ([18F]F-Py-TFP)20 and N-[2-(4-
[18F]fluorobenzamido)ethyl]maleimide ([18F]FBEM)21 
Despite its widespread use, the radiosynthesis of [18F]SFB is cumbersome and several purification 
steps are needed. The advantage of [18F]F-Py-TFP is that it can be labelled in a one-step reaction and 
purification can be performed using solid phase extraction cartridges. Both fluorine-18 labelled active 
esters [18F]SFB and [18F]F-Py-TFP can be conjugated to biomolecules via the amine of the side-chain 
of lysines. Fluorine-18 labelled prosthetic groups containing a maleimide moiety (e.g. N-[2-(4-
[18F]fluorobenzamido)ethyl]maleimide ([18F]FBEM))21 can be coupled in a site-specific way with a 
biomolecule via a maleimide-thiol reaction.  
7.1.3 18F-Click chemistry 
An exciting recent development in bio-conjugation strategies for radiolabelled imaging agents has 
been the deployment of the copper(I)-catalyzed Huisgen [2,3]-cycloaddition between alkynes and 
azides (CuAAC), which is widely referred to as the ‘click reaction’.22 Click reactions are defined more 
broadly as those that meet the necessary criteria of being selective, high yielding, and having fast 
reactions kinetics. Numerous 18F-labelled PET radiotracers have been prepared via CuAAC and to a 
lesser extent through Staudinger ligation. However, slow reaction kinetics of the Staudinger ligation 
and the requirement for a cuprous catalyst limit the utility of the method.23 Cu(I) ions are generally 
cytotoxic, causing oxidative degradation of DNA molecules and proteins, via formation of hydroxyl 
radicals in vivo.24 Additionally the possibility that the Cu(I) catalyst can bind to biomolecules may lead 
to various problems, such as blocking or reducing the biological activity, as well as the rate of the 
CuAAC reaction. Moreover, Cu(I) ions can compete in chelation when metallic radionuclides (64Cu, 
68Ga) are used and as metal catalysts tend to clog HPLC columns, they can cause difficulties in 
product purification.25 The above reasons have led to the search for alternative fast and copper-free 
click chemistry concepts applicable to radiochemistry.26 This approach can be based on a 
bioorthogonal inverse-electron-demand Diels-Alder (IEDDA) “click” reaction between tetrazines (Tz) 
and trans-cyclooctene derivatives (TCO) or a strain promoted Cu-free Huisgen click reaction.27  
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The advantage is that neither azides nor alkenes, tetrazines or trans-cyclooctene react with other 
functional groups commonly present in biomolecules. Hence, there is no need for protective group 
chemistry and the removal of Cu or other catalysts. Other advantages of the TCO/Tz strategy include 
fast reaction times, almost quantitative yields, no need for elevated temperatures, biocompatible 
reaction conditions and high selectivity.28 However, one should keep in mind that the first step in the 
process is derivatisation of the biomolecule of interest with a “Click A” group via standard 
conjugation methods. Ideally this conjugation reaction should be site-specific. After this conjugation 
step the derivatised biomolecules can be fully characterised and stored in aliquots. Subsequently, the 
fluorine-18 labelled “click B” group can be added to the derivatised biomolecule to obtain the 
fluorine-18 labelled biomolecule in nearly quantitative yields. Another advantage is that different 
“Click B” groups, derivatised with other radionuclides or dyes, can be conjugated with the same 
biomolecule of interest for versatile applications in molecular imaging and therapy (Figure 7). A final 
purification step is often required to remove excess of “click B” compound after the conjugation 
reaction. 
 
Figure 7: Schematic representation of “click chemistry” in molecular imaging and therapy 
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7.1.4 Pretargeting approach for PET 
In cancer research, in vivo pretargeted PET imaging has emerged as an effective two-step approach 
that combines the high affinity and selectivity of antibodies with the rapid pharmacokinetics and 
favourable dosimetry of smaller molecules radiolabelled with short-lived radionuclides (e.g. fluorine-
18).29 The pretargeting approach involves the sequential administration of an antibody, derivatised 
with a suitable “Click A” group, and a low molecular mass radiolabelled moiety (“Click B”). Crucially, 
the radiolabelled “Click B” group is administered after a predetermined lag period (3-4 days) to allow 
the antibody sufficient time to accumulate at the target site (e.g. cancer cells). Additionally, the 
period between the two injections should be long enough so that residual antibody can be cleared 
from the circulation to achieve good target-to-background ratios.30 This approach can be based on 
the bioorthogonal IEDDA “click” reaction between tetrazines and trans-cyclooctene derivatives. 
Pretargeting is a very appealing approach that can be used for therapeutic applications as well if the 
“click B” group is labelled with a therapeutic radionuclide. However, pretargeting is a more complex 
approach compared to the use of directly radiolabelled tracer agents for imaging or radiotherapy. 
Many hurdles still have to be overcome and it will require careful optimisation in order to be 
successfully translated into a clinical setting. 
7.2 Inorganic approaches for labelling biomolecules with fluorine-18  
Besides conventional carbon-fluorine radiolabelling methods, different inorganic approaches can be 
used for labelling of biomolecules with fluorine-18. Several non-carbon elements favour strong bonds 
(i.e. high bond enthalpy) with fluorine, preserve high kinetic stability of the fluorine containing 
compounds formed and have a lower activation energy for their formation in comparison to carbon-
fluorine bonds.10 These chemical properties were the basis for a new field in 18F-radiochemistry. 
Currently, boron, silicon and aluminium are three elements under investigation. The strength of the 
inorganic approach is that it can entail only one, potentially very fast, radiochemical reaction step, 
which can be easily automated for routine production. Furthermore, time-consuming and rather 
complex drying steps are avoided since the reaction can take place in, at least partially, aqueous 
media.10 
7.2.1 Boron and silicon 
Boron-fluorine bonds are some of the most thermodynamically stable covalent bonds known (>730 
KJ/mol). The high silicon-fluorine bond energy (>570 KJ/mol) has also drawn attention to its potential 
for 18F-labelling.31 Radiofluorination of trifluoroboronates (RBF3
-) and fluorosilane/fluorosilanol 
(silicon-fluoride acceptors, SIFA) is performed through either leaving group displacement or isotopic 
exchange (Figure 8). However, hydrolysis of trifluoroboronates to their corresponding boronic acids 
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(RB(OH)2) can be problematic in an aqueous environment. In the case of silicon, the limited stability 
of the Si-F bond in vivo is a major problem but the inconvenience can be adequately reduced by using 
lipophilic bulky alkyl groups which gives rise to steric hindrance that preserves the silicon-fluorine 
bond.31 The most recent generation of exchange carriers, AmBF3
- and SIFAlin, bear a quaternary 
ammonium cation which reduces the (undesired) lipophilicity of SIFA and increases the stability of 
RBF3
- (Figure 8).32,33 Both [18F]SIFA and R[18F]BF3
- techniques have been mainly used for radiolabelling 
of peptides and could eventually result in a kit-like radiolabelling approach. However, at this moment 
there is still room for improvement regarding the specific activity, the pharmacokinetics and the in 
vivo stability of the radiolabelled constructs.  
 
Figure 8: Schematic overview of isotopic exchange reactions with AmBF3
- and SIFAlin (adapted from 
Bernard-Gauthier et al.)31 
7.2.2 Aluminium 
Al18F-chelation is a relatively new approach and has gained a lot of attention, using only minute 
amounts of biomolecule (nmol range). In this method, 18F- is firmly bound to Al3+ (>670 KJ/mol) to 
form an aluminium fluoride moiety. At low fluoride concentration, Al3+ forms monofluoride species 
({AlF}2+). When the concentration of fluoride increases, aluminium fluoride species constitute the 
series AlFn
3+-n, where n ranges from one to six. {AlF}2+ can be chelated by a suitable chelator and this 
metal chelating agent becomes a bifunctional chelator (BFC) when it accommodates another reactive 
functional group for stable attachment to biomolecules.7 Aluminium forms octahedral complexes, 
therefore a pentadentate ligand is desired, leaving only one binding site open for the fluorine-18 ion. 
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Figure 9: One-step radiolabelling with fluorine-18 via the Al18F-method 
McBride et al. were the first to explore the Al18F-method. As proof of principle they radiolabelled a 
peptide, suitable for a bispecific antibody pretargeting method, with {AlF}2+.34 Initially, the authors 
examined diethylene triaminepentaacetic acid (DTPA, Figure 10), an acyclic octadentate ligand, as a 
potential chelator for {AlF}2+. They observed a promising radiochemical yield using a low amount of 
DTPA-peptide, however the formed complexes were not sufficiently stable for in vivo applications.35 
The authors pointed out that the biggest challenge is finding a stable Al18F-ligand that remains intact 
for several hours in vivo.  
 
Figure 10: Chemical structure of diethylene triaminepentaacetic acid (DTPA), 1,4,7-triazacyclononane-
1,4-diacetate (NODA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) 
The most promising chelators tested until now are the pentadentate (N3O2-donor) ligand 1,4,7-
triazacyclononane-1,4-diacetate (NODA, Figure 10) and the hexadentate (N3O3-donor) ligand 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA, Figure 10).36 It has been demonstrated that the most 
stable aluminium complexes are based on multidentate ligands with negatively charged oxygen 
donor groups. X-ray crystal structures of Al18F-complexes revealed that Al3+ is located at the centre of 
a slightly distorted octahedral complex and bound to fluorine pointing to an axial position.35,37 
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Labelling studies of NODA-benzyl derivatives showed that the presence of groups adjacent to the 
ligand can have a significant interaction with the complexation. A carbonyl group on the NODA-ring 
spaced more than three or four carbons had little influence on its labelling potency (78-86%), 
whereas a carbonyl near-at-hand could form an additional coordination group that reduced the 
labelling yield drastically (11-24%). This demonstrated that in the presence of a competing intra-
molecular metal binding ligand atom (forming a hexadentate ligand), Al3+ could be coordinated by all 
six donor atoms and 18F- is then displaced from the initially formed {Al18F}2+ complex.  
The last years, a wide range of peptides have been labelled using the Al18F-method by several 
groups.38 Not only relative small peptides such as αvβ3 integrin-binding peptides, but also larger 
peptides, such as exendin-4 and affibodies, were successfully labelled with {AlF}2+. The first clinical 
study using a 18F-labelled peptide was published in 2013.39 Although these macrocyclic chelators 
show a lot of potential, the high temperatures required for the complexation reaction (≥100 °C) is 
still the main shortcoming that limits widespread application of this radiolabelling approach. 
In an attempt to use the Al18F-method for radiolabelling of heat-sensitive biomolecules, Bhalla and 
coworkers reported late stage 18F- incorporation via halide exchange (Cl-/18F-) of preformed metal 
complexes at room temperature.40 However, this elegant approach requires high amounts of 
precursor to obtain satisfactory radiochemical yields. Finally the Al18F-strategy has been applied to 
label heat-sensitive antibody Fab’ fragments via a two-step process using the Al18F-labelled 
prosthetic group Al18F-NODA-MPAEM.41 
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OBJECTIVES AND OVERVIEW OF THE THESIS 
Positron emission tomography (PET) is a sensitive, non-invasive imaging technology that produces 
three-dimensional images showing the dynamic in vivo concentration of radiotracers, which are 
usually labelled with short-lived positron emitting radioisotopes. Among β+-emitting radioisotopes, 
the halogen fluorine-18 is the most commonly used due to its optimal chemical properties and 
almost ideal nuclear decay characteristics. The Al18F-method is a relatively new approach that allows 
the radiofluorination of biomolecule-bound chelators in a one-step procedure and in aqueous media. 
This method avoids the laborious and time-consuming multistep procedures that are used routinely 
in labelling of biomolecules with fluorine-18. Although many previous studies demonstrated the 
versatility of the Al18F approach to radiolabel peptides, the approach has limited applicability for heat 
sensitive biomolecules due to high temperatures required for the complexation reaction (≥ 100 °C) 
when used with macrocyclic complexing agents such as NOTA and NODA. Therefore, an alternative 
chelator that eliminates the heating step is desired as it could result in a kit-based radiolabelling 
method in aqueous media.  
In Chapter II we developed new acyclic pentadentate ligands which, unlike NODA, display a less rigid 
structure to reduce the activation energy of the complexation reaction. The area of improvement 
includes radiolabelling at moderate temperatures (≤40 °C), whilst maintaining sufficient in vivo 
stability. The stability of the new Al18F-complexes was tested and in order to obtain a better 
understanding of the different factors influencing the formation and stability of the Al18F-complexes, 
we carried out more in-depth experiments with ligand H3L3. As a proof of concept, we successfully 
developed the urea-based PSMA inhibitor [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 ([18F]AlF-PSMA-L3) and 
performed an ex vivo biodistribution in healthy mice to evaluate the pharmacokinetics of the Al18F-
labelled compound. 
Although the acyclic chelator H3L3 proved to be a good lead candidate for labelling of heat-sensitive 
biomolecules with fluorine-18, there was still room for improvement regarding the stability of Al18F-
complexes. Therefore, in Chapter III we designed new restrained complexing agents (RESCA1-5) for 
application of the Al18F strategy at room temperature in an attempt to improve the stability of the 
resulting Al18F-complexes. Restrained complexing agent 1 (RESCA1) is an acyclic pentadentate ligand 
with an N2O3 coordinative set and this new chelator allows radiolabelling of heat-sensitive 
biomolecules via the Al18F-method in one radiolabelling step at moderate temperature. The new AlF 
chelator, RESCA1, provides an efficient, generic approach to label heat-sensitive biomolecules with 
fluorine-18 for PET applications. As a proof of concept, RESCA1 was conjugated to the heat-sensitive 
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protein human serum albumin (HSA) and the construct was labelled with {Al18F}2+ at ambient 
temperature. Ex vivo biodistribution and microPET studies in healthy rats were performed to assess 
the in vivo stability of Al18F-RESCA1-HSA. 
Prostate-specific membrane antigen (PSMA) is overexpressed in a majority of primary and metastatic 
prostate cancer patients and is a very promising target for specific prostate cancer imaging and 
therapy. In chapter IV we have developed two new Al18F-labelled urea-based PSMA inhibitors, 
[18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-RESCA1. Cell uptake and internalisation experiments 
with LNCaP (PSMA+) and PC-3 (PSMA-) cells, ex vivo biodistribution studies in healthy mice and 
microPET studies in prostate tumour bearing mice were performed to evaluate the prostate cancer 
PET-imaging properties of the Al18F-tracers. The results were compared with those of [18F]AlF-PSMA-
L3 and [68Ga]Ga-HBEDD-CC-PSMA, currently the most widely used PSMA-radioligand. 
Nanobodies are promising tools in molecular imaging and have many advantages in comparison with 
full-size antibodies. Fluorine-18 is the radionuclide of choice for radiolabeling of nanobodies in view 
of their short biological half-life. In Chapter V we aimed to demonstrate that RESCA1 provides an 
efficient approach to radiolabel nanobodies with fluorine-18 at ambient temperature. We derivatised 
nanobodies targeting the CRIg receptor with RESCA1, labelled it with {Al18F}2+ and evaluated the 
stability of the tracer in vitro. Furthermore, we developed a generic radio-HPLC-HRMS system for the 
analysis and quality control of radiolabelled nanobodies. Ex vivo biodistribution studies in healthy 
mice and microPET studies in CRIg-/- mice were performed to evaluate the pharmacokinetics and 
specificity of the Al18F-labelled nanobody, respectively.  
Finally, the overall discussion of this dissertation and the future prospects of the project are provided 
in chapter VI. 
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ABSTRACT 
 
The Al18F labelling method is a relatively new approach that allows radiofluorination of biomolecules 
such as peptides and proteins in a one-step procedure and in aqueous solution. However, the 
chelation of the {Al18F}2+ core with the macrocyclic chelators NOTA or NODA requires heating to 100-
120 °C. Therefore, we have developed new polydentate ligands for complexation of {Al18F}2+ with 
good radiochemical yields at a temperature of 40 °C. The stability of the new Al18F-complexes was 
tested in phosphate buffered saline (PBS) pH 7.4 and in rat plasma. The stability of the [18F]AlF-L3 
complex was found to be comparable to that of the previously reported [18F]AlF-NODA complex up to 
60 minutes in rat plasma. Moreover, the biodistribution of [18F]AlF-L3 in healthy mice showed 
absence of in vivo defluorination since no significant bone uptake was observed, whereas the major 
fraction of activity at 60 min p.i. was observed in liver and intestines, indicating hepatobiliary 
clearance of the radiolabelled ligand. The acyclic chelator H3L3 proved to be a good lead candidate 
for labelling of heat-sensitive biomolecules with fluorine-18. In order to obtain a better 
understanding of the different factors influencing the formation and stability of the complex, we 
carried out more in-depth experiments with ligand H3L3. As a proof of concept, we successfully 
conjugated the new AlF-chelator with the urea-based PSMA inhibitor Glu-NH-CO-NH-Lys to form Glu-
NH-CO-NH-Lys(Ahx)L3 and a biodistribution study in healthy mice was performed with the Al18F-
labelled construct. This new class of AlF-chelators may have a great impact on PET radiochemical 
space as it will stimulate the rapid development of new fluorine-18 labelled peptides and other heat-
sensitive biomolecules. 
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1. INTRODUCTION 
Positron emission tomography (PET) is a sensitive, non-invasive imaging technology that produces 
three-dimensional images showing the in vivo concentration of radiotracers, which are usually 
labelled with short-lived positron emitting radioisotopes such as 15O, 13N, 11C, 68Ga, 18F, 64Cu, 89Zr and 
124I.1 Fluorine-18 is the most frequently used PET radionuclide as it combines several advantages like 
favourable decay properties (t1/2 =109.8 min, ~ 97% ß
+-emission, 635 keV maximum positron energy), 
low β+-trajectory (< 2 mm in water), small atom size and moreover, it is readily produced in large 
quantities (>400 GBq/batch) with a cyclotron. The half-life is long enough to allow multistep 
synthesis, transportation to remote hospitals without an on-site cyclotron and it is short enough to 
avoid extended irradiation of patients.2 
The Al18F labelling method is a relatively new approach that allows radiofluorination of biomolecules 
such as peptides and proteins in a one-step procedure and in aqueous medium.3,4 This method 
avoids laborious multistep procedures often required when secondary labelling agents are used to 
radiolabel biomolecules with fluorine-18.5,6,7 Conventional radiofluorination strategies involve 
carbon-fluorine bond formation in anhydrous aprotic solvents. In contrast, the Al18F-strategy involves 
the formation of aluminium monofluoride ({Al18F}2+) which is trapped by a suitable chelator –mostly 
bound to a biomolecule- in aqueous medium. McBride et al. published the first study using a chelator 
for {Al18F}2+ labelling in 2009.4 The most promising chelators tested until now are the hexadentate 
ligand 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)8,9 and the pentadentate ligand 1,4,7-
triazacyclononane-1,4-diacetic acid (NODA)(Figure 1).10,11  
Although these macrocyclic chelators show a lot of promise for radiolabelling peptides with fluorine-
18, the chelation of the {Al18F}2+ core with NOTA or NODA requires heating to 100-120 °C. These 
harsh reaction conditions are problematic when the chelator is coupled to heat-sensitive 
biomolecules.12 Therefore it would be desirable to have an improved chelator that allows efficient 
chelation of {Al18F}2+ at moderate temperature (<40 °C). This could ultimately allow development of a 
kit-based, room temperature fluorine-18 radiolabelling method for heat-sensitive biomolecules. 
Although there are reports from Bhalla and coworkers on late stage 18F- incorporation via halide 
exchange (Cl-/18F-) of preformed metal complexes at room temperature and also a recent attempt 
from Malik et al. on radiofluorination of a prostate cancer imaging agent via {Al18F}2+ chelation at 
ambient temperature, new chelators for the Al18F method are warranted.13,14 
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Figure 1: Chemical structures of H3L1-8, NODA, NOTA and N-benzyl-NODA 
In the present study, we synthesised new polydentate ligands that allow chelation of {Al18F}2+ at 
moderate temperatures (<40 °C). These new chelators, unlike NODA and NOTA, consist of a flexible 
structure to reduce the activation energy of the complexation reaction. Macrocyclic chelators exhibit 
a high stability once the metal complex is formed, but they generally require high temperatures to 
rearrange the ligand structure in order to accommodate the {Al18F}2+ moiety.15 However, replacing 
the macrocyclic by a more flexible acyclic structure can compromise the stability of the complex. To 
avoid this, the original coordinative set of NODA (N3O2) was modified, replacing one nitrogen by an 
oxygen atom (N2O3). Indeed, negatively charged oxide donor atoms are more effective Al-chelators 
than nitrogen and sulphur among others.16 Therefore, novel chelators H3L1-8 (Figure 1) were 
synthesised. These novel derivatives have been evaluated as such (i.e. without being conjugated to 
biomolecules) to fully assess the {Al18F}2+-core chelation efficiency and the in vivo and in vitro stability 
of the corresponding fluorine-18 labelled chelates. Furthermore, in order to gain a better 
understanding of the different factors influencing the formation and stability of the complex, we 
carried out more in-depth experiments with ligand H3L3. In addition, as a proof of concept, we 
conjugated the ligand H3L3 with a urea-based inhibitor of the prostate-specific membrane antigen 
(PSMA), Glu-NH-CO-NH-Lys,17 to form Glu-NH-CO-NH-Lys(Ahx)H3L3 and performed a biodistribution 
study in healthy mice with the Al18F-labelled construct. PSMA is overexpressed in a majority of 
primary and metastatic prostate cancers and can be considered as a promising target for specific 
prostate cancer imaging and therapy.18-19 Although the urea-based inhibitor of PSMA can tolerate 
New chelators for low temperature Al18F-labelling of biomolecules  
Page | 28  
high temperature radiolabelling procedures, the proposed method can straightforwardly be applied 
to radiolabel heat-sensitive biomolecules, such as the 55-kDa fragment antigen-binding (FAB), the 28-
kDa single-chain variable fragment (scFv) or 15-kDa antibody fragments derived from heavy-chain 
only antibodies (VHH or nanobodies).12  
2. MATERIALS AND METHODS 
2.1 General 
All reagents and solvents were purchased from Sigma-Aldrich (Bornem, Belgium), Fluka (Bornem, 
Belgium), Fisher (Doornik, Belgium) or Acros Organics (Geel, Belgium). Fluorine-18 was produced on 
site using a cyclotron (IBA Cyclone 18/9, IBA, Louvain-la-Neuve, Belgium) by irradiation of H2
18O with 
18-MeV protons. Radioactivity was measured using an ionisation chamber based activity meter 
(Capintec Radioisotope Calibrator CRC-721, Ramsey, NJ, USA).  
Identification of the molecular ion mass of various compounds was achieved using a Dionex Ultimate 
3000 LC System (Thermo Fisher Scientific, Sunnyvale, USA) coupled in series to an ultra-high 
resolution time-of-flight mass spectrometry (TOF-HRMS) (MaXis impact, Bruker, Bremen, Germany), 
equipped with orthogonal electrospray ionisation (ESI) interface. Acquisition and processing of data 
were conducted using HyStar and Compass DataAnalysis (version 3.2, Bruker), respectively. 
Calculated monoisotopic mass values were obtained using Compas IsotopePattern (version 3.2, 
Bruker). Thin layer chromatography (TLC) was used for rapid analysis of reaction mixtures. The TLC 
plates were silica-based (Silica gel 60 plates, Merck, Darmstadt, Germany).  
Preparative high performance liquid chromatography (prep-HPLC) was carried out with a system 
consisting of a Merck-Hitachi L-6200 pump and an XTerra preparative C18 10 µm 10 mm x 250 mm 
column (Waters, Milford, USA). The mobile phase consisted of a gradient of water and acetonitrile, 
eluted at a flow rate of 5 mL/min. The eluate was analysed for its UV absorbance (Merck Hitachi L-
4200 UV-VIS detector) at 254 nm. 
Chemical structure elucidation was performed using proton-nuclear magnetic resonance (1H-NMR) at 
400 MHz, carbon-nuclear magnetic resonance (13C-NMR) at 101 MHz and fluorine-nuclear magnetic 
resonance (19F{1H}-NMR) at 376 MHz on a Bruker AVANCE 400 MHz spectrometer (5 mm probe, 
Bruker AG, Fällanden, Switzerland). 
Instant thin layer chromatography-silica gel (iTLC-SG) papers (Varian, Diegem, Belgium) were 
developed in an elution chamber using a mixture of acetonitrile and water (75:25, v/v). 
Autoradiography was performed using phosphor storage screens (super-resolution screen, Perkin 
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Elmer, Waltham, USA). Screens were read in a Cyclone Plus system (Perkin Elmer) and analysed using 
Optiquant software (Perkin Elmer). 
2.2 Complexation of {Al18F}2+ 
2.2.1 {Al18F}2+solution  
[18F]F- was separated from [18O]H2O by trapping on a SepPak Light Accel plus QMA anion exchange 
cartridge (Cl- form; Waters). The cartridge was washed with water (3 mL) and [18F]F- (148-333 MBq) 
was eluted from the cartridge with an aqueous solution of sodium chloride 0.9% (0.3 mL). The 
obtained [18F]F- solution (50 µl) was added to 22.5 µL of 2 mM aluminum chloride (AlCl3) in sodium 
acetate buffer (0.1 M, pH 4). The solution was incubated at rt for 5 min to form {Al18F}2+. 
2.2.2 Synthesis and purification of [Al18F]-complexes 
A solution of each ligand (1 mL, 150 µM) in sodium acetate buffer (0.1 M, pH 4) was added to 
separate vials which contained a freshly prepared {Al18F}2+ solution. The closed vials were heated in 
an oil bath at different temperatures for 12 min and the radiochemical yields (RCY’s) were 
determined by iTLC-SG (H3L1 and H3L3 n=3, H3L2, H3L4-8 and N-benzyl-NODA n=1).  
The resulting mixtures were purified using a Sep-Pak Plus Alumina-N-Cartridge (Waters, pre-rinsed 
with an aqueous solution of sodium chloride 0.9% (5 mL)). After loading of the crude reaction 
mixture, the cartridge was eluted with an aqueous solution of sodium chloride 0.9% (3 mL). The 
eluate was collected and each of the purified [Al18F]-complexes was analysed using iTLC-SG and/or 
radio-HPLC-HRMS (Acquity UPLC BEH C18, 1.7 µm, 2.1 mm x 150 mm, Waters) with gradient elution at 
a flow rate of 0.6 mL/min A: H2O B: ACN, 0-2 min 5% B, 2 to 8 min 5% B to 95% B, 8-10 min 95% B, 10 
to 12 min 95% B to 5% B). 
2.3 Stability tests of [18F]AlF-L1-4 and [18F]AlF-N-benzyl-NODA in phosphate buffered saline 
(PBS) and rat plasma 
Al18F-complexes were synthesised and purified as described above by heating the mixtures at 40 °C 
for 12 min ([18F]AlF-L1-3) or at 110 °C for 12 min ([18F]AlF-L4 and [18F]AlF-N-benzyl-NODA). A volume 
of 200 µL of each solution of purified [Al18F]-complex was added to PBS (1 mL, 0.1 M pH 7.4) or rat 
plasma (1 mL). These mixtures were incubated at 37 °C and analysed by iTLC-SG at 10, 30, 60, 120, 
180 and 240 min after the start of the incubation. Plasma samples were denatured by addition of the 
plasma solution (50 µL) to acetonitrile (50 µL). The mixture was stirred and centrifuged (1300 g, 3 
min). Finally the supernatant was analysed using iTLC-SG. 
2.4 Biodistribution studies  
Quantification of radioactivity for biodistribution studies was performed using an automated gamma-
counter equipped with a 3-inch NaI(Tl) well crystal coupled to a multichannel analyzer, mounted in a 
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sample changer (Perkin Elmer 1480 Wizard 3q). Counts were corrected for background radiation, 
physical decay and counter dead time. 
Animals were housed in individually ventilated cages in a thermo-regulated (~22 °C), humidity-
controlled facility under a 12h-12h light-dark cycle, with access to food and water ad libitum. All 
animal experiments were conducted according to the Belgian code of practice for the care and the 
use of animals, after approval from the university animal ethics committee. 
The biodistribution studies of [18F]AlF-L3, [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 and {Al18F}2+ were 
carried out in healthy male Naval Medical Research Institute (NMRI) mice (body weight: 30-40 g) at 
10 and 60 min post injection (p.i.) (n = 4/time point). Mice were injected with the [18F]AlF-L3 complex 
(2 MBq) or with {Al18F}2+ (5.55 MBq) or with [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 (2 MBq) with or 
without coadministration of 2 mg/kg 2-PMPA via a tail vein under anesthesia (2.5% isoflurane in O2 at 
1 L/min flow rate) and sacrificed by decapitation at above specified time points. Blood and major 
organs were collected in tared tubes and weighed. The radioactivity in blood, organs and other body 
parts was counted using the automated γ-counter. For calculation of total radioactivity in blood, 
bone and muscle, tissue mass was assumed to be, respectively, 7, 12 and 40% of the total body 
mass.28,29  
2.5 [18F]AlF-L3: additional experiments 
2.5.1 Effect of pH 
A solution of H3L3 (1 mL, 150 µM) was prepared in sodium acetate buffer (0.1 M) at different pH 
values ranging from pH 3 to pH 5.5. The buffer solution was added to a vial which contained a freshly 
prepared {Al18F}2+ solution. The vials were heated at 40 °C for 12 min and the RCYs were determined 
by iTLC-SG (n=3). 
2.5.2 Effect of reaction volume 
Different stock solutions (900, 750, 600, 300, 150 µM) of H3L3 in sodium acetate buffer (0.1 M, pH 4) 
were prepared. Respectively 165, 200, 250, 500 and 1000 µl of the H3L3 stock solutions were added 
to 73 µl of freshly prepared {Al18F}2+ solution. With this protocol reaction volumes ranging from 238 
µl to 1073 µl were obtained, without changing the concentration of the ligand. The vials were heated 
at 40 °C for 12 min and the RCYs were determined by iTLC-SG. 
2.5.3 Effect of organic solvents 
Different stock solutions of H3L3 (150 µM) in sodium acetate buffer (0.1 M, pH 4) were prepared 
containing acetonitrile or ethanol, ranging from 0 to 80%. 1 ml of each solution was added to a vial 
containing 73 µl of freshly prepared {Al18F}2+ solution. The vials were heated at 40 °C for 12 min and 
the RCYs were determined by iTLC-SG. 
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2.5.4 Effect of relative amount of 19F- 
After cyclotron production, [18F]F- was separated from [18O]H2O as described higher and [
18F]F- (3500-
5500 MBq) was eluted from the anion exchange cartridge with an aqueous solution of sodium 
chloride 0.9% (0.5 mL). The solution of [18F]fluoride was further diluted 1000 times with a solution of 
sodium chloride 0.9%. The highly diluted solution of [18F]fluoride (50 µl, 350-550 kBq) and 20, 40, 80 
or 160 µl of Na19F solution (1 mM) was added to 22.5 µl of 2 mM aluminum chloride (AlCl3) in sodium 
acetate buffer (0.1 M, pH 4). Sodium acetate buffer (0.1 M, pH 4) was added to obtain a total volume 
of 233 µl. A solution of H3L3 (1 mL, 150 µM) in sodium acetate buffer (0.1 M, pH 4) was added to the 
vials which contained the freshly prepared {Al18/19F}2+ solutions. The vials were heated at 40 °C for 12 
min and the RCYs were determined by iTLC-SG. 
2.5.5 Effect of H3L3 to Al
3+ ratio  
Different stock solutions of AlCl3 (2000, 1000, 500, 100, 50, 25 and 10 µM) in sodium acetate buffer 
(0.1 M, pH 4) were prepared. From these solutions 22.5 µl was added to [18F]F- solution (50 µl) and 
the mixtures were incubated at rt for 10 min to form {Al18F}2+. Different stock solutions of H3L3 in 
sodium acetate buffer (0.1 M, pH 4) were prepared: 150, 100, 75, 50 and 25 µM. The freshly 
prepared {Al18F}2+ solutions were added to 1 mL of the H3L3 stock solutions. With this protocol H3L3 
to Al3+ ratios ranging from 652 to 0.54 were obtained. The vials were heated at 40 °C for 12 min and 
the RCYs were determined by iTLC-SG. 
2.5.6 Stability of [18F]AlF-L3 in different buffers ranging from pH 2 to pH 8 
200 µl of the purified Al18F-L3 solution was added to 1 mL of sodium phosphate buffer (0.1 M, pH 2 or 
pH 3), sodium acetate buffer (0.1 M, pH 4, pH 5 or pH 6), PBS buffer (0.1 M, pH 7) or Tris-HCl buffer 
(0.1 M, pH 8). These mixtures were incubated at room temperature and analyzed by iTLC-SG at 30 
and 60 min after the start of the incubation.  
2.6 Remote controlled radiosynthesis and purification of Al18F-labelled Glu-NH-CO-NH-
Lys(Ahx)L3  
[18F]fluoride was produced (40 GBq) and trapped on a SepPak Light Accel plus QMA anion exchange 
cartridge as described above. The [18F]F- was eluted from the cartridge with an aqueous solution of 
sodium chloride 0.9% (0.25 mL) and added to 5 µl of 20 mM aluminum chloride (AlCl3) in sodium 
acetate buffer (0.1 M, pH 4.5). The solution was incubated at rt for 5 min to form {Al18F}2+. A solution 
of Glu-NH-CO-NH-Lys(Ahx)L3 (0.115 mL, 2.58 mM) was added and the reaction vial was heated at 40 
°C for 12 min. After dilution with water (0.5 mL), the crude reaction mixture was purified with semi-
preparative HPLC (XBridge C18, 5 µm, 4.6 mm x 150 mm, Waters) using the following method. Solvent 
A (ammonium acetate 0.05M pH 5.5) and solvent B (EtOH), flow rate 1 ml/min. The elution gradient 
was 100% A to 80% A over 0-25 min. UV detection of the eluate was performed at 254 nm. The 
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[18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 peak was isolated and identification was performed by radio-HPLC 
(XBridge C18, 3.5 µm, 3.0 mm x 100 mm, Waters) using gradient elution at a flow rate of 0.8 ml/min 
(A: ammonium acetate 0.05M pH 5.5 B: acetonitrile, 0 to 25 min 0% B to 20% B) and by ESI-MS 
((m/z): found, 873.3261 [M]-  calculated for C39H51AlFN6O14 873.3257). 
3. RESULTS & DISCUSSION 
McBride and others have reported the Al18F-labelling method using bis-carboxylate derivatives of 
1,4,7-triazacyclononane for a “one-pot” radiolabelling of a diverse range of biomolecules.8,20 
However, the need for elevated temperatures (100-120 °C) limits its widespread applicability 
because of the thermal instability of many (high MW) biomolecules.12 Therefore, we designed new 
acyclic ligands with an N2O3 coordinative set or N3O2 bis-phenol structure (Figure 1). 
3.1 Synthesis 
The ligands H3L1-4 have an ethylenediamine-N,N’-diacetic acid scaffold in common, but the tertiary 
amines are substituted with different groups (benzyl, 2-hydroxybenzyl, 2-pyridylmethyl, acetic acid). 
H3L1 was synthesised in two steps with 50% overall yield (see Supporting information, S1), starting 
from N-benzylethylenediamine, by nucleophilic substitution of ethyl bromoacetate, followed by 
saponification of the ethyl esters. H3L2-4 were synthesised with overall yields ranging from 20 to 48% 
using a similar pathway (see Supporting information, S2-S4), starting from ethylenediamine or N-
benzylethylenediamine: first, a reductive amination of the primary amines with an aldehyde 
(salicylaldehyde or 2-pyridine carboxaldehyde), followed by nucleophilic substitution using tert-butyl 
bromoacetate, and finally deprotection of the tert-butyl esters. H3L5 and H2L7 have a common 
synthetic pathway (see Supporting information, S5 and S7), starting from N-Boc-ethylenediamine. 
After a reductive amination to incorporate the 2-hydroxybenzyl substituent, nucleophilic substitution 
of benzyl bromide by the same nitrogen atom, followed by removal of the Boc-protecting group 
afforded intermediate 9. This compound was then subjected to another reductive amination using 
salicylaldehyde to yield the key compound 10. This key compound was then used to synthesise H3L5 
by nucleophilic substitution using bromoacetic acid, and also to synthesise H2L7 by nucleophilic 
substitution using 2-(Boc-amino)ethyl bromide followed by deprotection of the primary amine. H3L5 
and H2L7 were produced with 42% and 9% overall yields over 5 and 6 steps, respectively. H3L6 is a 
structural isomer of H3L3. It was synthesised in two steps (see Supporting information, S6) starting 
from compound 10, an intermediate in the syntheses of H3L5 and H2L7. Tert-butyl bromoacetate was 
used for nucleophilic disubstitution of the primary amine, and subsequent deprotection of the tert-
butyl esters afforded H3L6 with 30% overall yield. H2L8 has a scaffold based on 1,4,7-triazaheptane. 
The benzyl and 2-hydroxybenzyl N-substituents were introduced by nucleophilic substitution using 
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benzyl bromide and reductive amination using salicylaldehyde. H2L8 was prepared in two steps, with 
50% overall yield (see Supporting information, S8). 
3.2 Complexation of {Al18F}2+ 
The effectiveness of the novel chelators for complexation of {Al18F}2+ was tested. The new ligands 
were incubated with {Al18F}2+ at different temperatures (from rt to 110 °C) for 12 min and the 
radiochemical yields (RCYs) were determined by instant thin layer chromatography (iTLC) (Figure 2). 
It was observed that only ligands containing the fragment ethylenediamine-N,N’-diacetic acid (H3L1-
L4) were able to efficiently chelate aluminium fluoride. Ligands without this arrangement of 
functional groups (H3L5-8) did not complex aluminium fluoride with good RCY under the conditions 
tested (see Supporting information, Table S1). This was corroborated when the reactivities of the 
two structural isomers H3L3 and H3L6 were compared. While the first ligand chelated {Al
18F}2+ at 
moderate temperatures (77% at 40 °C), H3L6 was not able to complex {Al
18F}2+ efficiently, even at 110 
°C only a low RCY of 8% was observed. Moreover, a thorough analysis of the results revealed that a 
pentadentate ligand with three carboxylic acids and without a phenol moiety is more reactive than a 
pentadentate ligand with only two carboxylic acids and a phenol. This combination of donating 
groups (H3L1) resulted in a RCY of more than 90%, even at rt. This observation can be explained by 
the pH of the reaction mixture as an acidic pH (4-4.5) is required for chelation to prevent hydrolysis 
of aluminium fluoride in solution,21 which would cause a significant drop in RCY. At pH 4 the 
carboxylic acids (pKa 3-4) are partially deprotonated and available to form an ionic bond with the 
aluminium ion, phenols on the other hand have a higher pKa (9-10) and are almost fully protonated 
at pH 4.5 and thus significantly less available to chelate {Al18F}2+. 
Chelators H3L2 and H3L3 displayed a substantial increase of the RCY when the reaction was carried 
out at 40 °C as compared to room temperature (20-25 °C). Nevertheless, raising the temperature to 
60, 80 or 110 ºC did not further improve the RCY. Similar temperature dependence was observed for 
H2L4, but in this case the higher RCYs were observed from 60 °C on. This demonstrates that a phenol 
(H3L2-3) is more suitable to complex {Al
18F}2+ than a pyridine nitrogen atom (H2L4) under these mild 
reaction conditions. Under the pH conditions required for the chelation of {Al18F}2+ (i.e. pH 4-5), the 
nitrogen atom on the pyridine ring is protonated, resulting in a positive charge that could hinder the 
complexation of {Al18F}2+ at low temperature. 
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Figure 2: Al18F-complexation efficiency of H3L1-4 and N-benzyl-NODA at different temperatures (150 
nmoles ligand, 46 nmoles AlCl3, sodium acetate buffer 0.1 M pH 4, 12 min). X-axis displays the 
reaction temperature, while the Y-axis displays the radiochemical yield as percentage of starting 
fluorine-18 radioactivity (H3L1 and H3L3: n=3; H3L2, H2L4 and N-benzyl-NODA: n=1) 
All studied metal complexes were successfully purified using Sep-Pak Plus Alumina-N-cartridges, 
following a previously reported procedure.11 An example of iTLC analysis of Al18F-L3, before and after 
alumina-N-cartridge purification is shown in Figure S1 (see Supporting information). The purified 
Al18F-complexes were characterised with radio-HPLC-HRMS and the proposed structures of the 
complexes are presented in Figures S2-S5 (see Supporting information). As derived from the 
molecular ion mass, the AlF-complexes formed with ligands H3L1-3 have a negative overall charge 
whereas H2L4 forms a neutral complex with {Al
18F}2+.The stable complexes Al19F-Ln and Al
19F-N-
benzyl-NODA were also prepared and identified with HPLC-HRMS (see Supporting information). Al19F-
L1, Al19F-L3 and Al19F-N-benzyl-NODA were further identified with 1H and 13C NMR (see Supporting 
information, Figure S6-8). 
3.3 In vitro and in vivo stability studies 
The stability of [18F]AlF-L1-4 and [18F]AlF-N-benzyl-NODA in phosphate buffered saline (PBS) (0.1 M, 
pH 7.4) at 37 °C and in rat plasma at 37 °C is shown in Figure 3. The stability of Al18F-L3 was 
comparable to that of [18F]AlF-N-benzyl-NODA up to 60 minutes of incubation. After 60 minutes the 
percentage of intact [18F]AlF-L3 starts to decrease slowly, indicating demetallation and/or 
defluorination. After 240 min of incubation, 70% and 66% of [18F]AlF-L3 was still intact in PBS and in 
rat plasma, respectively. The percentage of intact [18F]AlF-N-benzyl-NODA after 240 min was 
respectively 88% and 87% in PBS and in rat plasma. Regarding complexes [18F]AlF-L1, [18F]AlF-L2 and 
[18F]AlF-L4, substantial degradation occurred between 10 and 30 min of incubation. As expected, the 
degradation occurred faster in rat plasma than in PBS, possibly because in rat plasma competing 
metals and different endogenous chelators (for example apo-transferrin15) are present that can 
hamper the stability of the AlF-complexes. The limited stability of [18F]AlF-L1 is probably due to the 
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fact that either the complex is not rigid enough to retain the {Al18F}2+ moiety or the low basicity of 
the acetate groups makes the Al-O bond weaker (in comparison with phenol on H3L3). In either case, 
the complex is more labile causing a faster demetallation. The instability of the complex with the 
hexadentate ligand [18F]AlF-L2 can be explained by demetalation and/or defluorination in the 
presence of an uncoordinated donor atom. We hypothesise that at pH 7 the uncoordinated donor 
atom competes with fluoride to bind to aluminium, thus causing fast defluorination. The formation of 
a complex with a hexadentate ligand and the consequent defluorination could be explained by the 
chelation effect despite the fact that the Al-F bond is stronger than an Al-O bond. The instability of 
Al18F-L4 confirms that phenols form more stable complexes with {Al18F}2+ than pyridines. 
 
Figure 3: Stability of [18F]AlF-L1 (n=1), [18F]AlF-L2 (n=1), [18F]AlF-L3 (n=3), [18F]AlF-L4 (n=1) and 
[18F]AlF-N-benzyl-NODA (n=1) in PBS or rat plasma at 37 °C  
A biodistribution study with [18F]AlF-L3 was carried out in healthy mice (Figure 4), and the results 
were compared to the distribution profile of {Al18F}2+. Free fluorine-18 as well as {Al18F}2+ are known 
to accumulate in bone.22,23 As expected, there was extensive bone uptake for {Al18F}2+, with 60%ID 
(10 min p.i.) and 83%ID (60 min p.i.) and the excretion pathway for the metal fragment was mainly 
via the renal route. The biodistribution of [18F]AlF-L3 demonstrated high in vivo stability, since no 
significant bone uptake was observed, which would indicate {Al18F}2+ or 18F-fluoride release. The 
major fraction of activity at 60 min p.i. was observed in liver and intestines indicating hepatobiliary 
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clearance of the radiolabelled ligand. In comparison, [18F]AlF-N-benzyl-NODA also was rapidly cleared 
from blood, showed low bone uptake but was mainly cleared renally.11 It is difficult to predict 
whether the excretion pathway of the metal chelate will eventually influence the excretion of 
corresponding biomolecule conjugates. Probably, this effect needs to be taken into account when 
radiolabelling relatively small biomolecules, such as urea-based PSMA inhibitors for specific prostate 
cancer imaging.  
 
Figure 4: Biodistribution of {Al18F}2+ and [18F]AlF-L3 after iv injection in healthy male NMRI mice at 10 
and 60 minutes p.i. (n=4/group). Results are presented as percentage of injected dose (%ID). 
 
3.4 Studies of different parameters influencing the complexation yield 
The optimal pH range for labelling H3L3 was found to be between 4 and 5, but even at pH 5.5 high 
RCYs were still observed, indicating that also acid-sensitive proteins can be labelled with the 
proposed method (Figure 5A). If the pH is too low, the preferred fluoride species in equilibrium is 
likely to be HF.24 Moreover, the results suggest that the carboxylic acid groups need to be sufficiently 
deprotonated to efficiently chelate the {Al18F}2+ moiety since at pH 3-3.5 the RCY dropped 
significantly (<20%). 
The reaction volume did not affect the radiochemical yield in the range of 238 µL to 573 µL (RCY > 
90%). However, when the volume exceeded 1 mL the RCY decreased to 82%. Other groups already 
described improvement of {Al18F}2+ labelling yields in the presence of acetonitrile or ethanol.15 We 
also observed an increase of the RCY from 77% to 95% in the presence of 20% of either ethanol or 
acetonitrile. Small amounts of organic solvent are compatible with biomolecules but excessive 
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percentages should be avoided to prevent denaturation. In conclusion, optimal results were obtained 
at pH 4.5-5, a total reaction volume less than 1 ml and in the presence of 20% acetonitrile or ethanol. 
Purification and quality control of radiolabelled peptides is usually performed with RP-HPLC in acidic 
conditions e.g. using trifluoroacetic acid 0.1% w/v in the mobile phase (pH 2). However, most metal 
complexes are found to de-ligate fairly quickly at this pH.15 Therefore the stability of [18F]AlF-L3 was 
determined in different buffers ranging from pH 2 to pH 8. The results show that the [18F]AlF-L3 
complex is not stable at pH <4. After 60 min of incubation, the percentage of intact tracer dropped to 
58%, 68% and 75% at pH 2, 3 and 4, respectively. In contrast, the [18F]AlF-L3 complex was very stable 
(> 95%) for at least 60 min in the pH range from 5 to 8 (see Supporting information, Figure S9). 
Recovery of fluorine-18 in the form of fluoride is an important validation parameter in the quality 
control of fluorine-18 labelled radiopharmaceuticals because retention of [18F]fluoride on HPLC 
columns may result in an overestimation of the radiochemical purity. Ory et al.25 have shown that 
[18F]fluoride recovery increases with increasing pH and thus it is recommended to use a mobile phase 
with a pH higher than 5 for silica-based C18 columns for both quality control and semi-preparative 
HPLC of fluorine-18 labelled PET radiopharmaceuticals. Consequently, for both reasons an 
appropriate buffer should be selected for HPLC purification and analysis of the Al18F-complexes.  
Another critical parameter for efficient labelling is the 18/19F--to-Al3+ ratio and the Al3+-to-ligand ratio 
in the reaction mixture. The number of fluorine-18 atoms in a batch of [18F]F- is typically negligible 
(13 GBq corresponds to 0.2 nmoles of fluorine-18) in comparison with the number of fluorine-19 
atoms. The main origin of fluorine-19 is the [18O]water dispensing (loading) and delivery (unloading) 
system of the target, which often contains teflon (PTFE) tubings.26 The specific activity of fluorine-18 
tracers is usually in the range of 56-112 GBq/µmol. Hence, it should be kept in mind that there is a 
considerable amount of fluorine-19 present in a batch of [18F]F- (for example 3.7 GBq corresponds to 
33-66 nmoles of fluorine for a specific activity of 56-112 GBq/µmol). To determine the effect of 
increasing amounts of fluorine on the chelation yield, increasing amounts of fluorine-19 (apart from 
the fluorine-19 present in 50 µL highly diluted (1/1000) [18F]F- solution) were added to a fixed 
amount of AlCl3 (40 nmoles) and H3L3 (150 nmoles). Figure 5B shows a decrease of labelling 
efficiency when higher amounts of fluorine-19 were added to the reaction mixture. This could be 
explained by the fact that not only {AlF}2+ is formed, but with increasing amounts of fluorine-19 also 
other species, such as {Al18/19F2}
+ and Al18/19F3 can potentially be formed which are less efficiently 
chelated by H3L3 and as a result the RCY drops.
27 The specific activity of fluorine-18 thus proves to be 
an important parameter for the Al18F chelation yield.  
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Figure 5: A: Comparative labelling efficiencies of H3L3 at different pH values (n=3) B: Effect of the 
amount of 19F- added to the reaction mixture on the RCY (%) of [18F]AlF-L3 (n=3)  
In another experiment, a fixed amount of 18F-fluoride spiked with 19F-fluoride (30 nmoles) was used 
and variable amounts of AlCl3 (20 nmoles to 320 nmoles) were added. Addition of more than 50 
nmoles of AlCl3 resulted in a significant drop of RCYs. Most likely AlOH-L3 is formed in these 
conditions and as a consequence there is less ligand available for chelation of {AlF}2+. The optimal 
H3L3 to Al
3+ molar ratio was found to be 3:1 (see Supporting information, Figure S10). 
3.5 Synthesis, radiosynthesis and preclinical evaluation of [18F]AlF-labelled Glu-NH-CO-NH-
Lys(Ahx)L3 
The best method to assess the in vivo stability and kinetic inertness of a chelate is to attach it to a 
suitable vector so that the complex remains in circulation for a longer period of time.15 The “naked” 
and negatively charged Al18F-L3 complex is cleared relatively fast from the body, and does not persist 
in vivo long enough to encounter challenge to its structural integrity. Therefore, as a proof of 
concept, the ligand H3L3 was derivatised and successfully conjugated with a hydrophilic urea-based 
inhibitor of PSMA, Glu-NH-CO-NH-Lys, to form Glu-NH-CO-NH-Lys(Ahx)L3 (see Supporting 
information, S9).18 The process of radiosynthesis and purification with preparative radio-HPLC was 
performed using a home-built remotely controlled system. Glu-NH-CO-NH-Lys(Ahx)L3 was labelled 
with {Al18F}2+ in a non-optimized yield of 25% (12 min 40 °C, pH 4.5). The batch (8.14 GBq) was 
produced and purified to a radiochemical purity higher than 98%, in 35 min (starting after elution of 
fluorine-18 from the anion exchange QMA cartridge). The specific activity was 27 GBq/µmol, 
calculated on the starting amount of Glu-NH-CO-NH-Lys(Ahx)L3. Analytical HPLC of the final product 
was performed and high resolution mass spectrometry (HRMS) analysis corroborated the identity of 
the radiotracer (see Supporting information, Figure S11). It was shown that the PSMA-binding 
fragment as such cannot bind the {Al18F}2+ core under the conditions tested (see Supporting 
information, Figure S12). [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 was stable (>95%) in saline at room 
temperature for at least three hours (see Supporting information, Figure S13). 
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Figure 6: Synthesis, Al18F-labelling, in vitro autoradiography on kidney slices, and in vivo 
biodistribution in healthy mice of [18F]AlF-labelled Glu-NH-CO-NH-Lys(Ahx)L3. Biodistribution (%ID/g) 
in healthy NMRI mice (n= 4 per time point) with or without coadministration of 2 mg/kg 2-PMPA 
(blocking agent) at 10 min or 60 min p.i. and autoradiography on kidney slices of healthy mice with 
(B) or without (A) blocking with 2-PMPA (100 µM).  
To assess the in vivo stability and to evaluate the distribution profile of the tracer, a biodistribution 
study was carried out in healthy mice (Figure 6). The compound demonstrated high in vivo stability, 
as no significant bone uptake was observed at 60 min p.i. (0.74 ± 0.07% ID/g). However, the 
hydrophilic tracer was cleared fast from plasma and PSMA negative tissue, therefore additional 
experiments with peptides that circulate longer in blood are needed to further evaluate the 
structural integrity of the [18F]AlF-L3 complex in vivo. Radio-iTLC-SG analysis of mouse urine samples 
60 min p.i. showed that >90% of activity was still present as an Al18F-complex and not as free 
fluorine-18 or {Al18F}2+(see Supporting information, Figure S14). The retention at 60 min p.i. in organs 
with reported high expression of PSMA such as kidneys (121± 11% ID/g) and spleen (4± 0.5% ID/g) 
was nearly completely blocked when the non-structural related inhibitor 2-
(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA) was coinjected to block PSMA-specific binding. 
These results indicate high affinity and specific binding of [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 for the 
PSMA receptor. The same effect was shown with in-vitro autoradiography on kidney slices of healthy 
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mice with or without blocking with 2-PMPA (Figure 6). The increased bone uptake at 60 min p.i. 
observed after coadministration of the blocking agent 2-PMPA is possibly the result of extended 
residence time in blood, which could indicate limited instability of the [18F]AlF-L3 complex in vivo. In 
conclusion, the first preclinical results of [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 look promising and this 
radiotracer will be further evaluated in mice bearing PSMA-positive tumors.  
4. CONCLUSIONS 
This study identified new chelators that allow efficient complexation of {Al18F}2+ using mild labelling 
conditions (temperature of 40 °C). These ligands display a less rigid structure than macrocyclic 
ligands such as NOTA and NODA, thus reducing the activation energy for the complexation reaction 
and consequently allowing low-temperature labelling. Optimal results were obtained at pH 4.5-5 and 
it has been shown that the specific activity of fluorine-18 proves to be an important parameter for 
the Al18F chelation yield. [18F]AlF-L3 complex demonstrated a stability in PBS and in rat plasma 
comparable to that of the previously reported Al18F-N-benzyl-NODA complex, up to 60 minutes. 
Although in vitro incubation in rat plasma showed slow decomposition, biodistribution of [18F]AlF-L3 
showed absence of bone uptake indicating that in vivo defluorination or demetalation if any, is 
limited. As a proof of concept, the ligand H3L3 was derivatised and successfully conjugated with a 
urea-based inhibitor of PSMA. [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 was produced with high 
radiochemical purity in 35 min. The compound demonstrated high in vivo stability, proven by the 
absence of significant bone uptake, and the first preclinical results in healthy mice look promising.  
In conclusion, the acyclic chelator H3L3 demonstrated to be a good lead candidate for labelling of 
heat-sensitive biomolecules with fluorine-18. However, there is still room for improvement regarding 
the stability of the [18F]AlF-L3 complex, so that the synthesis of improved derivatives is warranted. 
We are confident that this new class of AlF chelators may provide an efficient approach to label 
peptides and biomolecules with fluorine-18 at ambient temperature. 
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ABSTRACT 
 
Most methods for radiolabelling biomolecules with fluorine-18 are laborious and require multistep 
procedures with moderate overall labelling yields. The Al18F-labelling strategy involves chelation of 
aluminium mono[18F]fluoride ({Al18F}2+) in aqueous medium by a suitable chelator conjugated to a 
biomolecule. Although many previous studies demonstrated the versatility of the Al18F approach to 
radiolabel peptides, the approach has limited applicability for heat sensitive biomolecules due to 
high temperatures required for the complexation reaction (≥ 100 °C) when used with macrocyclic 
complexing agents such as NOTA and NODA. Therefore, we designed new restrained complexing 
agents (RESCA1-5) for application of the Al18F strategy at room temperature. Restrained complexing 
agent 1 (RESCA1) is an acyclic pentadentate ligand with an N2O3 coordinative set and this new 
chelator allows radiolabelling of heat-sensitive biomolecules via the Al18F-method in one 
radiolabelling step at moderate temperature. As a proof of concept, RESCA1 was conjugated to the 
heat-sensitive protein human serum albumin (HSA) and the construct was efficiently labelled with 
{Al18F}2+ at ambient temperature. [18F]AlF-RESCA1-HSA showed excellent stability and favourable 
properties for PET blood pool imaging applications. The new AlF chelator provides an efficient, 
generic approach to label heat-sensitive biomolecules with fluorine-18 for PET applications. 
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1. INTRODUCTION 
Positron emission tomography (PET) provides non-invasive, sensitive and specific imaging of 
biochemical and physiological phenomena in vivo, which can be used to study the function of cells, 
receptors, neurotransmitters, genes and drug pharmacokinetics.1 Among β+-emitting radioisotopes, 
the radiohalogen fluorine-18 is the most commonly used in PET due to its optimal chemical 
properties and almost ideal nuclear decay characteristics.2 The low maximum energy (0.635 MeV) of 
its positron emission enables high resolution images as a result of the short range tissue penetration 
prior to annihilation. The half-life of 109.8 min is short enough to avoid prolonged irradiation of 
subjects, yet still long enough to allow multistep synthesis, extended in vivo investigations and, 
permits commercial distribution to remote imaging centres without an on-site cyclotron.3  
The Al18F-labelling strategy involves chelation in aqueous medium of aluminium mono[18F]fluoride 
({Al18F}2+) by a suitable chelator conjugated to a biomolecule.4 Aluminium forms octahedral 
complexes, therefore a pentadentate ligand is desired, leaving one binding site open for the fluorine 
ion. The most frequently used chelator for Al18F-labelling is the pentadentate ligand 1,4,7-
triazacyclononane-1,4-diacetate (NODA).5 Although this macrocyclic chelator shows a lot of potential, 
the high temperature required for the complexation reaction (≥100 °C) is still the main shortcoming 
that limits widespread application of this radiolabelling approach.6 Therefore, an alternative chelator 
that eliminates the heating step is desired as it could result in a kit-based radiolabelling method. Kit 
preparation of 18F-labelled PET tracers has the potential to partially substitute current technetium-
99m tracers considering that (1) PET is a superior imaging technology over SPECT,7 (2) recent 
problems with availability of technetium-99m generators due to molybdenum-99 disruptions is 
affecting the continuity of patient care worldwide,8 and (3) growing availability of compact “dose-on-
demand” cyclotrons.9 
Recently, new polydentate ligands have been developed in our laboratory that can chelate {Al18F}2+ at 
moderate temperatures (≤40 °C). Successful labelling of two compounds, 2-[benzyl({2-
[bis(carboxymethyl)amino]ethyl})amino]acetic acid (H3L1) and 2-(benzyl(2-((carboxymethyl)(2-
hydroxybenzyl)amino)ethyl)amino)acetic acid (H3L3) was established (Figure 1).
10 These new 
chelators have less rigid structures, compared to NODA, reducing the activation energy required for 
complexation. Both H3L1 and H3L3 have excellent labelling properties but, unfortunately, Al
18F-L1 is 
not stable in vitro. On the other hand, Al18F-L3 showed good stability in rat plasma up to 2 h but 
suffers from decomplexation after longer time-periods. Hence, there is still room for improvement 
regarding the stability of these newly developed {Al18F}2+-chelator complexes. 
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Figure 1: Chemical structure of N-benzyl-NODA, H3L1, H3L3 and RESCA1-5 
The aim of the present study was to design new restrained complexing agents (RESCAs) which display 
a less rigid structure than the established macrocyclic AlF-ligands in order to reduce the activation 
energy of the complexation reaction. The area of improvement includes radiolabelling at moderate 
temperatures (≤40 °C), whilst maintaining sufficient in vivo stability. Novel chelators, RESCA1-5 
(Figure 1), have been synthesised and the {Al18F}2+-core chelation efficiency and the in vitro and in 
vivo stability of the corresponding fluorine-18 labelled chelates has been evaluated as such (i.e. 
without being conjugated to biomolecules). Furthermore, in order to gain a better understanding of 
the different factors influencing the formation and stability of the complex, we carried out more in-
depth experiments with ligand RESCA1. Labelling efficiency as a function of temperature, pH and 
[Al3+/ligand]-ratio was studied in detail. As a proof of concept and to evaluate the stability and kinetic 
inertness of the chelate in vivo, RESCA1 was conjugated to human serum albumin (HSA) and the 
conjugate was labelled with {Al18F}2+. 
2. MATERIALS & METHODS 
2.1 General 
All reagents and solvents were purchased from Sigma-Aldrich (Bornem, Belgium), Fluka (Bornem, 
Belgium), Fisher (Doornik, Belgium) or Acros Organics (Geel, Belgium). Fluorine-18 was produced on 
site using a cyclotron (IBA Cyclone 18/9, IBA, Louvain-la-Neuve, Belgium) by irradiation of H2
18O with 
18-MeV protons. Radioactivity was measured using an ionisation chamber based activity meter 
(Capintec Radioisotope Calibrator CRC-721, Ramsey, NJ, USA).  
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Determination of the molecular ion mass of various compounds was achieved using a Dionex 
Ultimate 3000 LC System (Thermo Fisher Scientific, Sunnyvale, USA) coupled in series to an ultra-high 
resolution time-of-flight mass spectrometer (TOF-HRMS, MaXis impact, Bruker, Bremen, Germany), 
equipped with orthogonal electrospray ionisation (ESI) interface. Acquisition and processing of data 
were conducted using HyStar and Compass DataAnalysis (version 3.2, Bruker), respectively. 
Calculated monoisotopic mass values were obtained using Compas IsotopePattern (version 3.2, 
Bruker). Thin layer chromatography (TLC) was used for rapid analysis of reaction mixtures. The TLC 
plates were silica-based (Silica gel 60 plates, Merck, Darmstadt, Germany).  
The synthesis and characterisation of compounds RESCA1-5 and RESCA-TFP is described in patent 
WO/2016/065435. Chemical structure elucidation was performed using proton-nuclear magnetic 
resonance spectrometry (1H-NMR) at 400 MHz, carbon-nuclear magnetic resonance spectrometry 
(13C-NMR) at 101 MHz and fluorine-nuclear magnetic resonance spectrometry (19F-NMR) at 376 MHz 
on a Bruker AVANCE 400 MHz spectrometer (5 mm probe, Bruker AG, Fällanden, Switzerland). 
Instant thin layer chromatography- silica gel (iTLC-SG) papers (Varian, Diegem, Belgium) were used 
with a mixture of acetonitrile and water (75:25, v/v) as the mobile phase. Autoradiography was 
performed using phosphor storage screens (super-resolution screen, Perkin Elmer, Waltham, USA). 
Screens were read in a Cyclone Plus system (Perkin Elmer) and analysed using Optiquant software 
(Perkin Elmer). 
2.2 Complexation of {Al18F}2+ 
2.2.1 {Al18F}2+solution  
[18F]F- was separated from [18O]H2O by trapping on a SepPak Light Accel plus QMA anion exchange 
cartridge (Cl- form; Waters, Milford, USA). The cartridge was washed with water (3 mL) and [18F]F- 
(148-333 MBq) was eluted with an aqueous solution of sodium chloride 0.9% (0.3 mL). The obtained 
[18F]F- solution (50 µl) was added to 22.5 µL of 2 mM aluminium chloride (AlCl3) in sodium acetate 
buffer (0.1 M, pH 4). The solution was incubated at room temperature (rt) for 5 min to form {Al18F}2+. 
2.2.2 Synthesis and purification of [Al18F]-complexes 
A solution of each ligand (1 mL, 150 µM) in sodium acetate buffer (0.1 M, pH 4) was added to a vial 
which contained a freshly prepared {Al18F}2+ solution. The closed vials were heated in an oil bath at 
different temperatures for 12 min and the radiochemical yields (RCYs) were determined by iTLC-SG. 
The resulting mixtures were purified using a Sep-Pak Plus Alumina-N-cartridge (Waters, pre-rinsed 
with an aqueous solution of sodium chloride 0.9% (5 mL)). After loading of the crude reaction 
mixture, the cartridge was eluted with an aqueous solution of sodium chloride 0.9% (3 mL). The 
eluate was collected and each of the purified [Al18F]-complexes was analysed using iTLC-SG and/or 
   Chapter III 
 
Page | 51  
radio-UPLC-HRMS (Acquity UPLC BEH C18 column, 1.7 µm, 2.1 mm x 150 mm, Waters) with gradient 
elution at a flow rate of 0.6 mL/min A: H2O B: ACN, 0-2 min 5% B, 2 to 8 min 5% B to 95% B, 8-10 min 
95% B, 10 to 12 min 95% B to 5% B). 
2.3 In vitro stability tests of [18F]AlF-RESCA1-5 in phosphate buffered saline (PBS) and rat 
plasma 
Al18F-complexes were synthesised and purified as described above by heating the mixtures at 40 °C 
for 12 min. A volume of 200 µL of each solution of purified [Al18F]-complex was added to PBS (1 mL, 
0.1 M pH 7.4) or rat plasma (1 mL). The mixtures were incubated at 37 °C and analysed by iTLC-SG at 
10, 30, 60, 120, 180 and 240 min after the start of the incubation. Plasma samples were denatured by 
addition of the plasma solution (50 µL) to acetonitrile (50 µL). The mixture was stirred and 
centrifuged (1300 g, 3 min). Finally the supernatant was analysed using iTLC-SG. 
2.4 [18F]AlF-RESCA1: additional experiments on labelling efficiency 
2.4.1 Influence of pH 
A solution of RESCA1 (1 mL, 150 µM) in sodium acetate buffer (0.1 M, pH 3, 3.5, 4, 4.5, 5, 5.5), 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (0.1 M; pH 6 or 6.5) or 
tris(hydroxymethyl)aminomethane hydrochloride (tris-HCl) buffer (0.1 M; pH 7.5 or 8) was added to 
different vials containing 50 µL (3.7 MBq) of a freshly prepared {Al18F}2+ solution. The mixtures were 
incubated at 25 °C and radiochemical yields were determined by iTLC-SG at 12 min after the start of 
the incubation (n= 3). The pH values of the reaction mixtures were verified after sufficient decay. 
2.4.2 Influence of the [Al3+/ligand] ratios 
An aqueous solution of [18F]F- (50 µL, 3.7 MBq) was added to 34, 23, 12, or 6 µL of 2 mM AlCl3 in 
sodium acetate buffer (0.1 M, pH 4.5). The solutions were incubated at rt for 5 min to form {Al18F}2+. 
A solution of RESCA1 (1 mL; 150, 75, 50, or 25 µM) in sodium acetate buffer (0.1 M, pH 4.5) was 
added. The mixtures were incubated at 25°C and radiochemical yields were determined by iTLC-SG at 
12 min after the start of the incubation (n=3). 
2.5 Biodistribution and microPET studies  
Quantification of radioactivity for biodistribution studies was performed using an automated gamma 
counter equipped with a 3-inch NaI(Tl) well crystal coupled to a multichannel analyser, mounted in a 
sample changer (Perkin Elmer 1480 Wizard 3q). Counts were corrected for background radiation, 
physical decay and counter dead time. 
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Animals were housed in individually ventilated cages in a thermo-regulated (~22 °C), humidity-
controlled facility under a 12h-12h light-dark cycle, with access to food and water ad libitum. All 
animal experiments were conducted according to the Belgian code of practice for the care and the 
use of animals, after approval from the university animal ethics committee. 
The biodistribution study of [18F]AlF-RESCA1 was carried out in healthy male Naval Medical Research 
Institute (NMRI) mice (body weight: 30-40 g) at 10 and 60 min post injection (p.i.) (n = 4/time point). 
Mice were injected with the [18F]AlF-RESCA1 complex (2 MBq) via a tail vein under anesthesia (2.5% 
isoflurane in O2 at 1 L/min flow rate) and sacrificed by decapitation at above specified time points. 
The biodistribution study of [18F]AlF-RESCA1-HSA was carried out in healthy female Wistar rats (body 
weight: 187-225 g) at 1 h, 3 h and 6 h p.i. (n = 4/time point). Rats were injected with the [18F]AlF-
RESCA1-HSA complex (2-7.5 MBq) via a tail vein under anesthesia (2.5% isoflurane in O2 at 1 L/min 
flow rate) and sacrificed by decapitation at above specified time points. Blood and major organs 
were collected in tared tubes and weighed. The radioactivity in blood, organs and other body parts 
was counted using the automated γ-counter. For calculation of total radioactivity in blood, bone and 
muscle, tissue mass was assumed to be, respectively, 7, 12 and 40% of the total body mass.11,12 
Results are presented as standardised uptake values (SUV). Blood data points in rats were fitted with 
a one component exponential equation to determine blood biological half-life. Small-animal whole-
body PET imaging was performed on rats using a FOCUSTM 220 microPET scanner (Concorde 
Microsystems, Knoxville, US) and PMOD software (v 3.2, PMOD Technologies, Zürich, Switzerland). 
2.6 Synthesis of RESCA1-HSA 
A solution of RESCA1-tetrafluorophenyl ester (RESCA1-TFP, 80 µL, 5.64 x 10-6 moles) in DMSO was 
added in a 15 molar excess to a solution of human serum albumin (1.5 ml, 3.7609 x 10-7 moles, CAF-
DCF, Brussels, Belgium) in 0.05 M sodium bicarbonate pH 8.6 and the mixture was incubated for 2 h 
at rt. The conjugate was purified by gel filtration (PD-10 desalting column, GE Healthcare Bio-Science 
AB, Uppsala, Sweden) and the concentration of RESCA1-HSA was determined spectrophotometrically 
at 280 nm.  
2.7 Radiosynthesis and purification of [18F]AlF-RESCA1-HSA 
[18F]fluoride was produced (3.9 GBq) and trapped on a SepPak Light Accel plus QMA anion exchange 
cartridge as described above. [18F]F- was eluted from the cartridge with an aqueous solution of 
sodium chloride 0.9% (0.3 mL) and the eluate was diluted with water (2.7 mL). [18F]F- solution (250 µl, 
1.25 GBq) was added to 25 µL of 2 mM aluminium chloride (AlCl3) in sodium acetate buffer (0.1 M, 
pH 4.5). The solution was incubated at rt for 5 min to form {Al18F}2+. A solution of RESCA1-HSA (0.5 
mL, 75 nmoles) in sodium acetate buffer (0.1 M, pH 4.6) was added to the freshly prepared {Al18F}2+ 
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solution and was incubated at ambient temperature (20-22 °C) for 12 min. After incubation, the 
mixture was purified by gel filtration on a disposable PD-10 column (GE Healthcare), equilibrated 
with phosphate buffered saline. Radiochemical identity and purity were assessed by size-exclusion 
chromatography on a Superdex 200 10/300 GL column (GE Healthcare) using sodium phosphate 
buffer (0.01 M, pH 7.4, 0.14 M NaCl), as eluent at a flow rate of 0.5 mL/min. UV detection of the 
eluate was performed at 280 nm. The identity of the main compound was confirmed using non-
radioactive HSA as reference material. 
3. RESULTS AND DISCUSSION 
The last years, a wide range of peptides have been labelled using the Al18F-method by several 
groups.13 Not only relative small peptides such as αvβ3 integrin-binding peptides, but also larger 
peptides, such as exendin-4 and affibodies, were successfully labelled with {AlF}2+. The first clinical 
study using a peptide labelled with fluorine-18 using this method was published in 2013.14 Although 
the macrocyclic chelators used in the published methods show a lot of potential, the high 
temperatures required for the complexation reaction (≥100 °C) is still a limitation for the widespread 
application of this radiolabelling approach. Therefore, the availability of a chelator that allows 
efficient chelation of {Al18F}2+ at moderate temperature (<40 °C) would be a major improvement. In 
an effort to develop such chelator, structural changes were investigated on promising pentadentate 
ligands, recently developed in our laboratory.10  
One of these recently developed chelators, H3L1, showed excellent chelation efficiency at rt (RCY 
≥90%). However, almost complete dissociation of the Al18F complex was observed after 2 h 
incubation in rat plasma. In contrast, [18F]AlF-L3 complex exhibited rat plasma stability comparable to 
that of Al18F-N-benzyl-NODA up to 60 minutes, but at later time points significant defluorination was 
observed. Moreover, prominent bone uptake was observed in microPET studies with Al18F-L3-PSMA, 
suggesting in vivo defluorination (chapter IV). Hence, there is still room for improvement regarding 
the stability of these {Al18F}2+-chelator complexes. 
3.1 Synthesis  
Brechbiel et al. reported that the incorporation of a trans-cyclohexyl moiety into the backbone of the 
ligand diethylenetriamine penta-acetic acid (DTPA) to form CyDTPA sterically hinders breakage of 
metal chelate rings.16 As a result, the 212Bi-complex with the ligand CyDTPA showed significantly 
increased stability in comparison with 212Bi-DTPA as such. We explored whether incorporation of a 
trans-cyclohexyl moiety into H3L1, to form restrained complexing agent 1 (RESCA1), would also 
increase steric rigidity of the AlF-complex, improving the orientation of the chelating groups and as a 
result improving the stability of the resulting AlF-complex. RESCA1 is an acyclic pentadentate ligand 
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with an N2O3 coordinative set and was efficiently synthesised in a three-step reaction starting from 
commercially available chemicals with an overall yield of 65%. The first results revealed that RESCA1 
was as efficient as H3L1 to chelate {Al
18F}2+, with high reactivity (RCY ≥85%) at rt (Figure 2). 
Encouraged by these promising results and in an attempt to broaden the range of chelators, we 
decided to develop more derivatives of RESCA1 with refined changes in the backbone (RESCA 2-5, 
Figure 1). RESCA2 is the “cis” derivative of RESCA1 (N-methyl instead of N-benzyl substituent) and 
RESCA3 has a trans-cyclohexenyl moiety in the backbone. RESCA4 and RESCA5 have a phenyl ring and 
trans-cyclopentyl moiety in the backbone, respectively.  
3.2 Complexation of {Al18F}2+ 
The novel chelators (RESCA1-5) were compared with H3L1 and N-benzyl-NODA for efficiency of 
{Al18F}2+ chelation and stability of the corresponding complexes. The ligands were incubated with 
{Al18F}2+ at different temperatures (from rt to 110 °C) for 12 min and the RCYs were determined by 
iTLC (Figure 2). It was observed that ligands RESCA1-5 showed efficient chelation of {Al18F}2+at all 
tested temperatures with RCYs higher than 60%. Chelators RESCA2 and RESCA4 displayed substantial 
increase of the RCY when the reaction was carried out at 40 °C as compared to room temperature 
(20-25 °C). The standard deviation on the results obtained with RESCA5 is relatively high, possibly 
indicating limited stability of the [18F]AlF-RESCA5 complex during analysis. 
 
Figure 2: Al18F-complexation efficiency of H3L1, RESCA1-5 and N-benzyl-NODA at different 
temperatures (150 nmoles ligand, 46 nmoles AlCl3, sodium acetate buffer 0.1 M pH 4.5, 12 min). X-
axis displays the reaction temperature, while the Y-axis displays the radiochemical yield as 
percentage of starting fluorine-18 radioactivity (H3L1, RESCA1-5: n=3 and N-benzyl-NODA: n=1) 
All studied metal complexes were successfully purified (to > 98% purity) using Sep-Pak Plus Alumina-
N-cartridges, following a previously reported procedure.17 RESCA5 however was obtained with a 
purity of only 93%, determined by iTLC. The purified Al18F-complexes were characterised with radio-
HPLC-HRMS. As derived from the molecular ion mass, the AlF-complexes with ligands RESCA1-5 all 
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have a negative charge. The complex Al19F-RESCA1 was prepared and identified with UPLC-HRMS and 
the structure of Al19F-RESCA1 was further confirmed with 1H- and 13C-NMR. 
3.3 In vitro stability of [18F]AlF-RESCA1-5 
Several factors are known to hamper the stability of an AlF-complex; (1) other metal ions (e.g. Fe2/3+ 
and Ca2+) readily present in plasma are able to compete with {AlF}2+ for binding to the chelator15, and 
(2) plasma proteins, such as the iron-binding blood plasma glycoprotein apo-transferrin, can 
potentially transchelate the {Al18F}2+ moiety out of the initial complex.18 The stability of [18F]AlF-L1, 
[18F]AlF-RESCA1-5 and [18F]AlF-N-benzyl-NODA in phosphate buffered saline (PBS) (0.1 M, pH 7.4) at 
37 °C and in rat plasma at 37 °C is presented in Figure 3. [18F]AlF-RESCA1 showed excellent stability in 
PBS and rat plasma, comparable to that reported for [18F]AlF-N-benzyl-NODA, for at least 4 hours. 
After 240 min of incubation, 88% and 91% of Al18F-RESCA1 was still intact in PBS and in rat plasma, 
respectively. The percentage of intact [18F]AlF-N-benzyl-NODA after 240 min was respectively 88% 
and 87% in PBS and in rat plasma. It seems that the incorporation of the trans-cyclohexyl moiety into 
the backbone of ligand H3L1 to form RESCA1 did not affect the reactivity to chelate {AlF}
2+ at room 
temperature. On the other hand, the kinetic inertness of the corresponding [18F]AlF-RESCA1 complex 
was drastically improved compared to H3L1, probably due to the increased steric rigidity and 
improved orientation of the chelating moieties. However, additional information on the structure of 
AlF-RESCA1 by X-ray diffraction studies is necessary to confirm above assumptions.  
The “cis” derivative RESCA2, not only showed lower RCYs compared to RESCA1, also the stability of 
the corresponding AlF-complex was negatively affected with, as expected, a faster degradation in rat 
plasma than in PBS. After 240 min of incubation, 62% and 37% of [18F]AlF-RESCA2 was intact in PBS 
and in rat plasma, respectively. These results confirm that the orientation of the chelating groups is 
not only of major importance for the reactivity but for the stability of the formed complex as well. 
The complex of Al18F with RESCA3 displayed good stability in PBS and rat plasma up to 60 minutes 
incubation. However, after 60 minutes the percentage of intact [18F]AlF-RESCA3 started to decrease 
slowly, indicating demetallation and/or defluorination. After 240 min of incubation, 52% and 36% of 
Al18F-RESCA3 was still intact in PBS and in rat plasma, respectively. This shows that small changes in 
the backbone (trans-cyclohexenyl ring instead of trans-cyclohexyl ring) seem to have a major effect 
on the stability of the formed complex. The instability of [18F]AlF-RESCA4 could be explained by the 
reduced electrophilic properties of the nitrogen atoms due to the presence of the phenyl ring. It 
seems that changing the trans-cyclohexyl ring into a trans-cyclopentyl ring (RESCA5) results in 
inferior stability, probably due to unfavourable orientation of the chelating groups. Small changes in 
the backbone of RESCA1 resulted in minor to major loss of stability of the corresponding {AlF}2+ 
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complexes and thus, RESCA1 is the lead candidate for radiolabelling heat-sensitive biomolecules via 
the Al18F-method. 
 
Figure 3: In vitro stability of Al18F-complexes in PBS and rat plasma. Stability of [18F]AlF-L1 (n=1), 
[18F]AlF-RESCA1-5 (n=3) and [18F]AlF-N-benzyl-NODA (n=1) in PBS and rat plasma at 37 °C. Almost 
complete decomplexation (0.2% intact tracer) of [18F]AlF-L1 in rat plasma is observed after 2 hours. 
[18F]AlF-RESCA1 shows excellent stability in rat plasma, comparable to that of the reported [18F]AlF-N-
benzyl-NODA, for at least 4 hours.  
Purification and quality control of radiolabelled peptides is usually performed with RP-HPLC in acidic 
conditions, e.g. using trifluoroacetic acid 0.1% m/v in the mobile phase (pH 2).19 However, metal 
complexes usually have lower stability at acidic pH.15 Therefore the stability of [18F]AlF-RESCA1 was 
determined in different buffers ranging from pH 2 to pH 8 and was found to be stable within this pH 
range. Mild degradation at the lowest investigated pH value (pH 2) was observed (91% and 88% was 
intact after 30 and 60 min, respectively). Consequently, an acidic buffer can be selected for HPLC 
purification and analysis of the [18F]AlF-RESCA1-constructs. 
3.4 In vivo stability of [18F]AlF-RESCA1 
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To further explore the in vivo stability and evaluate the biodistribution of [18F]AlF-RESCA1, a 
biodistribution study in NMRI mice was performed and results were compared to the biodistribution 
of free {Al18F}2+ (Figure 4). As expected, there was high bone uptake for {Al18F}2+ and the excretion 
pathway of the metal fragment was mainly via the renal route. In comparison, the biodistribution of 
[18F]AlF-RESCA1 demonstrated high in vivo stability, as no significant bone uptake, which serves as an 
indicator of fluorine-18 release, was observed.  
 
Figure 3: Biodistribution of {Al18F}2+ and [18F]AlF-RESCA1 after iv injection in healthy male NMRI mice 
at 10 and 60 min p.i. (n=4/group, 30-40 g). Results are presented as percentage of injected dose 
(%ID). For calculation of total radioactivity in blood, bone and muscle, tissue mass was assumed to be, 
respectively, 7, 12 and 40% of the total body mass. High bone uptake is observed for {Al18F}2+ and its 
excretion pathway is mainly via the renal route. Biodistribution of [18F]AlF-RESCA1 shows high in vivo 
stability, since no significant bone uptake, which serves as an indicator of fluorine-18 release, was 
observed. The major fraction of activity at 60 min p.i. is observed in the liver and intestines which 
indicates hepatobiliary clearance of [18F]AlF-RESCA1. 
The major fraction of activity at 60 min p.i. was observed in the liver and intestines due to 
hepatobiliary clearance of [18F]AlF-RESCA1. It has been postulated that due to the incorporation of 
the rather lipophilic trans-cyclohexyl building block, the radiolabelled ligand follows the 
enterohepatic pathway. Moreover, due to the negative charge, [18F]AlF-RESCA1 is possibly a 
substrate for organic anion-transporting polypeptides (OATP) in hepatocytes for excretion in bile. In 
comparison, [18F]AlF-N-benzyl-NODA was also rapidly cleared from the blood, showed a low bone 
uptake, but was mainly excreted via the renal route. It is difficult to predict whether the excretion 
pathway of the metal chelate as such will eventually influence the excretion of corresponding 
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biomolecule conjugates. Certainly, this effect needs to be taken into account when radiolabelling 
relatively small molecules, but the impact of this effect on larger biomolecules, such as HSA, is 
expected to be minimal and requires further evaluation. 
3.5 Parameters influencing the complexation yield 
The pH of the labelling buffer is critically important for the formation of {Al18F}2+-chelates. If the pH is 
too low, the carboxyl groups are protonated which will hinder the coordination of aluminium and 
moreover the dominant fluoride species in equilibrium is likely to be HF.20 The optimal pH range for 
labelling RESCA1 was found to be between 4.5 and 5, but even at pH 5.5-6 high RCYs were still 
observed, indicating that also acid-sensitive proteins can be labelled with the proposed method 
(Figure 4A). At even higher pH values, aluminium tends to form insoluble aluminium hydroxide. This 
results in lower RCYs and therefore it is of great importance that the pH of the reaction mixture is 
carefully controlled by a suitable buffer. Noteworthy is the fact that not all buffers are compatible 
with radiolabelling via the AlF-method. Examples of non-compatible buffers are citrate (pKa1=3.13, 
pKa2=4.76, and pKa3=6.39) and phosphate buffers (pKa1=2.15, pKa2=7.09, and pKa3=12.32). Citrate 
also forms a complex with aluminium ions whereas phosphates precipitates aluminium ions. For this 
reason a 2-(N-morpholino)ethanesulfonic acid (MES) buffer was used for an accurate estimation of 
the labelling efficiency at pH 6-6.5.  
Figure 4: A: Comparative labelling efficiencies of RESCA1 at different pH values (n=3) B: Effect of the 
amount of AlCl3 and RESCA1 added to the reaction mixture on the RCY (%) of [
18F]AlF-RESCA1 (n=3)  
Another critical parameter for efficient labelling is the 18/19F--to-Al3+ ratio and the Al3+-to-ligand ratio 
in the reaction mixture. We demonstrated previously with the chelator H3L3 that the specific activity 
of fluorine-18 proves to be an important parameter for the Al18F chelation yield.10 This could be 
explained by the fact that not only {AlF}2+ is formed, but with increasing amounts of fluorine-19 also 
other species, such as {Al18/19F2}
+ and Al18/19F3 can potentially be formed which are less efficiently 
chelated by the ligands, resulting in lower RCYs. The influence of the [Al3+] to [RESCA1] ratio is shown 
in Figure 4B. The RCYs obtained when using 150 nmoles of RESCA1 were 90 ± 6%, independently of 
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the AlCl3 concentration. When using 75 nmoles of RESCA1, the RCY was only 29 ± 5% with 69 nmoles 
of AlCl3 and reached a maximum of 85 ± 6% at 23 nmoles of AlCl3. When using 25 nmoles of RESCA1, 
the RCY decreased to 8 ± 6% with 69 nmoles of AlCl3, whereas the lowest concentration of AlCl3 
resulted in the highest RCY of 53.7 ± 0.7%. With an excess of Al3+ relative to RESCA1, most likely 
AlOH-RESCA1 is formed and as a consequence there is less ligand available for chelation of {Al18F}2+. 
The optimal ligand to Al3+ molar ratio was found to be 3:1. 
3.6 Labelling of human serum albumin (HSA) 
The best method to assess the in vivo stability and kinetic inertness of a chelate is to attach it to a 
suitable vector that is slowly cleared from plasma and thus remains in circulation for a long period of 
time. The “naked” and negatively charged [18F]AlF-RESCA1 complex is cleared relatively fast from the 
plasma, and does not persist in vivo in plasma long enough to challenge its structural integrity. To 
demonstrate the generic applicability of the proposed chelator for labelling of thermolabile 
biomolecules and to evaluate the kinetic inertness of the chelate in vivo, the bifunctional chelator 
RESCA1-TFP was conjugated via the amino group of the side-chain of lysines to the heat-sensitive 
protein HSA (Figure 5). HSA (66.5 kDa) is a globular protein with a primary sequence made up of 585 
amino acid residues and is the most abundant protein in human plasma (3.5-5 g/dL).21 It accounts for 
about 70% of the plasma colloid osmotic pressure. Albumin binds and carries a great variety of 
hydrophobic molecules such as metals, fatty acids, drugs and metabolites. Its high solubility, stability 
and plasma half-life of approximately 16-18 h, make HSA the ideal vector for PET blood pool imaging 
applications.22  
RESCA1-TFP ester was efficiently conjugated to HSA providing RESCA1-HSA with a chelator-to-protein 
ratio of 3, estimated by ESI-TOF-HRMS analysis. RESCA1-HSA was labelled with {Al18F}2+ in good RCY 
at mild conditions (>70%, 12 min, 25 °C, pH 4.5). A batch of [18F]AlF-RESCA-HSA (1.1 GBq) was 
produced and purified to a radiochemical purity higher than 95%, in less than 30 min after elution of 
fluorine-18 from the anion exchange QMA cartridge. [18F]AlF-RESCA-HSA showed excellent stability in 
vitro. After 4 h incubation in rat plasma at 37 °C, 91% of the Al18F-tracer was still intact as assessed by 
size exclusion chromotography.  
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Figure 5: Synthesis and radiolabelling of RESCA1-HSA with {Al18F}2+. RESCA1-TFP ester was conjugated 
to HSA providing RESCA1-HSA with a chelator-to-protein ratio of 3, estimated by ESI-TOF-HRMS 
analysis. Al18F-RESCA-HSA was prepared in high RCY (>70%) and purity (>95%) in less than 30 min 
(starting after elution of fluorine-18 from the anion exchange QMA cartridge). RCP = radiochemical 
purity 
Biodistribution of [18F]AlF-RESCA1-HSA in rats showed high retention in blood with 11.8 ± 0.6% ID/g, 
10.1 ± 0.7% ID/g and 8.0 ± 0.1% ID/g at 1 h, 3 h and 6 h, respectively, from which the blood biological 
half-life was calculated to be 8.6 h. Bone is a highly vascular tissue, this might explain the observed 
bone uptake at 1h p.i. However, only minor increase in bone uptake was observed over time, 
indicating high in vivo stability of the Al18F-labelled protein conjugate. Moreover, [18F]AlF-RESCA-HSA 
showed favourable properties for PET blood pool imaging applications. A whole body PET image of a 
healthy rat 180 min after intravenous injection of [18F]AlF-RESCA1-HSA is shown in Figure 6. The 
ventricles of the heart and the peripheral vasculature are well visualised. Other organs can be 
observed but retain lower concentrations of fluorine-18 than the central vasculature. The tissue 
concentrations in the microPET study are consistent with the biodistribution results at comparable 
times. We successfully labelled for the first time a heat-sensitive biomolecule via the Al18F-method in 
one radiolabelling step. Moreover [18F]AlF-RESCA1-HSA showed excellent stability and favourable 
properties for PET blood pool imaging applications. 
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Figure 6: Biodistribution of [18F]AlF-RESCA1-HSA in rats at 1 h, 3 h and 6 h p.i. (n=4/group; 187 g-225 
g) and whole-body PET image of a healthy rat 180 min after intravenous injection of [18F]A8F-RESCA1-
HSA. Results are presented as percentage of standardised uptake values (SUV). For calculation of 
total radioactivity in blood, bone and muscle, tissue mass was assumed to be, respectively, 7, 12 and 
40% of the total body mass. Blood data points were fitted with a one component exponential 
equation: y = 6,0233e-0,08x; R² = 0,9689, blood t1/2= 8.66 h. 
4. CONCLUSIONS 
Fluorine-18 is currently the radionuclide of choice for PET because of its favourable nuclear decay 
characteristics and ease of production. Clinicians in the molecular imaging community are not only 
interested in in using small organic molecules but also high molecular weight biomolecules and 
peptides are increasingly being considered for use as PET-radiopharmaceuticals.23 However, the 
incorporation of fluorine-18 into heat-sensitive and complex biomolecules creates substantial 
challenges for radiochemists. In this study we identified new restrained complexing agents (RESCA1-
5) that allow efficient complexation of {Al18F}2+ using mild labelling conditions. RESCA1 is an acyclic 
pentadentate ligand with an N2O3 coordinative set of donor atoms and was synthesised starting from 
commercially available chemicals. RESCA1 as such showed excellent labelling properties and its Al18F-
complex demonstrated high in vitro and in vivo stability. Small changes in the backbone of RESCA1, to 
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form RESCA2-5, resulted in minor to major loss of stability of the corresponding Al18F complexes and 
thus, RESCA1 was found to be the most promising lead candidate for radiolabelling heat-sensitive 
biomolecules via the Al18F-method. To demonstrate the generic applicability of the proposed method 
we successfully labelled the heat-sensitive biomolecule HSA at ambient temperature with {Al18F}2+ 
with high radiochemical purity in less than 30 minutes.  [18F]AlF-RESCA1-HSA showed excellent in 
vitro and in vivo stability. Moreover, [18F]AlF-RESCA1-HSA showed favourable properties for PET 
blood pool imaging applications. This new optimised radiolabelling method may have a great impact 
on PET radiochemical space as it could stimulate a rapid development of new fluorine-18 labelled 
heat-sensitive biomolecules. 
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ABSTRACT 
 
Prostate-specific membrane antigen (PSMA) is overexpressed in a majority of primary and metastatic 
prostate cancer patients and is a promising target for specific prostate cancer imaging and therapy. 
We have developed two new Al18F-labelled urea-based PSMA inhibitors, [18F]AlF-PSMA-NODA-MPAA 
and [18F]AlF-PSMA-RESCA1. Here we describe the preclinical evaluation of these tracers and the 
results with the new radioligands were compared with those of [18F]AlF-PSMA-L3 and [68Ga]Ga-
HBEDD-CC-PSMA, currently the most widely used PSMA-ligand. [18F]AlF-PSMA-NODA-MPAA and 
[18F]AlF-PSMA-RESCA1 were successfully produced with high yields and radiochemical purity in less 
than 30 min. Both compounds showed improved stability compared to [18F]AlF-PSMA-L3. Cell uptake 
and internalisation experiments with LNCaP (PSMA+) and PC-3 (PSMA-) cells revealed similar specific 
internalisation and cell accumulation for [18F]AlF-PSMA-RESCA1 and [68Ga]Ga-PSMA-HBED-CC. In 
contrast, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-L3 showed considerable lower uptake in 
LNCaP cells. All tracers were cleared fast from plasma and PSMA-negative tissue mainly by the 
kidneys but also hepatobiliary excretion was observed for [18F]AlF-PSMA-RESCA1. High specific 
accumulation of all tracers was observed in PSMA-expressing organs and PSMA+ LNCaP tumours. 
Autoradiography on human prostate tumour tissue demonstrated specific binding of all tested 
tracers to the human PSMA receptor. 
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1. INTRODUCTION 
Prostate cancer is the second most commonly diagnosed cancer among men worldwide.  Despite 
advances in surgical technique (radical prostatectomy), radiotherapy and brachytherapy, initial 
curative therapy fails in a significant proportion of men with prostate cancer.1 In men with 
biochemical failure, elevated prostate specific antigen (PSA) levels are observed after initial therapy 
indicating local recurrence of the disease and/or metastasis. In this context imaging techniques such 
as PET/CT or PET/MRI can play an important role in (re)staging and monitoring of patients with 
prostate cancer, especially where the disease has spread beyond the prostate gland.2 
[18F]Fluorocholine and [11C]choline are still considered the most validated tracers for detection of 
recurrent prostate cancer, however both suffer from poor sensitivity at low PSA levels.3 Prostate-
specific membrane antigen (PSMA), a transmembrane folate hydrolase, is overexpressed in a 
majority of primary and metastatic prostate cancer patients and is a promising target for specific 
prostate cancer imaging and therapy. The first widely used radiotracer to image the disease was the 
111In-labelled monoclonal antibody 7E11 (ProstaScintTM) that targets PSMA.4 However, ProstaScintTM 
is a technically demanding agent to administer because imaging can only be performed four to six 
days after administration of the agent, necessitating a second visit by the patient. More recently 
radiolabelled inhibitors of PSMA, bearing Glu-NH-CO-NH-Lys as a pharmacophore, showed the ability 
to image PSMA expressing tumors.5 Currently, [68Ga]Glu-NH-CO-NH-Lys-(Ahx)-[Ga-N,N’-bis[2-
hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N’-diacetic acid] ([68Ga]Ga-PSMA-HBEDD-CC), is 
the most widely used PSMA-ligand (Figure 1).6 This urea based PSMA inhibitor demonstrates 
excellent pharmacokinetics as well as stability in vivo, leading to its clinical applications worldwide for 
imaging of prostate cancer.7 Moreover, in patients with a low, rising PSA level, [68Ga]Ga-PSMA-
HBEDD-CC demonstrated a significantly higher detection rate for recurrent prostate cancer than 
[18F]fluorocholine and [11C]-choline.3 In conclusion, [68Ga]Ga-PSMA-HBEDD-CC PET/CT can be 
considered as an effective imaging tool for early detection of prostate cancer recurrence.  
However, for PET imaging, fluorine-18 (t1/2: 109.8 min) is the radionuclide of choice because of its 
favourable decay properties (~ 97% ß+-emission, 635-keV maximum positron energy), low β+-
trajectory (< 2 mm in water), small atom size and moreover, it is readily produced in large quantities 
(>400 GBq/batch) with a cyclotron. In contrast, gallium-68 (t1/2: 68 min) is a generator-based 
radionuclide that does not require an on-site cyclotron. Only limited amounts of radiotracer can be 
produced during one production (typically up to 1500 MBq). For PET tracers that are to be 
administered in a large number of patients, the relative small batch size can cause extended waiting 
lists for patients or require repeated productions with increased production costs. In contrast, the 
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half-life and multi-curie production of fluorine-18 allows multi-dose production and transportation of 
18F-based radiotracers to remote hospitals which is more challenging with 68Ga-based radiotracers.  
Chen and colleagues reported 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-
ureido)-pentanedioic acid ([18F]DCFPyL) as a promising 18F-labelled urea-based PSMA inhibitor for 
imaging of prostate cancer (Figure 1). The first clinical trials indicate that [18F]DCFPyL PET/CT provides 
high image quality and visualises small prostate lesions with excellent sensitivity.8 However, more 
clinical trials are needed to prove its superiority above [68Ga]Ga-PSMA-HBEDD-CC and the multi-step 
radiosynthesis is rather complex, which might limit its worldwide application.  
 
Figure 1: Chemical structures of [68Ga]Ga-PSMA-HBEDD-CC, [18F]AlF-PSMA-L3 and [18F]DCFPyL 
A promising approach for 18F-labelling of biomolecules consists of chelation of {Al18F}2+ by 
biomolecules conjugated to a chelator in aqueous environment. This methodology is promising in 
view of its potential to evolve to a simple “kit” type preparation. Recently, restrained complexing 
agent 1 (RESCA1), an acyclic pentadentate ligand able to complex {Al18F}2+ efficiently at 25 °C, was 
developed in the Laboratory of Radiopharmacy (Chapter III). Here we describe the preclinical 
evaluation of two new Al18F-labelled urea-based PSMA inhibitors, [18F]AlF-PSMA-NODA-MPAA and 
[18F]AlF-PSMA-RESCA1, to assess the influence of the used chelator on the prostate cancer PET-
imaging properties. Moreover, the results were compared with those of the established radiotracer 
[68Ga]Ga-PSMA-HBEDD-CC and the reported tracer [18F]AlF-Glu-NH-CO-NH-Lys(Ahx)L3 ([18F]AlF-
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PSMA-L3, Figure 1), which was previously developed in the Laboratory of Radiopharmacy (Chapter 
II).9 
2. MATERIALS AND METHODS 
2.1 General 
All reagents and solvents were purchased from Sigma-Aldrich (Bornem, Belgium), Fluka (Bornem, 
Belgium), Fisher (Doornik, Belgium) or Acros Organics (Geel, Belgium). Fluorine-18 was produced on 
site using a cyclotron (IBA Cyclone 18/9, IBA, Louvain-la-Neuve, Belgium) by irradiation of H2
18O with 
18-MeV protons. Radioactivity was measured using an ionisation chamber based activity meter 
(Capintec Radioisotope Calibrator CRC-721, Ramsey, NJ, USA).  
Determination of the molecular ion mass of various compounds was achieved using a Dionex 
Ultimate 3000 LC System (Thermo Fisher Scientific, Sunnyvale, USA) coupled in series to an ultra-high 
resolution time-of-flight mass spectrometer (TOF-HRMS) (MaXis impact, Bruker, Bremen, Germany), 
equipped with orthogonal electrospray ionisation (ESI) interface. Acquisition and processing of data 
were conducted using HyStar and Compass DataAnalysis (version 3.2, Bruker), respectively. 
Calculated monoisotopic mass values were obtained using Compas IsotopePattern (version 3.2, 
Bruker). Prostate tumour slices (LNCaP and PC-3), and slices from human prostate tissue were 
obtained using a cryotome (Shandon Cryotome FSE, Thermo Fisher Scientific). Slices (20 µm) were 
cut at a temperature between -15 °C and -18 °C and stored at -20 °C. The use of human tissue was 
approved by the ethical committee from UZ Leuven. (Study S54424: collection of human prostate 
tissue). Preparative high performance liquid chromatography (prep-HPLC) was carried out with a 
system consisting of a Merck-Hitachi L-6200 pump and an XTerra preparative C18 10 µm 10 mm x 
250 mm column (Waters, Milford, USA). The mobile phase consisted of a gradient of water and 
acetonitrile, eluted at a flow rate of 5 mL/min. The eluate was analysed for its UV absorbance (Merck 
Hitachi L-4200 UV-VIS detector) at 254 nm. 
ITLC-SG papers (Varian, Diegem, Belgium) were developed in an elution chamber using a mixture of 
acetonitrile and water (75:25, v/v). Autoradiography was performed using phosphor storage screens 
(super-resolution screen, Perkin Elmer, Waltham, USA). Screens were read in a Cyclone Plus system 
(Perkin Elmer) and analysed using Optiquant software (Perkin Elmer). 
Analytical radio-HPLC (XBridge C18 column, 3.5 μm, 3.0 mm x 100 mm, Waters, Milford, USA) was 
performed using gradient elution at a flow rate of 0.8 ml/min. Method pH 2: Solvent A (H2O, 0.1% 
TFA) and solvent B (acetonitrile, 0.1% TFA). The elution gradient was 95% A to 5% A over 0-30 min. 
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Method pH 7.4. Solvent A (phosphate buffered saline (PBS) 0.1M, pH 7.4) and solvent B (acetonitrile). 
The elution gradient was 100% A to 50% A over 0-30 min.  
2.2 Synthesis of PSMA-NODA-MPAA and PSMA-RESCA1 
2.2.1 Synthesis of NO2AtBu-MPAA 
A solution of di-tert-butyl 2,2'-(1,4,7-triazacyclononane-1,4-diyl)diacetate ( 0.100 g, 0.28 mmoles, 
NO2AtBu, Chematech, Dijon, France) in anhydrous acetonitrile (5 ml) was slowly added to a solution 
of 4-(bromomethyl)phenylacetic acid (0.25 mmoles) in anhydrous acetonitrile (3 ml). The mixture 
was allowed to stir at 0 °C and after two hours K2CO3 (0.20 mmoles) was added. Afterwards, the 
mixture was allowed to stir at room temperature overnight. The solution was filtered and the solvent 
removed under vacuum. The obtained oil was purified, using flash chromatography (Reveleris® X2 
Flash Chromatography System, Reveleris 40 g, C18 column (Grace, Deerfield, US)) equipped with an 
evaporative light scattering detector and UV detector (254 nm), and the following method. Solvent A 
(water) and solvent B (acetonitrile), flow rate 28 ml/min. The elution gradient was 100% A to 20% A 
over 0-12 min. Afterwards, the solvent was evaporated under reduced pressure affording NO2AtBu-
NODA-MPAA (56 mg, 40% yield). HRMS (ESI): Calcd. for C27H43N3O6 [M+H
+] 506.3225 ; found 
506.3261.    
2.2.2 Synthesis of PSMA-NODA-MPAA 
To a solution of Glu-NH-CO-NH-Lys(Ahx)tBu (72.6 mg; 0.12 mmoles, synthesis is decribed in 
supplemental information Chapter II) in dichloromethane (23 ml) were successively added N,N-
diisopropylethylamine (63.2 μL; 0.36 mmoles), O-(N-Succinimidyl)-N,N,N′,N′-tetramethyluronium 
tetrafluoroborate (TSTU) (91 mg; 0.30 mmoles) and NO2AtBu-NODA-MPAA (73.5 mg; 0.15 mmoles). 
The mixture was stirred at rt overnight. The solvent was then evaporated under reduced pressure 
and the concentrate was diluted with a mixture of water/acetonitrile (50:50, 1 ml) and purified by 
preparative RP-HPLC using the following method. Solvent A (water) and solvent B (acetonitrile), flow 
rate 5 ml/min. The elution gradient was 80% A to 20% A over 0-30 min After HPLC purification, the 
compound was stirred in trifluoroacetic acid (2 mL) at rt for 12 h and the deprotection was 
monitored using LC-MS. Afterwards the solvent was evaporated under reduced pressure affording 
PSMA-NODA-MPAA (35.2 mg, 36% yield). HRMS (ESI): Calcd. for C37H57N7O13 [M+H
+] 808.4087; found 
808.4093 
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2.2.3 Synthesis of PSMA-RESCA1 
To a solution of Glu-NH-CO-NH-Lys(Ahx)tBu (72.3 mg; 0.12 mmoles) in dichloromethane (3 ml) were 
successively added N,N-diisopropylethylamine (41.5 μL; 0.238 mmoles), O-(N-Succinimidyl)-
N,N,N′,N′-tetramethyluronium tetrafluoroborate (TSTU) (90 mg; 0.299 mmoles) and di-tert-butyl 2,2'-
(((1R,2R)-2-((2-(tert-butoxy)-2-oxoethyl)(4-(2-oxo-2-(2,3,5,6-25 
tetrafluorophenoxy)ethyl)benzyl)amino)cyclohexyl)azanediyl)diacetate (64 mg; 0.12 mmoles, 
RESCA1tBu-AA, synthesis is described in patent WO/2016/065435). The mixture was stirred at rt 
overnight. The solvent was then evaporated under reduced pressure and the concentrate was 
diluted with a mixture of water/acetonitrile (50:50, 1 ml) and purified by preparative RP-HPLC using 
the following method. Solvent A (water) and solvent B (acetonitrile), flow rate 5 ml/min. The elution 
gradient was 80% A to 20% A over 0-30 min. After HPLC purification, the compound was stirred in 
trifluoroacetic acid (2 mL) at rt for 12 h. The deprotection was monitored using LC-MS. Afterwards 
the solvent was evaporated under reduced pressure affording PSMA-RESCA1 (10.5 mg, 10% yield). 
HRMS (ESI): Calcd. for C39H58N6O15 [M+H
+] 851.4033; found 851.4062 
2.3 Remotely controlled radiosynthesis and purification of [18F]AlF-PSMA-RESCA1 and [18F]AlF-
PSMA-NODA-MPAA 
[18F]F- was separated from [18O]H2O by trapping on a SepPak Light Accel plus QMA anion exchange 
cartridge (Cl- form; Waters). The cartridge was washed with water (3 mL) and [18F]F- was eluted from 
the cartridge with an aqueous solution of sodium chloride 0.9% (0.3 mL). [18F]F- was added to 5 µl of 
20 mM (100 nmoles) aluminium chloride (AlCl3) in sodium acetate buffer (0.1 M, pH 4.5). The 
solution was incubated at rt for 5 min to form {Al18F}2+. A solution of PSMA-RESCA1 or PSMA-NODA-
MPAA (115 µl, 2.58 mM) in sodium acetate buffer (0.1 M, pH 4.5) was added and the reactor was 
heated at rt (20-25°C) or 110°C respectively for 12 min. After dilution with water (0.5 mL), the crude 
reaction mixture was purified with HPLC (XBridge C18 column, 5 µm, 4.6 mm x 150 mm, Waters) using 
the following method. Solvent A (ammonium acetate 0.05M pH 5.5) and solvent B (EtOH), flow rate 1 
ml/min. The elution gradient was 100% A to 80% A over 0-25 min. UV detection of the eluate was 
performed at 254 nm. Identification of the [Al18F]-complexes was done by radio-LC-HRMS (Acquity 
UPLC BEH C18 column, 1.7 µm, 2.1 mm x 150 mm, Waters. 0.6 mL/min A: H2O B: ACN,  0-2 min 5% B, 
2 to 8 min 5% B to 95% B, 8-10 min 95% B, 10 to 12 min 95% B to 5% B). 
2.4 Stability tests of [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-RESCA1 in rat plasma 
A volume of 200 µL of radiotracer solution was added to freshly prepared rat plasma (1 mL). The 
mixtures were incubated at 37 °C and analysed by iTLC-SG at 10, 30, 60 and 180 min after the start of 
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the incubation. Plasma samples were denatured by addition of the plasma solution (50 µL) to 
acetonitrile (50 µL). The mixture was stirred and centrifuged (1300 g, 3 min). Finally the supernatant 
was analysed using iTLC-SG.  
2.5 Internalisation experiments 
Internalisation experiments were performed using a protocol described by Eder et al. with some 
minor modifications.6 LNCaP or PC-3 cells (200.000/well) were seeded in 24-well cell culture plates 
and incubated at 37 °C for 24 h. After washing with PBS, the cells were incubated with radiolabelled 
compounds [68Ga]Ga-PSMA-HBEDD-CC, [18F]AlF-PSMA-NODA-MPAA, [18F]AlF-PSMA-RESCA1 or 
[18F]AlF-PSMA-L3 for 45 min at 37 °C or at 4 °C. To determine specific cell accumulation, cells were 
blocked using the PSMA inhibitor 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA, Tocris 
Bioscience, Avonmouth, UK) to a final concentration of 100 µM. After 45 min, cells were washed 
three times with 0.250 mL of ice-cold PBS. Cells were incubated twice with 0.5 mL glycine-HCl in PBS 
(50 mM, pH 2.8) for 5 min at rt to remove radioactivity bound on the surface of the cells. The cells 
were washed again three times with ice-cold PBS and lysed using 0.250 mL lysis buffer (reagent A100, 
Chemometic, Allerod, Denmark). After 5 min incubation, 0.250 mL neutralisation buffer (reagent B, 
Chemometic) was added to raise the pH and avoid DNA degradation. The surface-bound and 
internalised fractions were counted using an automated gamma counter equipped with a 3-inch 
NaI(Tl) well crystal coupled to a multichannel analyser, mounted in a sample changer (Perkin Elmer 
1480 Wizard 3q). Counts were corrected for background radiation, physical decay and counter dead 
time. The amounts of cells per well were counted using an automated counting device 
(NucleoCounter® NC-200™, Chemometic) and results were expressed as percentage of applied 
radioactivity bound to 106 cells. Data are expressed as mean ± SD (n=3). 
2.6 Biodistribution and µPET studies  
Animals were housed in individually ventilated cages in a thermo-regulated (~22 °C), humidity-
controlled facility under a 12h-12h light-dark cycle, with access to food and water ad libitum. All 
animal experiments were conducted according to the Belgian code of practice for the care and the 
use of animals, after approval from the university animal ethics committee. 
The biodistribution studies of [68Ga]Ga-PSMA-HBEDD-CC, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-
PSMA-RESCA1 were carried out in healthy male Naval Medical Research Institute (NMRI) mice (body 
weight: 30-40 g) at 10 and 60 min post injection (p.i.) (n = 4/time point). Mice were injected with 2 
MBq [68Ga]Ga-PSMA-HBEDD-CC, Al18F-PSMA-NODA-MPAA or Al18F-PSMA-RESCA1 with or without co-
administration of 2 mg/kg 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA) via a tail vein under 
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anesthesia (2.5% isoflurane in O2 at 1 L/min flow rate) and sacrificed by decapitation at above 
specified time points. Blood and major organs were collected in tared tubes and weighed. 
Quantification of radioactivity in blood, organs and other body parts was performed using an 
automated gamma-counter equipped with a 3-inch NaI(Tl) well crystal coupled to a multichannel 
analyser, mounted in a sample changer (Perkin Elmer 1480 Wizard 3q). Counts were corrected for 
background radiation, physical decay and counter dead time. For calculation of total radioactivity in 
blood, bone and muscle, tissue mass was assumed to be, respectively, 7, 12 and 40% of the total 
body mass.10,11 Results are presented as percentage of injected dose (%ID) or %ID/g.  
10 X 106 cells of either LNCaP or PC-3 in 50% Matrigel (VWR, Radnor, US) were subcutaneously 
inoculated into the right shoulder of 7- to 8-week-old BALB/c nu/nu mice (body mass: 20-25 g) 
obtained from Janvier (Le Genest-Saint-Isle, France). The tumors were allowed to grow for 4 to 5 
weeks until approximately 0.5 to 0.75 cm3 in size. Small animal whole-body PET imaging on mice was 
performed using a FOCUSTM 220 microPET scanner (Concorde Microsystems, Knoxville, US). Prior to 
PET imaging, mice were anesthetised and kept under anesthesia throughout the whole procedure 
using 2.5% isoflurane in oxygen (2 L/min). Animals were injected intravenously with [68Ga]Ga-PSMA-
HBEDD-CC (6 MBq), [18F]AlF-PSMA-NODA-MPAA (11 MBq), [18F]AlF-PSMA-RESCA1 (11 MBq) or 
[18F]AlF-PSMA-L3 (11 MBq) and scanned dynamically for 60 min. Time activity curves (TACs) were 
generated for liver, tumor and kidneys with PMOD software (v 3.2, PMOD Technologies, Zürich, 
Switzerland). 
3 RESULTS AND DISCUSSION 
The prostate is located just below the urinary bladder, surrounding the urethra. Prostate 
enlargement happens to almost all men as they get older and can be benign or malignant. Prostate 
cancer is one of the most diagnosed cancers among men and PET is playing an important role in the 
staging and restaging of the disease. In the first stage it is important to know if the cancer has spread 
to any lymph nodes (N-staging). This initial staging will determine the further treatment strategy. 
After radical prostatectomy, external radiotherapy or brachytherapy the levels of prostate specific 
membrane antigen (PSA) in blood are monitored. Rise of PSA levels indicates local recurrence and or 
metastasis. An accurate restaging of the disease is of major importance because local recurrence or 
an oligometastatic disease can be treated with surgery or local radiotherapy and thus systemic 
hormonal therapy can be avoided. Therefore there is a high medical need for a highly sensitive and 
specific molecular imaging agent for (re)staging and monitoring of prostate cancer patients. PSMA is 
overexpressed in a majority of primary and metastatic prostate cancer patients and is a very 
promising target for specific prostate cancer imaging and therapy. Urea-based PSMA inhibitors are 
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low-molecular-weight peptidomimetics that -when appropriately labelled- can be used to image 
PSMA-expressing tumours.12 [68Ga]Ga-PSMA-HBEDD-CC is the most frequently used PSMA-
radioligand and has already demonstrated high potential for detection of recurrent prostate cancer.7 
However, labelling with fluorine-18 would offer advantages with respect to availability, production 
amount, and image resolution compared to labelling with gallium-68. [18F]DCFPyL is a promising 18F-
labelled urea-based PSMA inhibitor for imaging of prostate cancer. However, its radiosynthesis is 
rather complex starting from 6-[18F]fluoronicotinic acid-2,3,5,6-tetrafluoro-phenyl ester ([18F]-Py-
TFP).13 Though, Bouvet et al. described recently a synthesis method for [18F]DCFPyL via direct 
nucleophilic heteroaromatic substitution in a single reactor automated synthesis unit.14 As an 
alternative we describe here the use of new Al18F-labelled urea-based PSMA inhibitors. The 
advantage of using the Al18F-strategy is that the one-step radiolabelling is simple and might evolve 
into a “kit” type preparation. Recently, new acyclic pentadentate ligands were developed in 
Laboratory of Radiopharmacy of KU Leuven that are able to complex {Al18F}2+ efficiently at low 
temperatures (< 40 °C). The ligand H3L3 was derivatised and successfully conjugated with an urea-
based inhibitor of PSMA. [18F]AlF-PSMA-L3 was produced with high radiochemical purity and the first 
preclinical results in healthy mice appeared promising (Chapter II), however further preclinical 
evaluation is needed to assess the in vivo stability and tumour-targeting properties. Recently, we 
developed RESCA1, an acyclic pentadentate chelator that is able to complex {Al18F}2+ efficiently at 
25°C (Chapter III). [18F]AlF-RESCA1 shows superior stability in comparison with [18F]AlF-L3, 
comparable with the stability of [18F]AlF-N-benzyl-NODA. Here we report the radiosynthesis and 
preclinical evaluation of [18F]AlF-PSMA-RESCA1 and [18F]AlF-PSMA-NODA-MPAA. The results are 
compared with those of the established ligand [68Ga]Ga-PSMA-HBEDD-CC and the previously 
reported ligand [18F]AlF-PSMA-L3 (Chapter II). 
The tert-butyl protected bifunctional chelators RESCA1tBu-AA and NO2AtBu-MPAA were conjugated 
with a hydrophilic urea-based inhibitor of PSMA, Glu-NH-CO-NH-Lys, to form PSMA-RESCA1 and 
PSMA-NODA-MPAA, respectively (Figure 2). The process of radiosynthesis and purification with 
preparative radio-HPLC was performed using a home-built remotely controlled system. [18F]AlF-
PSMA-RESCA1 and [18F]AlF-PSMA-NODA-MPAA were prepared in high radiochemical yields (50-60%) 
and purity (>95%) in less than 35 minutes (starting after elution of fluorine-18 from the anion 
exchange QMA cartridge). In view of developing the radiochemistry into a kit preparation, RESCA1 
has the advantage that chelation of {Al18F}2+ can occur at room temperature whereas for NODA high 
temperatures (>100 °C) are required. The specific activity for both tracers was between 25 and 30 
GBq/μmol, calculated on the starting amount of PSMA-RESCA1 and PSMA-NODA-MPAA. Both tracers 
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were stable (>95%) in saline at room temperature for at least three hours and identification of the 
[Al19F]-complexes was done by radio-LC-HRMS (Table 1). 
 
Figure 2: Synthesis of PSMA-NODA-MPAA and PSMA-RESCA1  
Table 1: Analytical data of Ga-PSMA-HBED-CC, AlF-PSMA-L3, AlF-PSMA-NODA-MPAA and AlF-PSMA-
RESCA1
acompounds were labelled with 68Ga or {Al18F}2+, retention radiometric signal. 
As derived from the molecular ion mass, [18F]AlF-PSMA-RESCA1 and [18F]AlF-PSMA-L3 have a 
negative charge, located at the Al18F-complexes. In contrast, PSMA-NODA-MPAA and PSMA-HBED-CC 
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form neutral complexes with {Al18F}2+ and 68Ga3+ respectively. To compare the lipophilicity of all 
tracers at pH 2 and physiological pH (pH 7.4) we performed analytical HPLC analysis (Table 1). At pH 
2, [68Ga]Ga-PSMA-HBEDD-CC has the longest retention time (8.23 min), indicating high lipophilicity. 
However, in physiological conditions, the shortest retention time was observed for [68Ga]Ga-PSMA-
HBEDD-CC, indicating lower liphopilicity compared to the other ligands. This shift in retention time 
might be explained by deprotonation at pH 7.4 of the free carboxylic group present on the HBED-CC 
moiety that is not part of the gallium-complex. At pH 7.4, [18F]AlF-PSMA-RESCA1 has the longest 
retention time, indicating higher lipophilicity compared to the other ligands. This might be explained 
by the presence of the lipophilic trans-cyclohexyl moiety of RESCA1. 
After 3 h incubation in rat plasma at 37 °C, 93% of [18F]AlF-PSMA-RESCA1 and 96% of [18F]AlF-PSMA-
NODA-MPAA was still intact as assessed by instant thin layer chromatography (iTLC), indicating 
excellent stability of both compounds. In comparison, [18F]AlF-PSMA-L3 shows lower stability in vitro. 
Only 62% of tracer was still intact after 3 h incubation in rat plasma at 37 °C, indicating demetallation 
and/or defluorination over time. Cell uptake and internalisation experiments with LNCaP (PSMA+) 
cells revealed similar internalisation and cell accumulation for [68Ga]Ga-PSMA-HBED-CC and [18F]AlF-
PSMA-RESCA1 which could be blocked almost completely with the non-structural related PSMA 
inhibitor 2-PMPA, indicating that both processes were mediated by specific binding to PSMA (Figure 
3). 
Moreover, no significant accumulation was observed with PC-3 cells (PSMA-), confirming the specific 
interaction. For both compounds about 45% of the receptor bound fraction was internalised after 45 
min at 37 °C, whereas at 4 °C no significant internalisation was observed, as expected. In contrast, 
[18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-L3 showed considerable lower uptake in LNCaP cells 
than [68Ga]Ga-PSMA-HBED-CC and for both tracers minor non-specific uptake in PC-3 cells was 
observed, which was not observed for [18F]AlF-PSMA-RESCA1 or [68Ga]Ga-PSMA-HBED-CC. 
The results of the biodistribution study of [68Ga]Ga-PSMA-HBED-CC-, [18F]AlF-PSMA-RESCA1 and 
[18F]AlF-PSMA-NODA-MPAA in healthy mice are shown in Figure 4, the biodistribution of [18F]AlF-
PSMA-L3 in healthy mice was reported previously (Chapter II). The graphs show the uptake, 
presented as %ID, in different organs at 10 min and 60 min p.i. of the tracer. [18F]AlF-PSMA-RESCA1 
and [18F]AlF-PSMA-NODA-MPAA both showed high in vivo stability, since no significant bone uptake, 
which would be an indication of release of fluorine-18, was observed (0.80 ± 0.22% ID/g and 0.13 ± 
0.02% ID/g). [18F]AlF-PSMA-RESCA1 was cleared fast from PSMA-negative tissue and plasma mainly 
by the kidneys but also hepatobiliary excretion was observed, which might be explained by the more 
lipophilic properties of [18F]AlF-PSMA-RESCA1 at physiological conditions (HPLC retention in Table 1). 
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Figure 3: Cell binding and internalisation of [68Ga]Ga-PSMA-HBED-CC, [18F]AlF-PSMA-L3, [18F]AlF-
PSMA-RESCA1 and [18F]AlF-PSMA-NODA-MPAA. Specific cell uptake was evaluated by blockade with 
100 µM 2-PMPA. Values are expressed as percentage of applied radioactivity bound to 106 cells. Data 
are expressed as mean ± SD (n=3). Bound fraction is the sum of receptor-bound fraction and 
internalised fraction. 
In contrast, [68Ga]Ga-HBEDD-CC-PSMA, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-L3 were 
cleared mainly by the kidneys and almost no liver uptake was observed. The retention at 60 min p.i. 
of all tracers in organs with reported high expression of PSMA such as kidney and spleen was nearly 
completely blocked when the non-structural related inhibitor 2-PMPA was co-injected to block PSMA 
specific binding. Since 2-PMPA is a non-structurally related PSMA inhibitor, this indicates in vivo 
PSMA-specific retention of all tested tracers. The same effect was shown with in vitro 
autoradiography on kidney slices of healthy mice with or without blocking with 2-PMPA. Pronounced 
specific uptake was observed for all tracers in the renal cortex, which corresponds to the reported 
PSMA receptor distribution in the kidneys of mice.15 With reference to clinical application, PSMA 
expression is considerably lower in human kidneys compared to mouse kidneys.16 For [18F]AlF-PSMA-
RESCA1 and [18F]AlF-PSMA-NODA-MPAA no increased bone uptake was observed with co-injection of 
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2-PMPA (0.66 ± 0.48% ID/g and 0.15 ± 0.02% ID/g). In contrast [18F]AlF-PSMA-L3 showed pronounced 
bone uptake with co-injection of 2-PMPA (4.55 ± 1.39% ID/g) which indicates lower in vivo stability.  
 
Figure 4: Biodistribution (%ID) of [68Ga]Ga-HBED-CC-PSMA, [18F]AlF-PSMA-RESCA1 and [18F]AlF-PSMA-
NODA-MPAA with or without co-administration of 2 mg/kg 2-PMPA at 10 min and 60 min p.i. and 
autoradiography on kidney slices of healthy mice with (A’,B’ and C’) or without (A,B and C) blocking 
with 2-PMPA (100 µM).A: [68Ga]Ga-HBED-CC-PSMA, B: [18F]AlF-PSMA-RESCA1 and C: [18F]AlF-PSMA-
NODA-MPAA. For calculation of total radioactivity in blood, bone and muscle, tissue mass was 
assumed to be, respectively, 7, 12 and 40% of the total body mass. 
High accumulation of all tracers was observed on PSMA+ LNCaP tumour slices, visualised with digital 
autoradiography (Figure 5). The retention of all tracers was nearly completely blocked when 2-PMPA 
(100 µM) was added to the tracer solution, indicating PSMA-specific binding. No significant binding 
was observed on PSMA- PC-3 tumour slices, which again confirms the high specificity of all tested 
tracers. Autoradiography on human prostate tumour tissue showed specific affinity for the human 
PSMA receptor for all Al18F-labelled tracers. Pathological validation confirmed presence of tumour in 
the biopt, but only limited amount of tumour burden was observed. Nevertheless, significant uptake 
of all Al18F-tracers was observed, indicating high affinity and sensitivity for the human PSMA 
receptor. The observed heterogeneous focal uptake was comparable with the uptake of the 
established clinical tracer [68Ga]Ga-PSMA-HBED-CC and was nearly completely blocked when 2-PMPA 
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(100 µM) was added to the tracer solution. Normal human prostate tissue showed considerably 
lower uptake of all tracers which corresponds to the lower expression level of PSMA receptors in 
healthy prostate tissue. 
 
Figure 5: In vitro digital autoradiography on LNCaP (PSMA+)  tumor slices, PC-3 (PSMA-)  tumor slices , 
human prostate tumor tissue and healthy human prostate tissue with [68Ga]Ga-PSMA-HBED-CC, 
[18F]AlF-PSMA-L3, [18F]AlF-PSMA-RESCA1 and [18F]AlF-PSMA-NODA-MPAA with or without blocking 
with 2-PMPA (100 μM). Pathological validation of tumor burden on human prostate tissue: Biopt 
human prostate tumour tissue: very limited amount of tumour, Biopt normal human prostate tissue: 
no tumour 
Dynamic PET analysis of tumour inoculated mice revealed for all tracers rapid and high uptake of 
radioactivity in LNCaP (PSMA+) tumours (Figure 6) and high tumour-to-background ratios. [68Ga]Ga-
HBEDD-CC-PSMA, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-L3 were cleared fast by the kidneys 
and almost no liver uptake was observed. In contrast, [18F]AlF-PSMA-RESCA1 was cleared fast from 
PSMA-negative tissue and plasma by the kidneys but also hepatobiliary excretion was observed, 
which is consistent with the ex vivo biodistribution data. [68Ga]Ga-HBEDD-CC-PSMA and [18F]AlF-
PSMA-RESCA1 showed no significant uptake in PC-3 (PSMA-) tumors, confirming the specificity of 
both tracers. No microPET scans were performed with [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-
PSMA-L3 in PC-3 (PSMA-) tumour bearing mice. [18F]AlF-PSMA-L3 showed high LNCaP tumour uptake 
but also increased bone uptake was observed over time. Non-specific bone accumulation might 
Chapter IV 
Page | 81  
compromise the utility of this tracer for non-invasive imaging of prostate cancer metastasis, because 
most metastatic lesions occur in lymph nodes and in bone.4 Despite the lower stability and low in 
vitro cell accumulation, [18F]AlF-PSMA-L3 demonstrated high LNCaP tumour uptake in vivo with 
average SUVs of around 1.2. However, these results have to be interpreted carefully because of the 
limited number of scanned tumour mice and the lack of a direct head-to-head comparison with 
[68Ga]Ga-HBEDD-CC-PSMA.  
 
Figure 6: Whole-body coronal microPET image of BALB/c nu/nu mice bearing (PSMA+) LNCaP or 
(PSMA-) PC-3 xenografts. Summed images (30-60 min p.i., average volume time weighted), red arrows 
indicate position of LNCaP or PC-3 tumours. Graph A and B show the time-activity curves (SUV) in 
tumour for [68Ga]Ga-HBEDD-CC-PSMA and [18F]AlF-PSMA-RESCA1, microPET scans were performed in 
the same mice at the same day. Graph C shows the time-activity curves in tumour for [68Ga]Ga-
HBEDD-CC-PSMA (n=3), [18F]AlF-PSMA-RESCA1 (n=3), [18F]AlF-PSMA-NODA-MPAA (n=1) and [18F]AlF-
PSMA-L3 (n=3). 
In order to allow a head-to-head comparison of tumour uptake between [18F]AlF-PSMA-RESCA1 and 
[68Ga]Ga-HBEDD-CC-PSMA, we performed two microPET scans on the same day in the same LNCaP 
tumour bearing mice. In the morning we performed a microPET scan with [68Ga]Ga-HBEDD-CC-PSMA 
and 6 hours later, we repeated the experiment with [18F]AlF-PSMA-RESCA1 in the same mice (Figure 
6). [18F]AlF-PSMA-RESCA1 showed rapid and high uptake of radioactivity in LNCaP tumours (SUV5min 0. 
7 ± 0.2) which slightly decreased over time (SUV60min 0.5 ± 0.2). [68Ga]Ga-HBEDD-CC-PSMA showed 
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comparable but somewhat lower initial tumour uptake (SUV5min 0. 6 ± 0.1) than [18F]AlF-PSMA-
RESCA1 but the LNCaP (PSMA+) tumour uptake was constant or even slightly increased over time 
(SUV60min 0.6 ± 0.2). To conclude, all tracers showed rapid and high uptake of radioactivity in LNCaP 
(PSMA+) tumours with high tumour-to-background ratios.  
4 CONCLUSIONS 
Two new Al18F-labelled urea-based PSMA inhibitors were successfully produced with high yields and 
radiochemical purity in less than 30 min. The results of preclinical studies were compared with those 
of the established ligand [68Ga]Ga-PSMA-HBEDD-CC and the previously reported ligand [18F]AlF-
PSMA-L3.  Cell uptake and internalisation experiments with LNCaP (PSMA+) and PC-3 (PSMA-) cells 
revealed similar specific internalisation and cell accumulation for [18F]AlF-PSMA-RESCA1 and 
[68Ga]Ga-PSMA-HBED-CC. In contrast, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-L3 showed 
considerable lower uptake in LNCaP cells. Moreover, [18F]AlF-PSMA-L3 suffers from instability over 
time which compromises the utility of this tracer. All tracers were cleared fast from plasma and 
PSMA-negative tissue mainly by the kidneys but also hepatobiliary excretion was observed in the 
case of [18F]AlF-RESCA1-PSMA. High specific accumulation of all tracers was observed on PSMA+ 
LNCaP tumour slices and autoradiography on human prostate tumour tissue showed specific affinity 
for the human PSMA receptor. Dynamic PET analysis revealed rapid and high uptake of radioactivity 
in LNCaP (PSMA+) tumours and high tumour-to-background ratios for all examined tracers.  
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ABSTRACT 
 
Nanobodies are the smallest antigen-binding antibody fragments available and interact fast and with 
nanomolar affinity with their target. Unbound nanobodies are cleared rapidly from the blood and if 
radiolabelled with a positron emitting radionuclide, this results in high contrast PET images as early 
as 1 hour after administration. Here we describe a generic approach for a one-step radiolabelling of 
nanobodies via the Al18F-method at ambient temperature using the recently developed chelator 
“restrained complexing agent 1 (RESCA1)”. We derivatised the nanobody, NbV4m119, targeting the 
CRIg receptor, with RESCA1 and successfully labelled the construct with {Al18F}2+ in good 
radiochemical yields in less than 35 minutes. [18F]AlF-RESCA1-NbV4m119 showed excellent in vitro 
stability. Biodistribution and microPET studies in mice demonstrated that [18F]AlF-RESCA1-NbV4m119 
is excreted mainly via the renal pathway. However, in accordance with the high CRIg expression on 
Kupffer cells, also high liver uptake was observed in WT mice. In contrast, no significant liver uptake 
was observed in CRIg-/- mice indicating excellent specificity of the Al18F-labelled tracer. In addition, 
we optimised a generic radio-HPLC-HRMS system for analysis and quality control of radiolabelled 
nanobodies. Fluorine-18 labelled nanobodies can be considered as “magic bullets” for immuno-
imaging and this generic radiolabelling method may stimulate the development of other nanobody-
based radiotracers.  
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1. INTRODUCTION 
The molecular imaging technique immuno-positron emission tomography (immuno-PET) combines 
the selective localisation of monoclonal antibodies (mAbs) or antibody fragments at their target in 
vivo and the high resolution and sensitivity of PET. The immuno-PET tracer should exhibit a high 
target-to-background ratio, high target specificity, high stability, good solubility and low 
immunogenicity.1 The advantage of using mAbs as vector molecules in immuno-PET is their 
nanomolar affinity and high accumulation at the target site.2 Moreover, the availability of a large 
number of FDA-approved mAbs for imaging purposes can stimulate clinical translation.1 However, as 
a result of the long residence time in blood of full-length antibodies, imaging with sufficient contrast 
between target and non-target tissues can only be performed several days post injection with peak 
contrast mostly after 2-4 days. Hence, due to the slow kinetics, radiolabelling with long-lived 
radionuclides such as zirconium-89 (89Zr, t1/2: 3.3 days) or iodine-124 (
124I, t1/2: 4.2 days) is required 
which causes a high radiation burden for the patient (20-40 mSv per scan). The use of long-lived 
radionuclides is unpractical for routine clinical use and moreover, has a severe social impact on 
patients. For example, only limited visiting time of family is allowed for radioprotection reasons.  
Nanobodies (VHH) are the antigen-binding fragments (13-15 kDa) derived from heavy-chain-only 
antibodies occurring naturally in Camelid species.3 Nanobodies bind their antigens very fast and 
specifically with high affinity in vivo, whereas unbound nanobody is rapidly cleared from the blood by 
the kidneys.4 Using nanobodies labelled with a positron emitting radionuclide, high contrast PET 
images can be acquired as early as 1 hour after tracer administration.5 This early imaging allows the 
use of short-lived PET radionuclides such as gallium-68 (68Ga, t1/2: 68 min), fluorine-18 (
18F, t1/2: 109.8 
min) or copper-64 (64Cu, t1/2: 12.7 hours), resulting in more patient-friendly imaging procedures and 
lower radiation burden. Nanobodies are single-domain binders, therefore they have good solubility 
compared to other antibody fragments and can be easily generated against any antigen of interest 
with excellent expression yield in both Eschericia coli and yeast.1 Nanobodies could be considered as 
“magic bullets” for imaging, however, the high accumulation of unbound VHHs in kidneys, resulting in 
high renal radiation dose from radiolabelled nanobodies and more complicating analysis of nearby 
tissue should be taken into account.6 Nevertheless, the preclinical data reported to date with 
nanobody-derived probes is promising and nanobody-based molecular imaging might play an 
important role in the diagnosis and management of various diseases.7  
In the past, most nanobody-derived probes were labelled with technetium-99m (99mTc, t1/2: 6 hours) 
for SPECT imaging. When derivatised with a terminal hexahistidine tag, nanobodies can easily be 
radiolabelled based on 99mTc(I)-tricarbonyl chemistry, without any additional modification of the 
protein.8 99mTc-VHHs have been proposed as potential molecular imaging agents in several contexts, 
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such as oncology and inflammatory diseases. However, compared to SPECT, PET imaging offers 
indisputably superior images that are characterised by (1) higher spatial resolution, (2) superior 
imaging contrast, (3) less scatter, and (4) better attenuation correction.9 Therefore, PET has gained 
more clinical popularity over the last decade and also PET radionuclides have been applied for 
labelling of nanobodies. In accordance with the short biological half-life of the nanobody, both 68Ga 
and 18F are ideal radioisotopes for their labelling. Radiolabelling of anti-EGFR and anti-HER2 
nanobodies with 68Ga has been reported and is attractive because the radioisotope is available as a 
bench-top generator product and does not require a cyclotron as it is the case for fluorine-18.5,10 
However, fluorine-18 has several advantages such as favourable decay properties (~ 97% ß+-
emission, 635-keV maximum positron energy), low β+-trajectory (< 2 mm in water), small atom size 
and moreover, it is readily produced in large quantities (>400 GBq/batch) with a cyclotron. The half-
life is long enough to allow transportation to remote hospitals without an on-site cyclotron and it is 
short enough to avoid extended irradiation of patients. The success and medical importance of 2-
[18F]fluoro-2-deoxyglucose ([18F]FDG), have led to the installation of many of these expensive 
cyclotron infrastructures all over the world. Consequently, fluorine-18 is now readily available in an 
expanding number of  hospitals and research centres and the infrastructure is in place to expand its 
application far beyond [18F]FDG.11  
The Al18F labelling method is a relatively new approach that allows radiofluorination of biomolecules 
such as peptides and proteins in a one-step procedure.12 This method avoids laborious multistep 
procedures often required when secondary labelling agents, such as N-succinimidyl 4-
[18F]fluorobenzoate ([18F]SFB), are used to radiolabel biomolecules with fluorine-18.13 Conventional 
radiofluorination strategies involve carbon-fluorine bond formation in anhydrous aprotic solvents. In 
contrast, the Al18F-strategy involves the formation of aluminium monofluoride ({Al18F}2+) which is 
trapped by a suitable chelator –mostly conjugated to a biomolecule- in aqueous medium. Recently, 
we reported a new restrained complexing agent (RESCA1), which displays a less rigid structure than 
the established macrocyclic AlF-chelator 1,4,7-triazacyclononane-1,4-diacetate (NODA) in order to 
reduce the activation energy of the complexation reaction. The area of improvement includes 
radiolabelling at ambient temperatures (≤40 °C), whilst maintaining in vivo stability. The generic 
applicability of the proposed method was demonstrated by labelling the heat-sensitive biomolecule 
human serum albumin (HSA) at ambient temperature with {Al18F}2+ with high radiochemical purity in 
less than 30 minutes.  [18F]AlF-RESCA1-HSA showed excellent in vitro and in vivo stability and 
moreover, Al18F-RESCA1-HSA showed favourable properties for PET blood pool imaging applications 
(Chapter III). 
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The objective of current study was to efficiently radiolabel macrophage CRIg-targeting nanobodies 
via the Al18F-method for PET imaging of joint inflammation. The complement receptor of the Ig 
superfamily (CRIg) has a pronounced expression on Kupffer cells, which are resident liver 
macrophages, and CRIg is found to a certain extent on resident tissue macrophages subsets in 
various tissues, including normal synovium.14 However, it has been shown that CRIg is more 
abundant in rheumatoid arthritis (RA) synovial tissue and consequently, CRIg is a promising marker 
for specific molecular imaging of RA, allowing non-invasive quantification of joint inflammation.15 
Here, we describe a generic approach for Al18F-labelling, automated purification, characterisation 
and preclinical evaluation in mice of nanobodies (NbV4m119) targeting CRIg. 
2. MATERIALS AND METHODS 
2.1 General 
All reagents and solvents were purchased from Sigma-Aldrich (Bornem, Belgium), Fluka (Bornem, 
Belgium), Fisher (Doornik, Belgium) or Acros Organics (Geel, Belgium). Fluorine-18 was produced on 
site using a cyclotron (IBA Cyclone 18/9, IBA, Louvain-la-Neuve, Belgium) by irradiation of H2
18O with 
18-MeV protons. Radioactivity was measured using an ionisation chamber based activity meter 
(Capintec Radioisotope Calibrator CRC-721, Ramsey, NJ, USA). NbV4m119 and the CRIg-/- mice were 
generously provided by Geert Raes from the VIB laboratory of myeloid cell immunology. The 
synthesis and characterisation of compound RESCA-TFP is described in patent WO/2016/065435. 
2.2 Radio-LC-HRMS 
A Dionex Ultimate 3000 UPLC System (Thermo Fisher Scientific, Sunnyvale, USA) coupled in series to 
a 3- inch NaI(Tl) radioactivity detector and an ultra-high resolution time-of-flight mass spectrometer 
with electron spray ionisation (ESI) (MaXis impact, Bruker, Bremen, Germany) was used for analysis 
of the nanobody constructs. For deconvolution analysis of the raw mass spectral data the software 
program DataAnalysis (Bruker Daltonik, Bremen, Germany) was used. Calculated average neutral 
molecular ion mass values were obtained using Compas Isotope Pattern (version 3.2, Bruker). Both 
an Acquity UPLC BEH C18 column (1.7 µm, 2.1 mm x 150 mm, Waters) and a Zorbax SB-C3 column 
(1.8 µm, 3.0 mm x 100 mm, Agilent) were tested using following method. Solvent A (H2O, 0.1% 
HCOOH) and solvent B (acetonitrile; 0.1% HCOOH), flow rate 0.3 ml/min. The elution gradient was: 0-
1 min: 99% A; 1-7 min: from 99% A to 1% A; 7-10 min: 1% A; 10.1-12 min: 99% A. UV detection of the 
eluate was performed at 280 nm. 
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2.3 Synthesis of RESCA1-V4m119 Nb 
A solution of RESCA1-TFP (23 µl, 1.4294 x 10-6 moles) in DMSO was added in 12 molar excess to a 
solution of NbV4m119 (2.5 ml, 1.1912 x 10-7 moles,) in 0.05 M sodium bicarbonate pH 8.6 and the 
mixture was incubated for 3 h at room temperature. The conjugate was successfully purified by gel 
filtration (PD-10 desalting column, GE Healthcare Bio-Science AB, Uppsala, Sweden) and the 
concentration of RESCA1-NbV4m119 was determined spectrophotometrically at 280 nm (Nanodrop 
2000, Thermo Fisher scientific). Analysis of the purified compound was performed by size-exclusion 
chromatography on a Superdex 75 10/300 GL column (GE Healthcare) using sodium phosphate buffer 
(0.01 M, pH 7.4, 0.14 M NaCl), as eluent at a flow rate of 0.5 ml/min and with the LC-HRMS method 
described above. UV detection of the eluate was performed at 280 nm. 
2.4 Radiosynthesis and semi-automated purification of [18F]AlF-RESCA1-NbV4m119  
[18F]F- was separated from [18O]H2O by trapping on a SepPak Light Accel plus QMA anion exchange 
cartridge (Cl- form; Waters). The cartridge was washed with water (3 mL), [18F]F- was eluted from the 
cartridge with an aqueous solution of sodium chloride 0.9% (0.3 mL) and the eluate was diluted with 
water (2.7 ml). This [18F]F- solution (0.5 ml) was added to 12.5 µL of 2 mM aluminum chloride (AlCl3) 
in sodium acetate buffer (0.1 M, pH 4.5). The solution was incubated at room temperature (rt) for 5 
min to form {Al18F}2+. A solution of RESCA1-NbV4m119 (1.5 mL, 0.55 mg/ml) in sodium acetate buffer 
(0.1 M, pH 4.5) was added to the freshly prepared {Al18F}2+ solution and the mixture was incubated at 
ambient temperature (20-22°C) for 12 min. After incubation, the mixture was purified by preparative 
HPLC using three or four Hitrap desalting columns (GE Healthcare) in series. Radiochemical identity 
and purity were assessed by size-exclusion chromatography on a Superdex 75 10/300 GL column (GE 
Healthcare) using sodium phosphate buffer (0.01M, pH 7.4, 0.14 M NaCl), as eluent at a flow rate of 
0.5 ml/min. UV detection of the eluate was performed at 280 nm and a 3 inch NaI(Tl) radioactivity 
detector was coupled in series. The identity of the main compound was confirmed using unlabelled 
NbV4m119 as reference material. 
2.5 Stability studies of [18F]AlF-RESCA1-NbV4m119 in rat plasma 
A volume of 200 µL of [18F]AlF-RESCA1-NbV4m119 solution was added to rat plasma (1 mL). The 
mixture was incubated at 37 °C for 4 hours and analysed (10 µl) at 0, 1, 2, 3 and 4 h with size-
exclusion chromatography on a Superdex 75 10/300 GL column using sodium phosphate buffer 
(0.01M, pH 7.4, 0.14 M NaCl) as eluent at a flow rate of 0.5 ml/min.  
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2.6 Biodistribution  and microPET studies  
Quantification of radioactivity for biodistribution studies was performed using an automated gamma-
counter equipped with a 3-inch NaI(Tl) well crystal coupled to a multichannel analyser, mounted in a 
sample changer (Perkin Elmer 1480 Wizard 3q, Waltham, USA). Counts were corrected for 
background radiation, physical decay and counter dead time. Animals were housed in individually 
ventilated cages in a thermo-regulated (~22 °C), humidity-controlled facility under a 12h-12h light-
dark cycle, with access to food and water ad libitum. All animal experiments were conducted 
according to the Belgian code of practice for the care and the use of animals, after approval from the 
university animal ethics committee. The biodistribution study of [18F]AlF-RESCA1-NbV4m119 was 
carried out in healthy male C57BL/6 mice (body weight: 22-26 g) at 1 h and 3 h post injection (p.i.) (n 
= 3/time point) or in CRIg-deficient mice (CRIg-/-, C57BL/6 background, body weight: 20-23 g) at 3 h 
p.i. (n = 3/time point). Mice were injected with the Al18F-tracer (7-8 MBq) via a tail vein under 
anesthesia (2.5% isoflurane in O2 at 1 L/min flow rate) and sacrificed by decapitation at above 
specified time points. Blood and major organs were collected in tared tubes and weighed. The 
radioactivity in blood, organs and other body parts was counted using an automated γ-counter. For 
calculation of total radioactivity in blood, bone and muscle tissue mass was assumed to be, 
respectively, 7, 12 and 40% of the total body mass.16,17 Results are presented as percentage of 
injected dose (%ID) or in standardised uptake values (SUV). Small animal whole-body PET imaging on 
mice was performed using a FOCUSTM 220 microPET scanner (Concorde Microsystems, Knoxville, US) 
and PMOD software (v 3.2, PMOD Technologies, Zürich, Switzerland). 
2.7 Statistical analysis 
Quantitative data are expressed as mean ± standard deviation. Means were compared using the 
unpaired two-tailed Student t-test. Values were considered statistically significant for P < 0.05. 
3. RESULTS AND DISCUSSION 
Nanobodies can be considered as “magic bullets” for imaging and might play an important role in the 
diagnosis and management of various diseases.6 The objective of this study was to efficiently 
radiolabel macrophage CRIg-targeting nanobodies via the Al18F-method for PET imaging of joint 
inflammation. Zheng et al. generated successfully nanobody NbV4m119, that targets specifically 
CRIg.15 Moreover they radiolabelled NbV4m119 with the SPECT radionuclide 99mTc via standard 
99mTc(I)-tricarbonyl chemistry and could efficiently visualise joint inflammation in mice with collagen-
induced arthritis (CIA). Furthermore SPECT/CT with 99mTc-NbV4m119 could detect early signs of 
inflammation even before manifestation of anatomically visible signs of the disease. Compared to 
SPECT, PET imaging offers superior images. Among β+-emitting radioisotopes, the halogen fluorine-18 
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is the most commonly used due to its optimal chemical properties and almost ideal nuclear decay 
characteristics.18 Blykers et al. reported the 18F-labelling of nanobodies targeting the macrophage 
mannose receptor (MMR) for imaging of MMR-expressing tumor-associated macrophages (TAMs), 
providing prognostic information about the tumor stroma.19 The anti-MMR 3.49 Nb was labelled 
using the prosthetic group [18F]SFB with a 5-10% radiochemical yield using an optimised protocol 
yielding [18F]FB-anti MMR-3.49 Nb. However, the multistep synthesis is laborious (180 minutes, 
starting from [18F]F- and the final product was purified manually with a disposable PD-10 desalting 
column, resulting in suboptimal conditions regarding radioprotection for the radiochemist. 
Moreover, only limited amounts of purified product (200-500 MBq) were obtained with moderate 
specific activity (10 to 30 GBq/µmol). We now tested the Al18F-method using RESCA1 as chelator as a 
potential superior alternative for an efficient one-step radiolabelling of nanobodies at ambient 
temperature. 
 
Figure 1: A: LC-UV280 nm chromatogram of unlabelled NbV4m119 (Retention time (Rt): 5.5 min). B: 
MS spectrum of unlabelled NbV4m119. The theoretical average neutral molecular mass of the 
unlabelled NbV4m119 was 14577.85 Da [M] (Calculated for C643H950N188O196S4) and the observed 
mass after deconvolution was 14577.61 ± 0.02 Da [M]. 
Characterisation of a radiolabelled nanobody is important in order to assure that the radiolabelling 
procedure does not affect the nanobody integrity. We have therefore explored radio-liquid 
chromatography in combination with high-resolution mass spectrometry (radio-UPLC-HRMS) to 
analyse NbV4m119 prior to and after derivatisation/radiolabelling. An Acquity UPLC BEH C18 column 
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(1.7 µm, 2.1 mm x 150 mm, Waters) and a Zorbax SB-C3 column (1.8 µm, 3.0 mm x 100 mm, Agilent) 
were compared. First the MS settings and LC-parameters for a solution of the unlabelled NbV4m119 
were optimised. Gradients, flow rates and column temperatures were varied. The best analysis 
results were obtained with a Zorbax SB-C3 column at a flow rate of 0.3 ml/min with a column 
temperature of 40 °C (Figure 1). 
The theoretical average neutral molecular mass of unlabelled NbV4m119 is 14577.85 Da [M] 
(calculated for C643H950N188O196S4) and the observed mass after deconvolution was 14577.61 ± 0.02 
Da [M]. We also observed the presence of a deamination product with an observed mass of 14560.76 
± 0.02 Da (calculated for C643H947N187O196S4 [M]: 14560.82). This deamination product was expected 
and can be formed spontaneously during manipulation and storage of the protein. This radio-LC-
HRMS method allows detecting whether the disulfide bonds are still intact after the derivatisation 
procedure. Proteins with intramolecular disulfide bonds will shift two daltons when a disulfide is 
converted to two sulfhydryl groups. Disulfide bonds play an important role in the folding and stability 
of proteins which is crucial to assure that the nanobody retains its antigen affinity. After the 
successful characterisation of the unlabelled NbV4m119 with our LC-HRMS method, we derivatised 
the nanobody using the bifunctional chelator RESCA1-TFP and labelled the conjugate with {Al18F}2+ 
(Figure 2). NbV4m119 possesses five lysine residues in its amino acid sequence, therefore several 
lysine groups can react with the active ester via the free amino functionalities. RESCA1-TFP ester was 
efficiently conjugated to NbV4m119 providing RESCA1-V4m119 Nb with a chelator-to-protein ratio of 
1.5, estimated by ESI-TOF-HRMS analysis and no aggregates or degradation products were formed. 
The theoretical average neutral molecular masses for single and dual conjugation are 14979.2602 Da 
and 15397.7014 Da [M], respectively. The observed masses for RESCA1-NbV4m119 after 
deconvolution were 14979.35 ± 0.02 Da and 15397.69 ± 0.02 Da [M], respectively.  
RESCA1-V4m119 Nb was labelled with {Al18F}2+ in good radiochemical yield (RCY) in mild conditions 
(12 min, 25 °C, pH 4.5). The crude reaction mixture was purified using three or four Hitrap desalting 
columns in series yielding the purified batch [18F]AlF-RESCA1-NbV4m119 (eluting at 5-7 min) with a 
radiochemical yield of 45-53% (n=3). The best separation between [18F]AlF-RESCA1-V4m119 Nb and 
non-reacted Al18F-species was obtained using four Hitrap desalting columns in series. 
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Figure 2: Synthesis and radiolabelling of RESCA1-NbV4m119 with {Al18F}2+. RESCA1-TFP ester was 
conjugated to NbV4m119 providing RESCA1-NbV4m119 with a chelator-to-protein ratio of 1.5, 
estimated by ESI-TOF-HRMS analysis. The conjugate was purified by gel filtration (PD-10 desalting 
column). [18F]AlF-RESCA-NbV4m119 was prepared in high RCY (>45%). Purification was accomplished 
with preparative HPLC using 4 Hitrap desalting columns in series, resulting in the final product (2 GBq) 
with a high purity (>97%) in less than 35 min (starting after elution of fluorine-18 from the anion 
exchange QMA cartridge). LC-UV280 nm chromatogram and radio-chromatogram of purified Al18F-
RESCA1-NbV4m119 with a retention time of 5.6 min and 5.9 min respectively. 
 
Al18F-RESCA-NbV4m119 was thus obtained with a batch activity of about 2 GBq and a radiochemical 
purity higher than 97% in less than 35 min starting from the elution of fluorine-18 from the anion 
exchange cartridge. The specific activity ranged from 80 to 85 GBq/µmol. [18F]AlF-RESCA-NbV4m119 
was analysed with the optimised radio-LC-HRMS method, eluting at a retention time of 5.6 min. The 
UV detector and radiometric detector are coupled in series, which explains the minor delay in the 
radiometric signal. [18F]AlF-RESCA-NbV4m119 showed excellent stability in vitro. Analysis with size 
exclusion chromatography (SEC) revealed that 96% of the Al18F-tracer was still intact after 6 h 
incubation in the storage buffer (Na2HPO4 0.01M pH 7.4 + 0.14M NaCl) at room temperature and 
91.5% of the Al18F-tracer was still intact after 4 h incubation in rat plasma at 37°C (Figure 3).  
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Figure 3: A: Radio-chromatogram of [18F]AlF-RESCA1-NbV4m119 after 2 minutes incubation in rat 
plasma at 37°C, 97.9% of [18F]AlF-RESCA1-NbV4m119 (Rt 26.8 min) and 2.1% free Al18F-species,18F- 
and/or 18F-labelled degradation fragments (Rt 35.1 min) are observed B: Radio-chromatogram of 
[18F]AlF-RESCA1-NbV4m119 after 4 hours incubation in rat plasma at 37°C, 91.5% [18F]AlF-RESCA1-
NbV4m119 (Rt 26.8 min) and 8.5% free Al18F-species,18F- and/or 18F-labelled degradation fragments 
(Rt 35.1 min) are observed 
A biodistribution study with [18F]AlF-RESCA1-NbV4m119 was carried out in healthy wild-type (WT) 
mice at 1 h and 3 h p.i., the results are expressed as percentage of injected dose (%ID) (Figure 4). 
Since the molecular size of nanobodies is below the threshold for renal glomerular filtration, 
nanobodies are generally cleared fast from blood, mainly via renal clearance. High uptake in kidneys 
(27.5 ± 1.8%ID and 9.8 ± 1.8%ID at 1 h and 3 h p.i. respectively) and urine/bladder (23.0 ± 2.9%ID and 
46.5 ± 6.2%ID at 1 h and 3 h p.i. respectively) were observed. Only 0.7 and 1.6%ID of the radioactivity 
was observed in blood after 1 h and 3 h p.i. respectively, indicating fast blood clearance.  
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Figure 4: Biodistribution of [18F]AlF-RESCA1-NbV4m119 in naïve wild-type mice (WT, n=3/group; 22-
26 g) at 1 h and 3 h p.i. Results are presented as percentage of injected dose (%ID). For calculation of 
total radioactivity in blood, bone and muscle, tissue mass was assumed to be, respectively, 7, 12 and 
40% of the total body mass. 
Zheng et al. investigated CRIg mRNA levels in collagen-induced arthritis (CIA) mice to determine 
whether this marker is expressed homogeneously in the body or specifically in certain tissues during 
inflammation.15 High CRIg mRNA levels were found in liver (the CRIg receptor has a pronounced 
expression on Kupffer cells) and low or undetectable quantities in bone marrow, lymph nodes, 
spleen and lungs. In accordance with the tissue mRNA studies performed by Zheng et al., [18F]AlF-
RESCA1-NbV4m119 showed high uptake in liver (20.2 ± 1.0%ID and 14.5 ± 2.3%ID at 1 h and 3 h p.i. 
respectively), but low uptake in other organs. Fluorine-18 in the form of fluoride as well as {Al18F}2+ 
are known to accumulate in bone.20,21 Although we showed excellent in vitro stability of [18F]AlF-
RESCA1-NbV4m119 in rat plasma, relative high bone uptake was observed ex vivo at 3 h p.i. (10.1 ± 
3.0%ID), indicating demetallation or defluorination of the compound. Another explanation for the 
increased bone uptake could be that [18F]AlF-RESCA1-NbV4m119 or small 18F-labelled degradation 
fragments have specific retention in bone marrow, resulting in bone accumulation. Non-specific bone 
accumulation might compromise the utility of this tracer for noninvasive quantification of joint 
inflammation in vivo. To confirm the specificity of our Al18F-labelled nanobody targeting CRIg, we 
performed a biodistribution study at 3 h p.i on naïve CRIg-/- (CRIg knockout) mice.  
Figure 5 shows the results of the biodistribution study presented in standardised uptake values (SUV) 
in the different organs. The highest activity concentration at 3 h p.i. was observed in kidneys 
indicating renal clearance of the radiolabelled ligand. In CRIg-/- mice no specific uptake of [18F]AlF-
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RESCA1-NbV4m119 could be observed in the liver (SUV: 0.27 ± 0.1) or other organs. Liver uptake of 
[18F]AlF-RESCA1-NbV4m119 3 h p.i. in WT mice was significantly higher with a SUV value of 2.31 ± 
0.2, indicating excellent in vivo specificity of the tracer. Higher kidney uptake in the CRIg-/- mice at 3 h 
p.i compared with the kidney uptake in the WT mice at 3 h p.i. might be explained by the lower liver 
uptake in CRIg-/- mice, resulting in higher availability of [18F]AlF-RESCA1-NbV4m119 towards the renal 
elimination pathway. Furthermore, a relatively high bone uptake was observed in CRIg-/- mice, 
comparable to the observed bone uptake in WT mice, indicating that [18F]AlF-RESCA1-NbV4m119 as 
such does not show specific binding in bone tissue. Whole-body PET imaging clearly showed specific 
uptake of Al18F-RESCA1-NbV4m119 in the liver, whereas no liver uptake was observed in the CRIg 
knockout mice (Figure 5). 
 
Figure 5: Biodistribution of [18F]AlF-RESCA1-NbV4m119 in naïve wild-type mice (WT, n=3/group; 20-
23 g) mice and CRIg-/- mice (n=3/group; 19-21 g) at 3 h p.i. and coronal views of microPET imaging. 
Biodistribution results are presented as standardised uptake value (SUV).***P < 0.001. Summed 
images (30-60 min p.i., average volume time weighted) performed on naïve WT and CRIg-/- mice.  
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To further investigate the unexpected bone uptake, we analysed a urine sample of naïve WT mouse 3 
h after i.v. injection of [18F]AlF-RESCA1-NbV4m119. Surprisingly, size exclusion chromatography 
showed that urine contained only 2.2% of the intact compound [18F]AlF-RESCA1-NbV4m119, the rest 
of activity (97.9%) eluted at later time points under the form of small 18F-labelled degradation 
products, 18F- and/or different Al18F-species (Figure 6). Comparable results were obtained in urine 
samples of CRIg-/- mice 3 h p.i. of [18F]AlF-RESCA1-NbV4m119. 
Figure 6: Radio-chromatogram of urine sample of naïve WT mouse 3 h after i.v. injection of [18F]AlF-
RESCA1-NbV4m119. Only 2.2% of [18F]AlF-RESCA1-NbV4m119 (Rt 26.2 min) is still intact, the rest of 
activity (97.9%) elutes under the form of small 18F-labelled degradation products, 18F- and/or different 
Al18F-species (Rt 34.7 min) 
This high rate of in vivo degradation was unexpected. It seems that severe demetallation or 
defluorination occurs in the kidneys and that {Al18F}2+ or 18F- as such is released back into circulation, 
resulting in increased bone uptake values. However, further analysis of the degradation products in 
urine samples with reverse phase or ion exchange chromatography is necessary to identify the 
degradation products. Also ex vivo determination of blood metabolites would be interesting to find 
out if degradation of the Al18F-tracer occurs in blood or after glomerular filtration. Nevertheless, the 
calculated bone uptake is still limited and could be overestimated. Indeed, to calculate this 
parameter we assumed that 12 % of the body mass exists out of bone, which might be an 
overestimation in these mice. The in vivo PET imaging did not show significant bone uptake after 1 h 
and high liver-to background images were obtained, indicating favourable in vivo imaging properties 
of [18F]AlF-RESCA1-NbV4m119 with high specificity for CRIg. We successfully labelled for the first 
time a nanobody via the Al18F-method with high radiochemical yields. However, the first step of this 
approach is a non-specific derivatisation of the nanobody with one or more Al18F-chelators, resulting 
in batch-to-batch differences. Therefore site-specific incorporation of the chelator into the nanobody 
would even further improve this promising radiolabelling approach. 
4. CONCLUSIONS 
Nanobodies are promising tools in molecular imaging and have many advantages in comparison with 
full-size antibodies. Fluorine-18 is the radionuclide of choice in view of the short biological half-life of 
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nanobodies. We demonstrated that the Al18F-method using our recently developed chelator RESCA1 
provides an efficient approach to radiolabel nanobodies with fluorine-18 at ambient temperature. 
We successfully derivatised nanobodies targeting the CRIg receptor with RESCA1 and labelled the 
conjugate with {Al18F}2+ in good radiochemical yields at ambient temperature. [18F]AlF-RESCA1-
NbV4m119 was purified with preparative HPLC resulting in the Al18F-tracer with a radiochemical 
purity higher than 97% and the compound showed excellent in vitro stability. Furthermore, we 
successfully optimised a generic radio-HPLC-HRMS system for the analysis and quality control of 
radiolabelled nanobodies. Biodistribution studies in mice showed that [18F]AlF-RESCA1-NbV4m119 
was mainly excreted via the renal pathway but also high liver uptake was observed in normal WT 
mice, which is expected because CRIg receptors are highly expressed on Kupffer cells. Biodistribution 
and microPET studies in CRIg-/- mice demonstrated absence of significant uptake in liver, indicating 
excellent specificity of the Al18F-labelled tracer. Unexpectedly, almost no intact [18F]AlF-RESCA1-
NbV4m119 was found in urine at 3 h p.i. and relatively high bone uptake was observed, indicating in 
vivo instability of the tracer. However, in vivo PET imaging in mice did not show significant bone 
uptake at 1 h p.i. and high liver-to background images were obtained, indicating favourable in vivo 
imaging properties of [18F]AlF-RESCA1-NbV4m119 with high specificity for CRIg. This tracer will be 
further evaluated in CIA mice for quantification of joint inflammation. This generic radiolabelling, 
purification and characterisation method provides a general approach for radiolabeling of 
nanobodies with fluorine-18. 
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1. GENERAL DISCUSSION 
Positron emission tomography (PET) is a sensitive, non-invasive imaging technology that produces 
three-dimensional images showing the dynamic in vivo concentration of radiotracers, which are 
labelled with positron emitting radioisotopes. Among β+-emitting radioisotopes, the halogen 
fluorine-18 is the most commonly used due to its optimal chemical properties, almost ideal nuclear 
decay characteristics and ease of production of high activity batches with a cyclotron. 
Most methods for radiolabelling biomolecules with fluorine-18 are laborious and require multistep 
procedures with moderate overall labelling yields. Besides conventional carbon-fluorine 
radiolabelling methods, different inorganic approaches can be used for labelling of biomolecules with 
fluorine-18. Several non-carbon elements favour strong bonds (i.e. high bond enthalpy) with fluorine, 
preserve high kinetic stability of the fluorine containing compounds formed and have a lower 
activation energy for their formation in comparison to carbon-fluorine bonds. These chemical 
properties were the basis for a new field in 18F-radiochemistry. Currently, boron, silicon and 
aluminium are three elements under investigation. The strength of the inorganic approach is that it 
can entail only one, potentially very fast, radiochemical reaction step, which can be easily automated 
for routine production. Furthermore, time-consuming and rather complex drying steps are avoided 
since the reaction can take place in, at least partially, aqueous media.  
The Al18F-labelling strategy involves chelation of aluminium mono[18F]fluoride ({Al18F}2+) in aqueous 
medium by a suitable chelator conjugated to a biomolecule. McBride et al. published the first study 
using a chelator for {Al18F}2+ labelling in 2009. Numerous studies demonstrated the versatility of the 
Al18F approach to radiolabel peptides using macrocyclic complexing agents such as NOTA and NODA. 
However, this approach has up to now limited applicability for heat sensitive biomolecules due to 
high temperatures required (≥ 100 °C) for the complexation of {Al18F}2+ by macrocyclic chelators.    
Therefore the objective of this thesis was to develop new polydentate ligands that allow chelation of 
{Al18F}2+ at moderate temperatures (<40 °C), whilst maintaining in vivo stability. The availability of 
new Al18F-chelators may have a great impact on PET radiochemical space as it provides a versatile 
platform for fluorine-18 labelling of peptides and heat-sensitive biomolecules. Ultimately, this 
approach could result in a kit-based radiolabelling method that reduces the radiolabelling procedure 
to the simple addition of an aqueous {Al18F}2+ solution to a lyophilised kit. Kit preparation of 18F-
labelled PET tracers has the potential to substitute current technetium-99m tracers considering that 
(1) PET is a superior imaging technology over single photon emission computed tomography (SPECT), 
(2) recent problems with availability of technetium-99m generators due to molybdenum-99 
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disruptions is affecting the continuity of patient care worldwide, and (3) growing availability of 
compact cyclotrons. 
The first set of new chelators that we developed are acyclic ligands with an N2O3 coordinative set or 
N3O2 bis-phenol structure (Chapter II, Figure 1). It was observed that only ligands containing the 
fragment ethylenediamine-N,N’-diacetic acid (H3L1-L4) were able to efficiently chelate aluminium 
fluoride. Ligands without this arrangement of functional groups (H3L5-8) did not complex aluminium 
fluoride with good radiochemical yield (RCY) under the conditions tested. Successful labelling of two 
compounds, (H3L1) and (H3L3) was established. H3L1 and H3L3 both have excellent labelling 
properties but, unfortunately, Al18F-L1 was not stable in vitro. On the other hand, Al18F-L3 showed 
good stability in rat plasma up to 2 h but suffered from decomplexation after extended incubation 
times (Chapter II, Figure 2). Hence, there is still room for improvement regarding the stability of 
these {Al18F}2+-chelator complexes. 
We explored whether incorporation of a trans-cyclohexyl moiety into H3L1, to form restrained 
complexing agent 1 (RESCA1, Chapter III, Figure 1), would increase steric rigidity of the chelator, 
improving the orientation of the chelating groups and as a result improving the stability of the 
resulting AlF-complex. RESCA1 is an acyclic pentadentate ligand with an N2O3 coordinative set and 
the first results revealed that RESCA1 was as efficient as H3L1 to chelate {Al
18F}2+, with high reactivity 
(RCY ≥85%) at room temperature (rt). Encouraged by these promising results and in an attempt to 
broaden the range of chelators, we decided to develop more derivatives of RESCA1 with refined 
changes in the backbone (RESCA 2-5, Chapter III, Figure 1). However, small changes in the backbone 
of RESCA1, to form RESCA2-5, resulted in minor to major loss of stability of the corresponding Al18F 
complexes and thus, RESCA1 was found to be the most promising lead candidate for radiolabelling 
heat-sensitive biomolecules via the Al18F-method. 
This metal chelating agent becomes a bifunctional chelator (BFC) when it accommodates another 
reactive functional group for stable attachment to biomolecules. Different RESCA1 based BFCs were 
synthesised for conjugation to various biomolecules (Figure 1). RESCA1-tetrafluorophenyl ester 
(RESCA1-TFP) and RESCA1-maleimide (RESCA1-mal) have already been synthesised and can be used 
to conjugate the chelator with the biomolecule via the side-chain of a lysine or to conjugate the 
chelator in a site-specific way with a biomolecule via a maleimide-thiol reaction, respectively. 
However, it would be interesting to develop more BFCs, based on RESCA1 to create a broad generic 
platform (Figure1). RESCA1-KYGGG can potentially be used for site-specific labelling of proteins using 
sortase-mediated reactions and RESCA1-tetrazine (RESCA1-Tz) can potentially be used for 
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conjugation to a biomolecule via inverse-electron-demand Diels-Alder (IEDDA) “click” reaction 
between tetrazines (Tz) and trans-cyclooctene (TCO) derivatives (Future perspectives).  
 
Figure 1: Chemical structures of RESCA1-TFP, RESCA1-mal, RESCA1-NCS, RESCA1-NH2, RESCA1-KYGGG 
and RESCA1-Tz 
 
To demonstrate the generic applicability of the proposed method we successfully labelled the heat-
sensitive biomolecule human serum albumin (HSA) at ambient temperature with {Al18F}2+ with high 
radiochemical purity in less than 30 minutes.  HSA (66.5 kDa) is a globular protein with a primary 
sequence made up of 585 amino acid residues and is the most abundant protein in human plasma 
(3.5-5 g/dl). Its high solubility, stability and circulatory half-life of approximately 16-18 h, make HSA 
the ideal vector for PET blood pool imaging applications and to evaluate the stability and kinetic 
inertness of the chelate in vivo. To our knowledge this was the first time that a heat-sensitive 
biomolecule was labelled via the Al18F-method in one radiolabelling step. A patent was filed to 
protect this innovative method which may have a great impact on PET radiochemical space as it will 
facilitate the development of new fluorine-18 labelled heat-sensitive biomolecules. It would be 
interesting to implement the Al18F-radiolabelling process on automated kit based synthesis modules 
(eg the “All-in-One module” (Trasis)) to further optimise and fully automate the Al18F-radiolabelling 
method, allowing to produce multiple Al18F labelled compounds with a single batch of {Al18F}2+. 
The pH of the labelling buffer is critically important for the formation of {Al18F}2+-chelates. If the pH is 
too low, the carboxyl groups are protonated which will hinder the coordination of aluminium and 
moreover the dominant fluoride species in equilibrium is likely to be HF. The optimal pH range for 
labelling N-benzyl-NODA was found to be between 3.8 and 4.2, whereas the optimal pH range for 
H3L3 and RESCA1 lies somewhat higher between 4.5 and 5. Even at pH 5.5-6 high RCYs were still 
observed, indicating that also acid-sensitive proteins can be labelled with the proposed method. At 
even higher pH values, aluminium tends to form insoluble aluminium hydroxide. This results in lower 
General discussion and future perspectives 
Page | 108  
RCYs and therefore it is of great importance that the pH of the reaction mixture is carefully controlled 
by a suitable buffer.  
As it was stated before, we aim to push the Al18F-approach to a kit-based strategy for radiolabelling 
heat-sensitive biomolecules. This assertion is backed up by the similarity of the labelling 
methodology of other radiometals (68Ga, 99mTc, etc…). McBride et al. reported a lyophilised kit for 
rapid radiofluorination of heat-stable peptides, based on the aluminium-fluoride procedure.1 The 
formulation was optimised for pH, buffer, peptide to Al3+ ratio, bulking agent and radioprotectant. 
However, a final purification step using solid-phase extraction was still needed to obtain the final 
product with sufficient radiochemical purity for injection. Moreover, organic solvents and high 
temperatures (≥ 100 °C) were required for the complexation reaction, harsh conditions which are not 
compatible with heat-sensitive biomolecules. In an ideal situation, the labelling is carried out in water 
or saline, at room temperature, in less than 20 minutes, using a minimal amount of precursor 
(biomolecule conjugated to a chelator). Moreover, almost quantitative conversion (RCYs >95%) 
would allow to skip the final purification step, thus simplifying the method. Unfortunately, unlike 
radiolabelling with radiometals that are carrier-free (no presence of a stable isotope of the 
radiometal), fluorine-18 is heavily contaminated with stable fluorine-19 (up to 1000-fold relative to 
fluorine-18 mass) causing a drop in the chelation yield and requiring a higher amount of precursor.  
A possible explanation for the decreased radiochemical yield as a function of the mass amount of 
fluorine could be the formation of other aluminum-fluoride Al18/19Fn
(3-n)+
(aq) (n = 1-6) species. Among 
all the metal-fluoride species, only the mono-fluoride can be efficiently chelated. Certainly, the 
addition of more aluminium in solution will lead to the formation of mainly aluminium mono-fluoride 
but as a consequence, more precursor would be required since there would be more “free” 
aluminium as well. With an excess of Al3+ relative to chelator, most likely the corresponding {AlOH}2+ 
complex is formed and as a consequence there is less ligand available for chelation of {Al18F}2+. The 
presence of increased amounts of precursor will have a negative impact on the specific activity since, 
ideally in a kit-based labelling no purification step is applied. The specific activity of fluorine-18 thus 
proves to be an important parameter for the Al18F chelation yield. In order to enhance the 
radiolabelling conditions, finding the sources of the 19F contamination is crucial. It has been reported 
that the main origin of fluorine-19 is the [18O]water dispensing (loading) and delivery (unloading) 
system of the target, which often contains teflon (PTFE) tubings. This will be thoroughly investigated, 
but also solvents (H2O), reagents (e.g. NaCl) anion-exchange columns and glasswork should be 
evaluated in an attempt to minimise 19F contamination. 
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Important to discuss is the difference between residualising and non-residualising radiolabels and its 
effect on kidney retention and tumor uptake of protein-based radiotracers. Most peptides and small 
proteins (< 60 kDa) are excreted via the renal elimination pathway. After glomerular filtration these 
compounds might undergo receptor-mediated reabsorption in the renal tubuli cells. This process is 
mainly mediated by the endocytic megalin and cubulin receptors that are highly expressed on the 
apical side of proximal tubule cells.2 Both receptors can interact with protein-based radioligands, 
followed by internalisation, transfer to the lysosomal compartment and degradation by proteolytic 
enzymes into amino acids and other (radio)catabolites. Lipophilic (radio)catabolites are able to 
diffuse through lysosomal and cellular membranes and thus leak out from cells, which is called the 
non-residualising effect.3 Therefore radiocatabolites are cleared faster from the kidneys when 
peptides or small proteins are labelled using non-residualising halogens such as fluorine-18, bromine-
86 or different iodine radioisotopes. In contrast, the use of residualising radiometals, including AlF-
NODA complexes4, results in extended retention of radioactivity in kidneys because these stable 
radiocomplexes are not able to diffuse out of the cells. We expect that the Al18F-RESCA complex will 
behave like most other residualising radiometals, however it could occur that the Al18F-complex is 
prone to degradation in the harsh environment of lysosomes and thus might behave rather as a non-
residualising radiolabel. The residualising effect is not only important regarding kidney retention but 
might also occur in target cells of interest (e.g. cancer cells) if there is a high rate of internalisation. In 
this case the residualising effect is beneficial as tumor uptake may be higher and last longer.  
Prostate-specific membrane antigen (PSMA) is overexpressed in a majority of primary and metastatic 
prostate cancer patients and is a promising target for specific prostate cancer imaging and therapy. 
Currently, [68Ga]Ga-PSMA-HBEDD-CC is the most widely used PSMA-ligand. This urea-based PSMA 
inhibitor demonstrates excellent pharmacokinetics as well as stability in vivo, leading to its clinical 
applications worldwide for imaging of prostate cancer. However, labelling with fluorine-18 would 
offer advantages with respect to availability, batch size, and image resolution compared to labelling 
with gallium-68. In chapter III and IV we have developed three new Al18F-labelled urea-based PSMA 
inhibitors, [18F]AlF-PSMA-L3, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-RESCA1. The urea-based 
inhibitor of PSMA, Glu-NH-CO-NH-Lys, can tolerate high temperature radiolabelling procedures, 
therefore NODA was suitable as chelator. The process of radiosynthesis and purification with 
preparative radio-HPLC was performed using a home-built remotely controlled system. However, it 
would be interesting to translate the synthesis of the most promising Al18F-tracer, [18F]AlF-PSMA-
RESCA1 into a “kit”-preparation for further clinical studies. We found out that the purification 
strategy using an alumina-N cartridge is not suitable in this case because of low recovery. However, 
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this purification strategy might be very useful for more lipophilic radiotracers labelled via the Al18F-
method. 
The Al18F-tracers were evaluated in a preclinical setup and the results were compared with those of 
[68Ga]Ga-HBEDD-CC-PSMA. Cell uptake and internalisation experiments with LNCaP (PSMA+) and PC-3 
(PSMA-) cells revealed similar PSMA-specific internalisation and cell accumulation for [18F]AlF-PSMA-
RESCA1 and [68Ga]Ga-PSMA-HBED-CC. Interestingly, [18F]AlF-PSMA-L3 showed considerably lower 
uptake in LNCaP cells but demonstrated high LNCaP tumour uptake in vivo. Aware of the limited 
stability of [18F]AlF-PSMA-L3 in rat plasma, we tested the stability of [18F]AlF-PSMA-L3 in the cell 
culture medium that was used for cell uptake and internalisation experiments. Indeed, cell culture 
medium contains metal ions, amino acids, vitamins and proteins that could hamper the stability of 
the Al18F-complex. As a consequence, this could influence results of cell uptake and internalisation 
experiments. After 45 min incubation in cell culture medium at 37 °C, only 67% of [18F]AlF-PSMA-L3 
was still intact as assessed by instant thin layer chromatography (iTLC), indicating demetallation 
and/or defluorination. This instability explains partially the lower in vitro cell binding of [18F]AlF-
PSMA-L3. In LNCap inoculated mice [18F]AlF-PSMA-L3 showed high LNCaP tumour uptake but also 
increased bone uptake was observed over time. Non-specific bone accumulation might compromise 
the utility of the tracer for non-invasive imaging of prostate cancer metastasis, because most 
metastatic lesions occur in lymph nodes and in the bone. Therefore [18F]AlF-PSMA-L3 is not the 
imaging tool of choice for early detection of prostate cancer recurrence.  
[68Ga]Ga-HBEDD-CC-PSMA, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-L3 were cleared fast by 
the kidneys and almost no liver uptake was observed. In contrast, [18F]AlF-PSMA-RESCA1 was cleared 
fast from plasma and PSMA-negative tissue by the kidneys but also hepatobiliary excretion was 
observed, which is consistent with the biodistribution data. Blocking studies with 2-PMPA proved 
that the observed retention in kidneys is predominatly due to PSMA-specific binding of the 
radiotracers rather than megalin/cubulin mediated residualising effect after glomerular filtration.  
Comparable specific tumor uptake was observed for [18F]AlF-PSMA-RESCA1 and [68Ga]Ga-HBEDD-CC-
PSMA in a head-to-head comparison. To conclude, [18F]AlF-PSMA-RESCA1 might be a promising tool 
for early detection of prostate cancer recurrence. It would be interesting to evaluate the 
pharmacokinetics of [18F]AlF-PSMA-RESCA1 in primates and finally, clinical evaluation is needed to 
compare the sensitivity of [18F]AlF-PSMA-RESCA1 with that of the established tracer [68Ga]Ga-HBEDD-
CC-PSMA in prostate cancer patients.  
Immuno-PET combines selective localisation of antibodies or antibody-fragments at their target in 
vivo and high resolution and sensitivity of PET. Immuno-PET might play an important role as a 
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diagnostic tool in cancer staging but also as dosimetry tool to predict the optimal doses of 
subsequent radioimmunotherapy (RIT). Nanobodies are the smallest antigen-binding antibody 
fragments available and interact fast and with nanomolar affinity with their target. In Chapter V we 
demonstrated that the Al18F-method using our chelator RESCA1, provides an efficient approach to 
radiolabel nanobodies with fluorine-18 at ambient temperature. We successfully derivatised (in a 
non-site-specific way) nanobodies targeting the CRIg receptor with RESCA1 and labelled it with 
{Al18F}2+ in good radiochemical yields in less than 30 minutes. Biodistribution studies showed that 
[18F]AlF-RESCA1-NbV4m119 was mainly excreted via the renal pathway but also high liver uptake was 
observed in normal WT mice, which is expected because CRIg receptors are highly expressed on 
Kupffer cells. Biodistribution and microPET studies in CRIg-/- mice demonstrated absence of liver 
uptake, indicating excellent specificity of the Al18F-labelled tracer. However, a relatively high bone 
uptake was observed in CRIg-/- mice, comparable to the observed bone uptake in WT mice, indicating 
in vivo instability of the tracer. To further investigate the unexpected bone uptake, we analysed urine 
samples using size exclusion chromatography 1 h and 3 h after i.v. injection of [18F]AlF-RESCA1-
NbV4m119. Only 11% and 2% of 18F-activity respectively, corresponded to intact [18F]AlF-RESCA1-
NbV4m119. This shows that although Al18F-RESCA1-NbV4m119 is stable in vitro in rat plasma, the 
radiotracer is metabolised to some extent in the kidneys. This high rate of in vivo degradation was 
also reported previously for 99mTc-labelled nanobodies targeting the epidermal growth factor 
receptor (EGFR). In this study the authors found that only 10% of labelled nanobody was intact in 
urine at 1 h p.i. indicating that this degradation is specific for nanobodies rather than to be 
dependent on the radiolabelling method. Nanobodies are efficiently reabsorbed in the renal proximal 
tubuli. Gainkam et al. showed elegantly that the megalin receptor plays an important role in this 
mechanism using megalin-knockout mice.2  
Figure 2A shows an ex vivo autoradiogram of a renal tissue slice of a naïve WT mouse injected with 
[18F]AlF-RESCA1-NbV4m119 and sacrificed at 1 h p.i.. The radioactivity is mainly concentrated in the 
renal cortex indicating that the kidney retention might be caused by tubular reabsorption and 
subsequent internalisation. One should consider the harsh environment in kidney lysosomes as a 
possible explanation for the observed elevated bone uptake. Indeed, after glomerular filtration 
[18F]AlF-RESCA1-NbV4m119 is internalised and transported to lysosomes. Here, AlF-RESCA1 might be 
degraded and as a result {Al18F}2+ or 18F- as such could be recycled back into circulation, resulting in 
increased bone uptake values. If above assumption is correct, bone uptake could be lowered by 
preventing tubular reabsorption of the tracer (Future perspectives).  
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Figure 2: A: Ex vivo autoradiography on renal tissue of naïve WT mouse injected with [18F]AlF-RESCA1-
NbV4m119 and sacrificed at 1 h after i.v. injection B: RP-HPLC analysis of the radiometabolite fraction 
eluting at 34.7 min on size exclusion HPLC of urine obtained from naïve WT mouse 1 h after i.v. 
injection of [18F]AlF-RESCA1-NbV4m119 (Chapter V, Figure 6). An Acquity UPLC BEH C18 column (1.7 
µm, 2.1 mm x 150 mm, Waters) was used with following method. Solvent A (H2O) and solvent B 
(acetonitrile), flow rate 0.3 ml/min. The elution gradient was: 0-1 min: 99% A; 1-7 min: from 99% A to 
1% A; 7-10 min: 1% A; 10.1-12 min: 99% A. Two major peaks are observed: peak 1, (Rt 0.6 min, 40 %) 
and peak 2 (Rt 3.6 min, 60%). C: Radio-chromatogram of plasma sample of naïve WT mouse 1 h after 
i.v. injection of [18F]AlF-RESCA1-NbV4m119 using size exclusion chromatography. A Superdex 75 
10/300 GL column (GE Healthcare) using sodium phosphate buffer (0.01M, pH 7.4, 0.14 M NaCl), as 
eluent at a flow rate of 0.5 ml/min was used. Three major peaks are observed: peak 1, protein-bound 
fraction (Rt 18.4 min, 19%), peak 2, [18F]AlF-RESCA1-NbV4m119 (Rt 26.8 min, 54%) and peak 3, free 
Al18F-species,18F- and/or 18F-labelled degradation fragments (Rt 35.1 min, 27%) 
In an attempt to further identify the radiometabolites in urine, we collected the metabolite fraction 
eluting at 34.7 min (Chapter V, Figure 6) and analysed it using reverse phase chromatography (Figure 
2B). The radiometabolites eluting at the void volume (peak 1, 40%) are probably {Al18F}2+, 18F- and/or 
very polar fluorine-18 containing degradation fragments of [18F]AlF-RESCA1-NbV4m119. The 
remaining fraction (60%) elutes later (peak 2) which indicates that this fraction consist out of a 
somewhat more lipophilic radiometabolite of [18F]AlF-RESCA1-NbV4m119. The in vivo stability of the 
tracer in blood was tested by analysing plasma 1 h after i.v. injection of [18F]AlF-RESCA1-NbV4m119 
using size exlusion chromatography (Figure 2C). The tracer was partially bound to other proteins 
present in plasma (peak 1, 19%), 54% of tracer was observed as intact [18F]AlF-RESCA1-NbV4m119 
(peak 2) and 27% of tracer was degraded in low molecular weight radiometabolites (peak 3). This 
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indicates good in vivo stability in blood of [18F]AlF-RESCA1-NbV4m119. Studies with [18F]AlF-RESCA1-
HSA, which is not excreted by the kidneys due to the high molecular weight of albumin, confirms the 
high in vivo stability in blood of the Al18F-RESCA1 complex because only minor increase in bone 
uptake was observed over time. PET imaging with [18F]Al18F-RESCA1-NbV4m119 did not show severe 
bone uptake at 1 h p.i. and images with high liver-to background ratios were obtained, indicating 
good in vivo imaging properties of Al18F-RESCA1-NbV4m119 with high specificity for CRIg. 
  
General discussion and future perspectives 
Page | 114  
2. FUTURE PERSPECTIVES 
The acyclic chelator RESCA1 demonstrated to be a good lead candidate for labelling of heat-sensitive 
biomolecules with fluorine-18, however more basic research is needed before this method can be 
used as a generic tool to radiolabel a diversity of biomolecules for PET applications. 
Further fundamental research is needed in order to fully understand the different factors that 
influence the radiolabelling yield of the Al18F-method. Among all the different aluminium-fluoride 
species, only mono-fluoride can be efficiently chelated by the proposed chelators. The identification 
of the different aluminium-fluoride species might be carried out by radio/UV-HPLC based on a 
methodology previously described.5 The development of an analysis method would also allow us to 
further investigate the stability of the new complexes and determine whether the loss of the 
radionuclide is due to defluorination (breaking of the Al-F bond) or demetallation.  
As derived from the molecular ion mass, the AlF-complexes formed with ligands H3L3 and RESCA1 
have a negative overall charge. The synthesis of new ligands with another coordinative set that 
would result in neutral or cationic complexes would allow us to understand how the net overall 
charge is affecting the biodistribution profile of Al18F-labelled peptides and more specifically if it 
affects the uptake and retention in kidneys. Additional information on the structure of AlF-RESCA1 is 
necessary to understand the orientation of the chelating moieties and to rationally design new 
ligands. Therefore, single-crystal X-ray diffraction study of Al19F-RESCA1 is desired. Synthesis and 
purification of the “cold” aluminium fluoride RESCA1 complex should be improved and different 
conditions should be tested to obtain a single crystal suitable for X-ray diffraction studies.  
 
Uptake and retention in kidneys is often a problem for radiolabelled peptides and smaller proteins, 
with a molecular weight less than 60 kDa, which can pass the glomerular basement membrane. A 
substantial part of these radiolabelled peptides or proteins may be reabsorbed and retained in the 
proximal tubule of the kidneys after glomerular filtration. This causes a high radiation burden for the 
kidneys, hinders diagnostic accuracy and limits radionuclide therapy applications. In many cases 
kidney retention might be reduced by (partially) blocking tubular reabsorption after pre- or co-
injection of basic amino acids and other reagents such as gelatin-based plasma expanders like 
Gelofusine. Another interesting approach to reduce radioactivity accumulation in the kidneys is 
based on conjugation of chelators to peptides or proteins by cleavable linkers. The radionuclide, 
together with the chelator will be cleaved off by specific brush-border enzymes in kidneys before 
internalisation in the proximal tubule. In the design of tracers with cleavable linkers, the linkers 
should be stable against enzymes in plasma and should be cleaved off specifically by the renal brush 
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border enzymes. It was shown that the use of glycyl-L-lysine or glycyl-L-tyrosine containing linkers 
provides impressive reduction of renal uptake of 125I-labelled antibody fragments.6 Both strategies for 
reducing renal accumulation could be explored for different Al18F-labelled peptides and proteins.  
In Chapter V we demonstrated that our Al18F-chelator RESCA1 provides an efficient approach to 
radiolabel nanobodies with fluorine-18 at ambient temperature. However, the first step of this 
approach is a non-specific derivatisation of the nanobody with one or more Al18F-chelators, resulting 
in potential batch-to-batch differences due to degree and site of derivatisation. Therefore, site-
specific incorporation of the chelator into the nanobody would even further improve this promising 
radiolabelling approach. A possible strategy is using the site-specific maleimide-thiol reaction for 
derivatisation of nanobodies. Another promising approach is combining the Al18F-method with the 
sortase-mediated conjugation method (Figure 2).7,8 
Figure 2: Sortase-mediated site-specific conjugation method. S. aureus sortase A recognises the C-
terminal sortag (LPETGG) of the nanobody and cleaves the peptide bond between T and G, with 
release of the downstream His-tag. Next, a nucleophilic attack of the triglycine-functionalised 
chelator (RESCA1-KYGGG) on the acyl-enzyme intermediate leads to the formation of a new peptide 
bond with the nanobody, resulting in the site-specifically conjugated nanobody. (adjusted from Massa 
et al.)9 
 
In cancer research, pretargeted PET imaging has emerged as an effective two-step approach that 
combines the affinity and selectivity of antibodies with the rapid pharmacokinetics and favourable 
dosimetry of smaller molecules radiolabelled with short-lived radionuclides (e.g. fluorine-18). This 
approach can be based on a bioorthogonal inverse-electron-demand Diels-Alder (IEDDA) “click” 
reaction between tetrazines and trans-cyclooctene (TCO) derivatives. Recently, new [18F]TCO-
dienophiles and tetrazines with high reactivity for the IEDDA reaction, improved in vivo stability and 
favourable pharmacokinetics were developed in the laboratory of Radiopharmacy. However, the 
synthesis of a 18F-labelled variant of tetrazine, which to date has eluded researchers, would be an 
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especially useful development in the field of the pretargeting approach.10 Standard radiolabelling 
approaches (harsh reaction conditions) cannot be used to introduce fluorine-18 in the tetrazine 
moiety because of the limited chemical stability. The proposed Al18F-method might be an ideal 
approach to overcome these problems. Therefore it would be interesting to conjugate a tetrazine 
moiety with RESCA1 and radiolabel this RESCA1-tetrazine (RESCA1-Tz) fragment with {Al18F}2+. 
Tetrazine-moieties are known to give solubility issues, therefore it may be necessary to introduce 
polar linkers (PEG-linkers) to counteract this problem.  
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SUMMARY 
Positron emission tomography (PET) is a sensitive, non-invasive imaging technology that produces 
three-dimensional images showing the in vivo concentration of radiotracers, which are usually 
labelled with short-lived positron emitting radioisotopes. Among β+-emitting radioisotopes, fluorine-
18 is currently the radionuclide of choice for PET because of its favourable nuclear decay 
characteristics and ease of production. Clinicians in the molecular imaging community are not only 
interested in in using small organic molecules but also high molecular weight biomolecules and 
peptides are increasingly being considered for use as PET-radiopharmaceuticals. However, the 
incorporation of fluorine-18 into heat-sensitive and complex biomolecules creates substantial 
challenges for radiochemists. 
The Al18F-labelling method is a relatively new approach that allows radiofluorination of biomolecules 
such as peptides and proteins in a one-step procedure and in aqueous solution. McBride et al. 
published the first study using a chelator for {Al18F}2+ labelling in 2009. Although many studies 
demonstrated the versatility of the Al18F approach to radiolabel peptides, the approach has limited 
applicability for heat sensitive biomolecules due to high temperatures required for the complexation 
reaction (≥ 100 °C) when used with macrocyclic complexing agents such as NOTA and NODA. 
Therefore the objective of this thesis was to develop new polydentate ligands that allow chelation of 
{Al18F}2+ at moderate temperatures (<40 °C), whilst maintaining in vivo stability. In this thesis, we 
identified new chelators that allow efficient complexation of {Al18F}2+ using mild labelling conditions, 
whilst maintaining in vivo stability. 
The first set of chelators that we developed are acyclic ligands with an N2O3 coordinative set or N3O2 
bis-phenol structure. It was observed that only ligands containing the fragment ethylenediamine-
N,N’-diacetic acid (H3L1-L4) were able to efficiently chelate aluminium fluoride. Ligands without this 
arrangement of functional groups (H3L5-8) did not complex aluminium fluoride with good RCY under 
the conditions tested. Successful labelling of two compounds, (H3L1) and (H3L3) was established. H3L1 
and H3L3 both have excellent labelling properties but, unfortunately, [
18F]AlF-L1 was not stable in 
vitro. [18F]AlF-L3 complex demonstrated a stability in PBS and in rat plasma comparable to that of the 
previously reported [18F]AlF-N-benzyl-NODA complex, up to 60 minutes, but suffered from 
decomplexation after extended incubation times. Although in vitro incubation in rat plasma showed 
slow decomposition, biodistribution of [18F]AlF-L3 showed absence of bone uptake indicating that in 
vivo defluorination or demetalation if any, is limited. Optimal labelling results were obtained at pH 
4.5-5 and it has been shown that the specific activity of fluorine-18 proves to be an important 
parameter for the Al18F chelation yield. The acyclic chelator H3L3 demonstrated to be a good lead 
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candidate for labelling of heat-sensitive biomolecules with fluorine-18. However, there was still room 
for improvement regarding the stability of the [18F]AlF-L3 complex, so that the synthesis of improved 
derivatives was warranted. 
We explored whether incorporation of a trans-cyclohexyl moiety into H3L1, to form restrained 
complexing agent 1 (RESCA1), would increase steric rigidity of the AlF-complex, improving the 
orientation of the chelating groups and as a result improving the stability of the resulting AlF-
complex. RESCA1 is an acyclic pentadentate ligand with an N2O3 coordinative set of donor atoms and 
was synthesised starting from commercially available chemicals. RESCA1 as such showed excellent 
labelling properties and its Al18F-complex demonstrated high in vitro and in vivo stability. Small 
changes in the backbone of RESCA1, to form RESCA2-5, resulted in minor to major loss of stability of 
the corresponding Al18F-complexes and thus, RESCA1 was found to be the most promising lead 
candidate for radiolabelling heat-sensitive biomolecules via the Al18F-method. To demonstrate the 
generic applicability of the proposed method we successfully labelled the heat-sensitive biomolecule 
Human Serum Albumin (HSA) at ambient temperature with {Al18F}2+ with high radiochemical purity in 
less than 30 minutes.  [18F]AlF-RESCA1-HSA showed excellent in vitro and in vivo stability. Moreover, 
[18F]AlF-RESCA1-HSA showed favourable properties for PET blood pool imaging applications.  
Prostate-specific membrane antigen (PSMA) is overexpressed in a majority of primary and metastatic 
prostate cancer patients and is a very promising target for specific prostate cancer imaging and 
therapy. Currently, [68Ga]Ga-PSMA-HBEDD-CC is the most widely used PSMA-ligand. This urea-based 
PSMA inhibitor demonstrates excellent pharmacokinetics as well as stability in vivo, leading to its 
clinical applications worldwide for imaging of prostate cancer. However, labelling with fluorine-18 
would offer advantages with respect to availability, batch size, and image resolution compared to 
labelling with gallium-68.  In this thesis we have developed three new Al18F-labelled urea-based 
PSMA inhibitors, [18F]AlF-PSMA-L3,  [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-RESCA1. Cell 
uptake and internalisation experiments with LNCaP (PSMA+) and PC-3 (PSMA-) cells revealed similar 
specific internalisation and cell accumulation for [18F]AlF-PSMA-RESCA1 and [68Ga]Ga-PSMA-HBED-
CC. In contrast, [18F]AlF-PSMA-NODA-MPAA and [18F]AlF-PSMA-L3 showed considerable lower uptake 
in LNCaP cells. Moreover, [18F]AlF-PSMA-L3 suffers from instability over time which compromises the 
utility of this tracer. All tracers were cleared fast from plasma and PSMA-negative tissue mainly by 
the kidneys but also hepatobiliary excretion was observed in the case of [18F]AlF-RESCA1-PSMA. High 
specific accumulation of all tracers was observed on PSMA+ LNCaP tumour slices and autoradiography 
on human prostate tumour tissue showed specific affinity for the human PSMA receptor. 
Comparable specific tumor uptake was observed for [18F]AlF-PSMA-RESCA1 and [68Ga]Ga-HBEDD-CC-
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PSMA in a head-to-head comparison in PSMA+ tumor bearing mice. To conclude, [18F]AlF-PSMA-
RESCA1 might be a promising tool for early detection of prostate cancer recurrence. 
Nanobodies are promising tools in molecular imaging and have many advantages in comparison with 
full-size antibodies. We demonstrated that the Al18F-method using RESCA1 provides an efficient 
approach to radiolabel nanobodies with fluorine-18 at ambient temperature. We successfully 
derivatised nanobodies targeting the CRIg receptor with RESCA1 and labelled the conjugate with 
{Al18F}2+ in good radiochemical yields at ambient temperature. [18F]AlF-RESCA1-NbV4m119 was 
purified with preparative HPLC resulting in the Al18F-tracer with a radiochemical purity higher than 
97% and the compound showed excellent in vitro stability. Furthermore, we successfully optimised a 
generic radio-HPLC-HRMS system for the analysis and quality control of radiolabelled nanobodies. 
Biodistribution studies in mice showed that [18F]AlF-RESCA1-NbV4m119 was mainly excreted via the 
renal pathway but also high liver uptake was observed in normal WT mice, which is expected 
because CRIg receptors are highly expressed on Kupffer cells. Biodistribution and microPET studies in 
CRIg-/- mice demonstrated absence of significant uptake in liver, indicating excellent specificity of the 
Al18F-labelled tracer. Almost no intact [18F]AlF-RESCA1-NbV4m119 was found in urine at 3 h p.i. and 
relatively high bone uptake was observed, indicating in vivo instability of the tracer. However, in vivo 
PET imaging in mice did not show significant bone uptake at 1 h p.i. and high liver-to background 
images were obtained, indicating favourable in vivo imaging properties of [18F]AlF-RESCA1-
NbV4m119 with high specificity for CRIg. This generic radiolabelling, purification and characterisation 
method provides a general approach for radiolabelling of nanobodies with fluorine-18. 
In conclusion, the acyclic chelator RESCA1 demonstrated to be a good lead candidate for labelling of 
heat-sensitive biomolecules with fluorine-18. This new class of AlF-chelators may have a great impact 
on PET radiochemical space as it will stimulate the rapid development of new fluorine-18 labelled 
peptides and other heat-sensitive biomolecules. However, more basic research is needed before this 
method can result in a kit-based, radiolabelling strategy.  
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SAMENVATTING 
Positron emissie tomografie (PET) is een gevoelige, niet-invasieve beeldvormingstechniek die toelaat 
de verdeling van een radioactief gemerkte ligand in vivo te visualiseren. Deze radioliganden zijn 
meestal gemerkt met kortlevende radionucliden zoals koolstof-11, gallium-68 of fluor-18. Fluor-18 is 
dankzij zijn bijna ideale vervaleigenschappen en eenvoudige productiemethode het meest gebruikte 
radionuclide voor PET. Er is tegenwoordig steeds meer interesse om ook hitte-gevoelige en complexe 
peptiden en biomoleculen te merken met fluor-18. Omdat de traditionele manier om fluor-18 in 
organische moleculen in te bouwen strenge condities vereist die niet compatibel zijn met fragiele 
biomoleculen, moeten andere methoden ontwikkeld worden.  
De Al18F-merkingsstrategie is een relatief nieuwe methode die kan gebruikt worden om fluor in 
peptiden en biomoleculen in slechts één synthesestap in te bouwen. Het eerste raport van zo’n 
merking die gebruik maakt van de Al18F-strategie werd in 2009 gepubliceerd door McBride et al. Op 
dit ogenblik heeft de Al18F-strategie slechts een beperkte toepasbaarheid omdat hoge temperaturen 
(≥ 100 °C) noodzakelijk zijn voor de complexatiereactie indien gebruikt gemaakt wordt van de reeds 
gekende macrocyclische chelatoren NODA en NOTA. Daarom was het hoofddoel van deze thesis het 
ontwikkelen van nieuwe chelatoren die wel toelaten om {Al18F}2+ te cheleren op kamertemperatuur. 
Een belangrijke vereiste is dat de gevormde Al18F-complexen voldoende stabiel zijn in vivo gedurende 
enkele uren. 
De eerste set van chelatoren die ontwikkeld werd gedurende deze thesis zijn alle acyclische 
chelatoren die bestaan uit een N2O3 coördinatieve set of een bis-fenol structuur. Het werd duidelijk 
dat enkel liganden (H3L1-L4) die een ethyleendiamine-N,N-diazijnzuur fragment bezitten in hun 
structuur efficiënt {Al18F}2+ kunnen complexeren. Bij de liganden (H3L5-8) die dit motief niet bezitten 
werd geen efficiënte complexatie waargenomen in deze studie. De liganden (H3L1) en (H3L3) konden 
beide succesvol gebruikt voor de complexatie van {Al18F}2+, maar helaas bleek reeds uit in vitro 
stabiliteitstesten dat het gevormde [18F]AlF-L1 niet stabiel was, dit in tegenstelling tot het gevormde 
[18F]AlF-L3. De in vitro stabilieteitstesten in ratplasma toonden aan dat [18F]AlF-L1 een gelijkaardige 
stabiliteit vertoont als [18F]AlF-N-benzyl-NODA tot 1 uur na incubatie. Op latere tijdstippen werd 
echter significante instabiliteit aangetoond voor [18F]AlF-L3. Desondanks bleek uit de resultaten van 
de ex vivo biodistributie in gezonde muizen met [18F]AlF-L3 dat er slechts in beperkte mate in vivo 
defluorinering of decomplexering plaatsvindt, aangezien er slechts beperkte botopname 
geobserveerd werd. De nieuw ontwikkelde acyclische chelator H3L3 heeft goede eigenschappen maar 
aangezien er nog ruimte is voor verbetering aangaande de stabiliteit, is de ontwikkeling van nieuwe 
derivaten noodzakelijk. 
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Er werd een trans-cyclohexyl fragment ingebouwd in H3L1 om zo “restrained complexing agent 1” 
(RESCA1) te vormen. We onderzochten of de sterische rigiditeit van het AlF complex en de oriëntatie 
van de chelerende groepen hierdoor zouden verbeteren om zo het gevormde AlF complex stabieler 
te maken. 
RESCA1 is een acyclisch pentadentaatligand (N2O3) en werd gesynthetiseerd uitgaande van 
commerciëel beschikbare chemicaliën. RESCA1 vertoonde uitstekende complexeringseigenschappen 
en in vitro en in vivo stabiliteitsstudies toonden aan dat het resulterende Al18F-complex zeer stabiel 
was. Kleine wijzigigen in de structuur van RESCA1 (RESCA2-5), leidden in mindere of meerdere mate 
tot stabiliteitsverlies van de overeenkomstige Al18F-complexen. Bijgevolg is RESCA1 tot dusver de 
meest geschikte chelator om hitte-gevoelige biomoleculen te merken met {Al18F}2+. De generische 
toepasbaarheid van deze methode werd aangetoond door het hitte-gevoelige proteïne Humaan 
Serum Albumine (HSA) succesvol met {Al18F}2+ te merken bij kamertemperatuur. [18F]AlF-RESCA1-HSA 
werd geproduceerd in minder dan 30 minuten met een hoge radiochemische zuiverheid. Het Al18F-
gemerkte biomolecule vertoonde uitstekende in vitro en in vivo stabiliteit. 
Prostaat-specifiek membraan antigen (PSMA) wordt overvloedig tot expressie gebracht bij de meeste 
vormen van primaire en gemetastaseerde prostaatkanker en is daardoor een veelbelovend doelwit 
voor beeldvorming en therapie van prostaatkanker. De PSMA inhibitor [68Ga]Ga-PSMA-HBEDD-CC is, 
dankzij zijn gunstige farmacokinetiek, specificiteit, sensitiviteit en in vivo stabiliteit, momenteel 
wereldwijd het meest gebruikte ligand voor beeldvorming van prostaatkanker met PET. Een fluor-18-
derivaat zou echter significante voordelen kunnen opleveren.   
In deze thesis hebben we drie Al18F-gemerkte PSMA inhibitors ontwikkeld: [18F]AlF-PSMA-L3,  
[18F]AlF-PSMA-NODA-MPAA en [18F]AlF-PSMA-RESCA1. Experimenten met LNCaP (PSMA+) en PC-3 
(PSMA-) cellen toonden vergelijkbare celopname en internalisatie aan voor [18F]AlF-PSMA-RESCA1 en 
[68Ga]Ga-PSMA-HBED-CC. [18F]AlF-PSMA-NODA-MPAA en [18F]AlF-PSMA-L3 daarentegen werden 
significant minder opgenomen in LNCaP cellen. Bovendien is [18F]AlF-PSMA-L3 instabiel, wat zijn 
bruikbaarheid beperkt. Alle radioliganden werden snel renaal geklaard uit plasma en PSMA-negatief 
weefsel. Bij [18F]AlF-RESCA1-PSMA werd ook hepatobiliaire klaring waargenomen. 
Autoradiografiestudies toonden hoge opstapeling van alle radioliganden aan in PSMA+ LNCaP 
tumorcoupes en studies op humaan prostaatkankerweefsel wezen op specifieke affiniteit voor de 
humane PSMA receptor. Vergelijkbare tumoropname werd waargenomen voor [18F]AlF-PSMA-
RESCA1 en [68Ga]Ga-HBEDD-CC-PSMA in PSMA+ xenograftmuizen. We kunnen dus besluiten dat 
[18F]AlF-PSMA-RESCA1 een beloftevolle PET-ligand zou kunnen zijn voor het vroegtijdig opsporen van 
prostaatkanker. 
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Nanobodies bezitten een hoge affiniteit en selectiviteit voor hun doelwit en hebben bovendien een 
korte biologische halfwaardetijd, vergelijkbaar met de fysische halfwaardetijd van fluor-18. Er werd 
aangetoond dat nanobodies doeltreffend kunnen gemerkt worden met fluor-18 op 
kamertemperatuur via de Al18F-methode met RESCA1. We derivatiseerden nanobodies gericht tegen 
de CRIg receptor met RESCA1 en merkten dit derivaat succesvol met {Al18F}2+. [18F]AlF-RESCA1-
NbV4m119 werd opgezuiverd met preparatieve hoge druk vloeistofchromatografie (HDVC) en 
leverde een Al18F-ligand op met een radiochemische zuiverheid van meer dan 97% en een 
uitstekende in vitro stabiliteit. Daarnaast optimaliseerden we een generisch radio-HDVC-HRMS (hoge 
resolutie massaspectrometrie) systeem voor de analyse en kwaliteitscontrole van de gemerkte 
nanobodies. Biodistributiestudies in muizen toonden aan dat [18F]AlF-RESCA1-NbV4m119 
voornamelijk uitgescheiden werd via de nieren. In gezonde muizen werd zoals verwacht ook hoge 
leveropname gezien, aangezien CRIg receptoren veel voorkomen op Kupffer cellen. Met 
biodistributie- en microPET studies in CRIg-/- muizen werd geen leveropname gezien, wat een 
uitstekende specificiteit van de Al18F-gemerkte radiotracer aantoonde. Tegen de verwachtingen in 
werd quasi geen intact [18F]AlF-RESCA1-NbV4m119 gevonden in de urine drie uur na injectie en 
biodistributie studies toonden een relatief hoge botopname aan, wat wijst op enige in vivo 
instabiliteit. Deze merkings-, karakterisatie- en opzuiveringsmethode kan generisch gebruikt worden 
voor het labelen van nanobodies met fluor-18. 
We kunnen besluiten dat de chelator RESCA1 tot dusver de beste ligand is voor het merken van hitte-
gevoelige biomoleculen en we zijn ervan overtuigd dat deze nieuwe klasse van chelatoren een 
belangrijke rol kan spelen in de verdere ontwikkeling van fluor-18 gemerkte PET liganden. Er moet 
echter nog bijkomend fundamenteel onderzoek uitgevoerd worden vooraleer deze strategie kan 
evolueren naar een klinisch bruikbare merkingskit. 
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